DRAVP_ID Sequence Sequence_Length Name Source Uniprot_ID PDB_ID Target_Organism Family Assay Activity Hemolytic_Activity Cytotoxicity_Activity Predicted_structure_ID Structure Linear_Cyclic N-terminal_Modification C-terminal_Modification Other_Modification Stereochemistry Binding_Target Mechanism Mass Formula Absent_amino_acids Common_amino_acids pI Basic_residues Acidic_residues Net_charge Polar_residues Hydrophobic_residues Hydrophobicity Boman_Index Half_Life_Mammalian_ Half_Life__Yeast_ Half_Life__E_coli_ Aliphatic_Index Extinction_Coefficient_cystines Absorbance_280nm Pubmed_ID Reference Author Title Doi Other_link Connectives DRAVPe01811 IFKAIWSGIKSLF 13 Hp1090 Heterometrus petersii "P0DJ02,T1DEJ9" None HCV Flaviviridae In vitro HCV RNA inhibitory assay [Ref.20950663]Hepatitis C virus (HCV): inhibition of viral infection in Huh7.5.1 cells(IC50 = 7.62 μg/ml (5.0 μM)). No hemolysis information or data found in the reference(s) presented in this entry "[Ref.20950663]the peptide concentration was less than 20 μg/ml, the viability of the peptide-treated cells was greater than 90%." DRAVPe01811.cif Linear Free Amidation None L membrane Has the ability to prevent the initiation step of HCV infection by direct interaction with HCV virus and readily disrupting their phospholipid membrane. 1509.85 C76H116N16O16 CDEHMNPQRTVY I 10 2 0 2 3 8 107.69 1282 20 hour 30 min >10 hour 127.69 5500 458.33 20950663 Peptides. 2011 Jan;32(1):11-9. "Yan R, Zhao Z, He Y, Wu L, Cai D, Hong W, Wu Y, Cao Z, Zheng C, Li W. " A new natural α-helical peptide from the venom of the scorpion Heterometrus petersii kills HCV. 10.1016/j.peptides.2010.10.008 Anti-HCV DRAVPe01810 GFGCPFNQGKCHRHCRSIRRRGGYCDGFLKQRCVCYRK 38 BmKDfsin3 Mesobuthus martensii Karsch A0A384E0Y8 None HCV Flaviviridae qPCR [Ref.31963532]Hepatitis C virus (HCV): inhibition of viral replication in Huh7.5.1 cells(IC50=3.35±1.1 µM). No hemolysis information or data found in the reference(s) presented in this entry "[Ref.31963532]Human hepatocellular carcinoma Huh-7.5.1 cells: CC50=60.63±1.36 µM." DRAVPe01810.cif Cyclic Free Free "Disulfide bonds between Cys4 and Cys25, Cys11 and Cys33, Cys15 and Cys35." L Not found "BmKDfsin3 is revealed to enter into cells. Using an upstream MyD88 dimerization inhibitor ST2345 or kinase IRAK-1/4 inhibitor I, the inhibition of p38 activation represses HCV replication in vitro." 4494.26 C190H299N69O47S6 AEMTW R 10 12 1 11 16 6 -92.37 -12439 30 hour >20 hour >10 hour 28.16 3355 90.68 31963532 Antibiotics (Basel). 2020 Jan 17;9(1):33. "Cheng Y, Sun F, Li S, Gao M, Wang L, Sarhan M, Abdel-Rahman MA, Li W, Kwok HF, Wu Y, Cao Z. " Inhibitory Activity of a Scorpion Defensin BmKDfsin3 against Hepatitis C Virus. 10.3390/antibiotics9010033 Anti-HCV DRAVPe01809 FIKRIARLLRKIF 13 Kn2-7 Synthetic construct(derived from BmKn2) No entry found None HIV Retroviridae Luciferase Assay [Ref.22536342]human Immunodeficiency viruses-1(HIV-1): inhibition of viral particle(EC50= 2.76 μg/ml (1.65 μM)). No hemolysis information or data found in the reference(s) presented in this entry [Ref.22536342]TZM-bl cells: CC50 = 38.46 µg/ml. DRAVPe01809.cif Linear Free Free None L Not found "Kn2-7 aggregates and inserts into viral envelope so that the hydrophobic peptide region aligns with the lipid core region and the hydrophilic peptide regions form the interior region of the pore, with the help of positive charge of peptide somehow" 1674.15 C81H140N24O14 CDEGHMNPQSTVWY IR 12.31 5 0 5 0 8 55.38 -2349 1.1 hour 3 min 2 min 157.69 0 0 22536342 PLoS One. 2012;7(4):e34947. "Chen Y, Cao L, Zhong M, Zhang Y, Han C, Li Q, Yang J, Zhou D, Shi W, He B, Liu F, Yu J, Sun Y, Cao Y, Li Y, Li W, Guo D, Cao Z, Yan H." Anti-HIV-1 activity of a new scorpion venom peptide derivative Kn2-7. 10.1371/journal.pone.0034947 Anti-HIV DRAVPe01808 MITHGCYTRTRHKHKLKKTL 20 SA-35 Synthetic construct No entry found None RSV Paramyxoviridae Antiviral assay [Ref.32124885]Respiratory syncytial virus (RSV):SA-35 caused a significant decrease of the RSV infectivity by 33 times at concentrations 1 mg/ml. No hemolysis information or data found in the reference(s) presented in this entry [Ref.32124885]MA-104 cells:CC50= 2.1 ± 0.1 mg/ml. DRAVPe01808.cif Linear Free Free None L Not found It is likely that these peptides exert anti-RSV activity through a combination of two mechanisms: destabilization of the viral envelope and competitive inhibition of attachment/fusion of the virus with the target cell. 2452.97 C107H182N36O26S2 ADEFNPQSVW KT 10.58 9 0 9 7 3 -111 -5711 30 hour >20 hour >10 hour 58.5 1490 78.42 32124885 J Mater Chem B. 2020 Apr 1;8(13):2607-2617 "Kozhikhova KV, Shilovskiy IP, Shatilov AA, Timofeeva AV, Turetskiy EA, Vishniakova LI, Nikolskii AA, Barvinskaya ED, Karthikeyan S, Smirnov VV, Kudlay DA, Andreev SM, Khaitov MR" "Linear and dendrimeric antiviral peptides: design, chemical synthesis and activity against human respiratory syncytial virus." 10.1039/c9tb02485a Anti-RSV DRAVPe01807 KRRGGGKLLKLLLKLLLKLLKC 22 NC-783 Synthetic construct No entry found None RSV Paramyxoviridae Antiviral assay [Ref.32124885]Respiratory syncytial virus (RSV):inhibition of viral infection in the MA-104 cell(IC50=0.04mg/ml). No hemolysis information or data found in the reference(s) presented in this entry [Ref.32124885]MA-104 cells:CC50= 0.04 ± 0.01 mg/ml. DRAVPe01807.cif Linear Free Free None L Not found It is likely that these peptides exert anti-RSV activity through a combination of two mechanisms: destabilization of the viral envelope and competitive inhibition of attachment/fusion of the virus with the target cell. 2505.32 C117H222N34O23S ADEFHIMNPQSTVWY L 11.27 8 0 8 4 10 31.36 -984 1.3 hour 3 min 2 min 177.27 0 0 32124885 J Mater Chem B. 2020 Apr 1;8(13):2607-2617 "Kozhikhova KV, Shilovskiy IP, Shatilov AA, Timofeeva AV, Turetskiy EA, Vishniakova LI, Nikolskii AA, Barvinskaya ED, Karthikeyan S, Smirnov VV, Kudlay DA, Andreev SM, Khaitov MR" "Linear and dendrimeric antiviral peptides: design, chemical synthesis and activity against human respiratory syncytial virus." 10.1039/c9tb02485a Anti-RSV DRAVPe01806 gikefkrivqrikdflrnlv 20 GI-20D Synthetic construct(derived from LL-37) No entry found None EBOV Filoviridae Plaque assay [Ref.32252021]Ebola Virus(EBOV):inhibition of viral infection in Hela cells(IC50=0.99 µM);inhibition of viral infection in primary macrophages(IC50=2.2 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe01806.cif Linear Free Amidation None D Not found "Act as CatB inhibitors to block the endosomal processing of EBOV GP, thus preventing virus entry." 2473.01 H-38O-19 ACDEFGHIKLMNPQRSTVWY ACDEFGHIKLMNPQRSTVWY 11 0 0 0 0 0 0 0 0 0 0 32252021 iScience. 2020 Apr 24;23(4):100999. "Yu Y, Cooper CL, Wang G, Morwitzer MJ, Kota K, Tran JP, Bradfute SB, Liu Y, Shao J, Zhang AK, Luo LG, Reid SP, Hinrichs SH, Su K." Engineered Human Cathelicidin Antimicrobial Peptides Inhibit Ebola Virus Infection. 10.1016/j.isci.2020.100999 Anti-EBOV DRAVPe01805 GXKRlVQRlKDXlRNLV 17 17BIPHE2 Synthetic construct(derived from LL-37) No entry found None EBOV Filoviridae Plaque assay [Ref.32252021]Ebola Virus(EBOV):inhibition of viral infection in Hela cells(IC50=0.71 µM);inhibition of viral infection in primary macrophages(IC50=5.6 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe01805.cif Linear Free Amidation The 'X' at position 2 and 12 indicates biphenylalanine. "Mixed(D-Leu5, 9, 13)" Not found "Act as CatB inhibitors to block the endosomal processing of EBOV GP, thus preventing virus entry." 2030.86 C61H103N25O12 ACEFHIMPSTWY R 11.72 5 1 4 2 3 -117.65 -6282 30 hour >20 hour >10 hour 57.06 0 0 32252021 iScience. 2020 Apr 24;23(4):100999. "Yu Y, Cooper CL, Wang G, Morwitzer MJ, Kota K, Tran JP, Bradfute SB, Liu Y, Shao J, Zhang AK, Luo LG, Reid SP, Hinrichs SH, Su K." Engineered Human Cathelicidin Antimicrobial Peptides Inhibit Ebola Virus Infection. 10.1016/j.isci.2020.100999 Anti-EBOV DRAVPe01803 RGAHINGRWDSRCHRF 16 FBP1 Synthetic construct No entry found None Influenza A virus Orthomyxoviridae Plaque reduction assay [Ref.35259078]influenza A virus(H1N1): inhibition of viral multicycle growth in MDCK cells(>50% inhibition at 100 μg/ml). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe01803.cif Linear Free Free None L HA FBP could have dual functions: blocked HA-mediated fusion by binding and inhibited endosomal acidification from interfering viral entry by the endocytic pathway. 1968.19 C83H126N34O21S EKLMPQTVY R 11.52 6 1 5 5 4 -139.38 -7256 1 hour 2 min 2 min 30.63 5500 366.67 35259078 Emerg Microbes Infect. 2022 Dec;11(1):926-937. "Zhao H, Meng X, Peng Z, Lam H, Zhang C, Zhou X, Chan JF, Kao RYT, To KK, Yuen KY." "Fusion-inhibition peptide broadly inhibits influenza virus and SARS-CoV-2, including Delta and Omicron variants. " 10.1080/22221751.2022.2051753 Anti-Anti-Influenza A virus DRAVPe01804 RGAHIKGRWDSRCHRF 16 FBP2 Synthetic construct No entry found None Influenza A virus Orthomyxoviridae Plaque reduction assay [Ref.35259078]influenza A virus(H1N1): inhibition of viral multicycle growth in MDCK cells(>50% inhibition at 50 μg/ml). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe01804.cif Linear Free Free None L HA FBP could have dual functions: blocked HA-mediated fusion by binding and inhibited endosomal acidification from interfering viral entry by the endocytic pathway. 1982.26 C85H132N34O20S ELMNPQTVY R 11.54 7 1 6 4 4 -141.88 -7147 1 hour 2 min 2 min 30.63 5500 366.67 35259078 Emerg Microbes Infect. 2022 Dec;11(1):926-937. "Zhao H, Meng X, Peng Z, Lam H, Zhang C, Zhou X, Chan JF, Kao RYT, To KK, Yuen KY." "Fusion-inhibition peptide broadly inhibits influenza virus and SARS-CoV-2, including Delta and Omicron variants. " 10.1080/22221751.2022.2051753 Anti-Anti-Influenza A virus DRAVPe01802 RGAHIKGRWKSRCHRF 16 FBP Synthetic construct No entry found None "Influenza A virus, Influenza B virus, SARS-CoV-2" "Orthomyxoviridae, Coronaviridae" Plaque reduction assay [Ref.35259078]influenza A virus(H1N1): inhibition of viral multicycle growth in MDCK cells(IC50=3.9 μg/ml);##influenza A virus(H3N2): inhibition of viral replication in MDCK cells(IC50=1.6 μg/ml);##influenza B virus: inhibition of viral replication in MDCK cells(IC50=7.1 μg/ml);##SARS-CoV-2 HKU001a: inhibition of viral replication in Vero E6 cells(IC50=2.9 μg/ml);##SARS-CoV-2 B.1.1.63: inhibition of viral replication in Vero E6 cells(IC50=3.0 μg/ml);##SARS-CoV-2 Delta: inhibition of viral replication in Vero E6 cells(IC50=3.9 μg/ml). [Ref.35259078]No significant haemolysis was observed when Turkey red blood cells (RBC) were treated with FBP. [Ref.35259078]no significant cytotoxicity was detected in MDCK cells treated with 1 mg/ml of FBP. DRAVPe01802.cif Linear Free Free None L HA FBP could have dual functions: blocked HA-mediated fusion by binding and inhibited endosomal acidification from interfering viral entry by the endocytic pathway.the notable antiviral activity and fusion inhibition activity of FBP on SARS-CoV-2 could be attributed to the inhibition of FBP on endosomal acidification 1995.34 C87H139N35O18S DELMNPQTVY R 12.01 8 0 8 4 4 -144.38 -6830 1 hour 2 min 2 min 30.63 5500 366.67 35259078 Emerg Microbes Infect. 2022 Dec;11(1):926-937. "Zhao H, Meng X, Peng Z, Lam H, Zhang C, Zhou X, Chan JF, Kao RYT, To KK, Yuen KY." "Fusion-inhibition peptide broadly inhibits influenza virus and SARS-CoV-2, including Delta and Omicron variants. " 10.1080/22221751.2022.2051753 "Anti-Anti-Influenza A virus, Anti-Influenza B virus, Anti-SARS-CoV-2" DRAVPe01801 IPLRGAFINGRWDSQCHRFS 20 U5 Synthetic construct No entry found None Influenza A virus Orthomyxoviridae Plaque reduction assay [Ref.35259078]influenza A virus(H1N1): inhibition of viral replication in MDCK cells(IC50=12.9 μg/ml); No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe01801.cif Linear Free Free None L HA Bind to the HA stem of group 1 influenza A virus. 2360.68 C105H158N34O27S EKMTVY R 10.26 4 1 3 6 7 -47 -4910 20 hour 30 min >10 hour 63.5 5500 289.47 35259078 Emerg Microbes Infect. 2022 Dec;11(1):926-937. "Zhao H, Meng X, Peng Z, Lam H, Zhang C, Zhou X, Chan JF, Kao RYT, To KK, Yuen KY." "Fusion-inhibition peptide broadly inhibits influenza virus and SARS-CoV-2, including Delta and Omicron variants. " 10.1080/22221751.2022.2051753 Anti-Anti-Influenza A virus DRAVPe01800 FINGRWDSQCHRFSNGAIACA 21 U4 Synthetic construct No entry found None Influenza A virus Orthomyxoviridae Plaque reduction assay [Ref.35259078]influenza A virus(H1N1): inhibition of viral replication in MDCK cells(IC50=6.6 μg/ml); No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe01800.cif Linear Free Free None L HA Bind to the HA stem of group 1 influenza A virus. 2353.62 C101H149N33O29S2 EKLMPTVY A 8.08 3 1 2 8 8 -21.43 -4084 1.1 hour 3 min 2 min 51.43 5625 281.25 35259078 Emerg Microbes Infect. 2022 Dec;11(1):926-937. "Zhao H, Meng X, Peng Z, Lam H, Zhang C, Zhou X, Chan JF, Kao RYT, To KK, Yuen KY." "Fusion-inhibition peptide broadly inhibits influenza virus and SARS-CoV-2, including Delta and Omicron variants. " 10.1080/22221751.2022.2051753 Anti-Anti-Influenza A virus DRAVPe01799 WEDWVR 6 C6b Synthetic construct(derived from gp36 membrane proximal external region of FIV) No entry found None FIV Retroviridae [Ref.30240422]Feline immunodeficiency virus (FIV): inhibition of virus replication in lymphoid cells(IC50>50 μg/ml). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe01799.cif Linear Free Free None L membrane Elicit antiviral activity by inhibiting the fusion of the FIV and host cell membrane. 889.97 C42H55N11O11 ACFGHIKLMNPQSTY W 4.37 1 2 -1 0 3 -151.67 -2175 2.8 hour 3 min 2 min 48.33 11000 2200 30240422 PLoS One. 2018 Sep 21;13(9):e0204042 "Grimaldi M, Stillitano I, Amodio G, Santoro A, Buonocore M, Moltedo O, Remondelli P, D'Ursi AM." Structural basis of antiviral activity of peptides from MPER of FIV gp36 10.1371/journal.pone.0204042 Anti-FIV DRAVPe01798 DWVRWI 6 C6a Synthetic construct(derived from gp36 membrane proximal external region of FIV) No entry found None FIV Retroviridae [Ref.30240422]Feline immunodeficiency virus (FIV): inhibition of virus replication in lymphoid cells(IC50=0.06-0.15 μg/ml). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe01798.cif Linear Free Free None L membrane Elicit antiviral activity by inhibiting the fusion of the FIV and host cell membrane. 874.01 C43H59N11O9 ACEFGHKLMNPQSTY W 5.84 1 1 0 0 4 -18.33 -1002 1.1 hour 3 min >10 hour 113.33 11000 2200 30240422 PLoS One. 2018 Sep 21;13(9):e0204042 "Grimaldi M, Stillitano I, Amodio G, Santoro A, Buonocore M, Moltedo O, Remondelli P, D'Ursi AM." Structural basis of antiviral activity of peptides from MPER of FIV gp36 10.1371/journal.pone.0204042 Anti-FIV DRAVPe01797 WEDWVRWI 8 C8 Synthetic construct(derived from gp36 membrane proximal external region of FIV) No entry found None FIV Retroviridae [Ref.30240422]Feline immunodeficiency virus (FIV): inhibition of virus replication in lymphoid cells(IC50=0.05-0.06 μg/ml). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe01797.cif Linear Free Free None L membrane Elicit antiviral activity by inhibiting the fusion of the FIV and host cell membrane. 1189.34 C59H76N14O13 ACFGHKLMNPQSTY W 4.37 1 2 -1 0 5 -68.75 -1450 2.8 hour 3 min 2 min 85 16500 2357.14 30240422 PLoS One. 2018 Sep 21;13(9):e0204042 "Grimaldi M, Stillitano I, Amodio G, Santoro A, Buonocore M, Moltedo O, Remondelli P, D'Ursi AM." Structural basis of antiviral activity of peptides from MPER of FIV gp36 10.1371/journal.pone.0204042 Anti-FIV DRAVPe01796 XGSGSGVALDPIDIAnti-SIVLNKAKSDLEESKEWIRRSNGKLDSI 42 Chol-PEG4-VG Synthetic construct No entry found None HPIV 3 Paramyxoviridae Plaque reduction assay "[Ref.28344321]Human parainfluenza viruse 3(HPIV 3): inhibition of virus infection in Vero cells(IC90=0.1 ± 0.0001 nM,IC50<0.0007 nM)." No hemolysis information or data found in the reference(s) presented in this entry [Ref.28344321]Vero cells: CC50>10000 nM. DRAVPe01796.cif Linear Acetylation Amidation The 'X' at position 1 indicates cholesterol-PEG4 conjugated cysteine. L membrane "Peptides derived from the HRC of paramyxovirus F proteins interfere with formation of the six-helix bundle in a dominant-negative manner by binding to the transiently exposed HRN coiled coil in the transient fusion intermediate, thereby inhibiting membrane fusion." 4510.27 C190H316N54O64 CFHMQTY S 5.05 6 7 -1 13 14 -38.33 -8236 102.14 5500 134.15 28344321 Sci Rep. 2017 Mar 8;7:43610. "Mathieu C, Augusto MT, Niewiesk S, Horvat B, Palermo LM, Sanna G, Madeddu S, Huey D, Castanho MA, Porotto M, Santos NC, Moscona A" Broad spectrum antiviral activity for paramyxoviruses is modulated by biophysical properties of fusion inhibitory peptides 10.1038/srep43610 Anti-HPIV 3 DRAVPe01795 XGSGSGVALDPIDIAnti-SIVLNKAKSDLEESKEWIRRSNGKLDSI 42 Chol-VG Synthetic construct No entry found None HPIV 3 Paramyxoviridae Plaque reduction assay "[Ref.28344321]Human parainfluenza viruse 3(HPIV 3): inhibition of virus infection in Vero cells(IC90=1.7 ± 0.42 nM,IC50=0.06 ± 0.035 nM)." No hemolysis information or data found in the reference(s) presented in this entry [Ref.28344321]Vero cells: CC50=9000 nM. DRAVPe01795.cif Linear Acetylation Amidation The 'X' at position 1 indicates cholesterol-conjugated cysteine. L membrane "Peptides derived from the HRC of paramyxovirus F proteins interfere with formation of the six-helix bundle in a dominant-negative manner by binding to the transiently exposed HRN coiled coil in the transient fusion intermediate, thereby inhibiting membrane fusion." 4510.27 C190H316N54O64 CFHMQTY S 5.05 6 7 -1 13 14 -38.33 -8236 102.14 5500 134.15 28344321 Sci Rep. 2017 Mar 8;7:43610. "Mathieu C, Augusto MT, Niewiesk S, Horvat B, Palermo LM, Sanna G, Madeddu S, Huey D, Castanho MA, Porotto M, Santos NC, Moscona A" Broad spectrum antiviral activity for paramyxoviruses is modulated by biophysical properties of fusion inhibitory peptides 10.1038/srep43610 Anti-HPIV 3 DRAVPe01794 VALDPIDIAnti-SIVLNKAKSDLEESKEWIRRSNGKLDSIGSGSGX 42 VG-PEG24-Chol Synthetic construct No entry found None HPIV 3 Paramyxoviridae Plaque reduction assay "[Ref.28344321]Human parainfluenza viruse 3(HPIV 3): inhibition of virus infection in Vero cells(IC90=0.1 ± 0.0003 nM,IC50=0.007 ± 0.007 nM);##Nipah virus(NiV):inhibition of virus infection in Vero cells(IC90~2 nM." No hemolysis information or data found in the reference(s) presented in this entry [Ref.28344321]Vero cells: CC50=1300 nM. DRAVPe01794.cif Linear Acetylation Amidation The 'X' at position 42 indicates cholesterol-PEG24 conjugated cysteine. L membrane "Peptides derived from the HRC of paramyxovirus F proteins interfere with formation of the six-helix bundle in a dominant-negative manner by binding to the transiently exposed HRN coiled coil in the transient fusion intermediate, thereby inhibiting membrane fusion." 4510.27 C190H316N54O64 CFHMQTY S 5.05 6 7 -1 13 14 -38.33 -8236 100 hour >20 hour >10 hour 102.14 5500 134.15 28344321 Sci Rep. 2017 Mar 8;7:43610. "Mathieu C, Augusto MT, Niewiesk S, Horvat B, Palermo LM, Sanna G, Madeddu S, Huey D, Castanho MA, Porotto M, Santos NC, Moscona A" Broad spectrum antiviral activity for paramyxoviruses is modulated by biophysical properties of fusion inhibitory peptides 10.1038/srep43610 Anti-HPIV 3 DRAVPe01792 VALDPIDIAnti-SIVLNKAKSDLEESKEWIRRSNGKLDSIGSGSGX 42 VG-Chol Synthetic construct No entry found None HPIV 3 Paramyxoviridae Plaque reduction assay "[Ref.28344321]Human parainfluenza viruse 3(HPIV 3): inhibition of virus infection in Vero cells(IC90=0.7 ± 0.26 nM,IC50=0.015 ± 0.07 nM)." No hemolysis information or data found in the reference(s) presented in this entry [Ref.28344321]Vero cells: CC50+10000 nM. DRAVPe01792.cif Linear Acetylation Amidation The 'X' at position 42 indicates cholesterol-conjugated cysteine. L membrane "Peptides derived from the HRC of paramyxovirus F proteins interfere with formation of the six-helix bundle in a dominant-negative manner by binding to the transiently exposed HRN coiled coil in the transient fusion intermediate, thereby inhibiting membrane fusion." 4510.27 C190H316N54O64 CFHMQTY S 5.05 6 7 -1 13 14 -38.33 -8236 100 hour >20 hour >10 hour 102.14 5500 134.15 28344321 Sci Rep. 2017 Mar 8;7:43610. "Mathieu C, Augusto MT, Niewiesk S, Horvat B, Palermo LM, Sanna G, Madeddu S, Huey D, Castanho MA, Porotto M, Santos NC, Moscona A" Broad spectrum antiviral activity for paramyxoviruses is modulated by biophysical properties of fusion inhibitory peptides 10.1038/srep43610 Anti-HPIV 3 DRAVPe01793 VALDPIDIAnti-SIVLNKAKSDLEESKEWIRRSNGKLDSIGSGSGX 42 VG-PEG4-Chol Synthetic construct No entry found None HPIV 3 Paramyxoviridae Plaque reduction assay "[Ref.28344321]Human parainfluenza viruse 3(HPIV 3): inhibition of virus infection in Vero cells(IC90=0.7 ± 0.007 nM,IC50=0.03 ± 0.04 nM)." No hemolysis information or data found in the reference(s) presented in this entry [Ref.28344321]Vero cells: CC50=4500 nM. DRAVPe01793.cif Linear Acetylation Amidation The 'X' at position 42 indicates cholesterol-PEG4 conjugated cysteine. L membrane "Peptides derived from the HRC of paramyxovirus F proteins interfere with formation of the six-helix bundle in a dominant-negative manner by binding to the transiently exposed HRN coiled coil in the transient fusion intermediate, thereby inhibiting membrane fusion." 4510.27 C190H316N54O64 CFHMQTY S 5.05 6 7 -1 13 14 -38.33 -8236 100 hour >20 hour >10 hour 102.14 5500 134.15 28344321 Sci Rep. 2017 Mar 8;7:43610. "Mathieu C, Augusto MT, Niewiesk S, Horvat B, Palermo LM, Sanna G, Madeddu S, Huey D, Castanho MA, Porotto M, Santos NC, Moscona A" Broad spectrum antiviral activity for paramyxoviruses is modulated by biophysical properties of fusion inhibitory peptides 10.1038/srep43610 Anti-HPIV 3 DRAVPe01791 VALDPIDIAnti-SIVLNKAKSDLEESKEWIRRSNGKLDSIGSGSGC 42 VG Synthetic construct No entry found None HPIV 3 Paramyxoviridae Plaque reduction assay "[Ref.28344321]Human parainfluenza viruse 3(HPIV 3): inhibition of virus infection in Vero cells(IC90=280 ± 247 nM,IC50=1 nM)." No hemolysis information or data found in the reference(s) presented in this entry [Ref.28344321]Vero cells: CC50>10000 nM. DRAVPe01791.cif Linear Acetylation Amidation None L membrane "Peptides derived from the HRC of paramyxovirus F proteins interfere with formation of the six-helix bundle in a dominant-negative manner by binding to the transiently exposed HRN coiled coil in the transient fusion intermediate, thereby inhibiting membrane fusion." 4502.08 C193H323N55O66S FHMQTY S 5.05 6 7 -1 14 14 -32.38 -8108 100 hour >20 hour >10 hour 102.14 5500 134.15 28344321 Sci Rep. 2017 Mar 8;7:43610. "Mathieu C, Augusto MT, Niewiesk S, Horvat B, Palermo LM, Sanna G, Madeddu S, Huey D, Castanho MA, Porotto M, Santos NC, Moscona A" Broad spectrum antiviral activity for paramyxoviruses is modulated by biophysical properties of fusion inhibitory peptides 10.1038/srep43610 Anti-HPIV 3 DRAVPe01790 SKVNGQSGRMEFFWTIAK 18 m15 /Leu17 Synthetic construct(derived from influenza viral HA) No entry found None Influenza A virus Orthomyxoviridae Infection assay [Ref.27623031]Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(>60% inhibition at 30 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe01790.cif Linear Free Free None L HA receptor binding domain (RBD) Block the HA–cell interactions by binding to the influenza host cell receptor sialyllactose and thus inhibit the viral entry. 2086.4 C94H144N26O26S CDHLPY FGKS 9.99 3 1 2 6 6 -48.89 -3109 1.9 hour >20 hour >10 hour 43.33 5500 323.53 27623031 ACS Infect Dis. 2016 Mar 11;2(3):187-93 "Chen Q, Guo Y" Influenza Viral Hemagglutinin Peptide Inhibits Influenza Viral Entry by Shielding the Host Receptor 10.1021/acsinfecdis.5b00139 Anti-Anti-Influenza A virus DRAVPe01789 SKVNGQSGRMEFFWTALK 18 m14 /lle16 Synthetic construct(derived from influenza viral HA) No entry found None Influenza A virus Orthomyxoviridae Infection assay [Ref.27623031]Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(>10% inhibition at 30 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe01789.cif Linear Free Free None L HA receptor binding domain (RBD) Block the HA–cell interactions by binding to the influenza host cell receptor sialyllactose and thus inhibit the viral entry. 2086.4 C94H144N26O26S CDHIPY FGKS 9.99 3 1 2 6 6 -52.78 -3109 1.9 hour >20 hour >10 hour 43.33 5500 323.53 27623031 ACS Infect Dis. 2016 Mar 11;2(3):187-93 "Chen Q, Guo Y" Influenza Viral Hemagglutinin Peptide Inhibits Influenza Viral Entry by Shielding the Host Receptor 10.1021/acsinfecdis.5b00139 Anti-Anti-Influenza A virus DRAVPe01787 SKVNGQSGRMAFFWTILK 18 m9 /Glu11 Synthetic construct(derived from influenza viral HA) No entry found None Influenza A virus Orthomyxoviridae Infection assay [Ref.27623031]Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(>50% inhibition at 30 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe01787.cif Linear Free Free None L HA receptor binding domain (RBD) Block the HA–cell interactions by binding to the influenza host cell receptor sialyllactose and thus inhibit the viral entry. 2070.44 C95H148N26O24S CDEHPY FGKS 11.17 3 0 3 6 7 -8.33 -1936 1.9 hour >20 hour >10 hour 65 5500 323.53 27623031 ACS Infect Dis. 2016 Mar 11;2(3):187-93 "Chen Q, Guo Y" Influenza Viral Hemagglutinin Peptide Inhibits Influenza Viral Entry by Shielding the Host Receptor 10.1021/acsinfecdis.5b00139 Anti-Anti-Influenza A virus DRAVPe01788 SKVNGQSGRMEFAWTILK 18 m11 /Phe13 Synthetic construct(derived from influenza viral HA) No entry found None Influenza A virus Orthomyxoviridae Infection assay [Ref.27623031]Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(>80% inhibition at 30 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe01788.cif Linear Free Free None L HA receptor binding domain (RBD) Block the HA–cell interactions by binding to the influenza host cell receptor sialyllactose and thus inhibit the viral entry. 2052.38 C91H146N26O26S CDHPY GKS 9.99 3 1 2 6 6 -43.33 -2915 1.9 hour >20 hour >10 hour 65 5500 323.53 27623031 ACS Infect Dis. 2016 Mar 11;2(3):187-93 "Chen Q, Guo Y" Influenza Viral Hemagglutinin Peptide Inhibits Influenza Viral Entry by Shielding the Host Receptor 10.1021/acsinfecdis.5b00139 Anti-Anti-Influenza A virus DRAVPe01786 SKVNGQSGRAEFFWTILK 18 m8 /Met10 Synthetic construct(derived from influenza viral HA) No entry found None Influenza A virus Orthomyxoviridae Infection assay [Ref.27623031]Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(>80% inhibition at 30 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe01786.cif Linear Free Free None L HA receptor binding domain (RBD) Block the HA–cell interactions by binding to the influenza host cell receptor sialyllactose and thus inhibit the viral entry. 2068.36 C95H146N26O26 CDHMPY FGKS 9.99 3 1 2 6 7 -38.33 -2852 1.9 hour >20 hour >10 hour 65 5500 323.53 27623031 ACS Infect Dis. 2016 Mar 11;2(3):187-93 "Chen Q, Guo Y" Influenza Viral Hemagglutinin Peptide Inhibits Influenza Viral Entry by Shielding the Host Receptor 10.1021/acsinfecdis.5b00139 Anti-Anti-Influenza A virus DRAVPe01785 SKVNGQAGRMEFFWTILK 18 m6 /Ser7 Synthetic construct(derived from influenza viral HA) No entry found None Influenza A virus Orthomyxoviridae Infection assay [Ref.27623031]Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(~60% inhibition at 30 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe01785.cif Linear Free Free None L HA receptor binding domain (RBD) Block the HA–cell interactions by binding to the influenza host cell receptor sialyllactose and thus inhibit the viral entry. 2112.48 C97H150N26O25S CDHPY FGK 9.99 3 1 2 5 7 -23.33 -2277 1.9 hour >20 hour >10 hour 65 5500 323.53 27623031 ACS Infect Dis. 2016 Mar 11;2(3):187-93 "Chen Q, Guo Y" Influenza Viral Hemagglutinin Peptide Inhibits Influenza Viral Entry by Shielding the Host Receptor 10.1021/acsinfecdis.5b00139 Anti-Anti-Influenza A virus DRAVPe01784 SKVNGASGRMEFFWTILK 18 m5 /GIn6 Synthetic construct(derived from influenza viral HA) No entry found None Influenza A virus Orthomyxoviridae Infection assay [Ref.27623031]Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(>60% inhibition at 30 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe01784.cif Linear Free Free None L HA receptor binding domain (RBD) Block the HA–cell interactions by binding to the influenza host cell receptor sialyllactose and thus inhibit the viral entry. 2071.42 C95H147N25O25S CDHPQY FGKS 9.99 3 1 2 6 7 -8.33 -2063 1.9 hour >20 hour >10 hour 65 5500 323.53 27623031 ACS Infect Dis. 2016 Mar 11;2(3):187-93 "Chen Q, Guo Y" Influenza Viral Hemagglutinin Peptide Inhibits Influenza Viral Entry by Shielding the Host Receptor 10.1021/acsinfecdis.5b00139 Anti-Anti-Influenza A virus DRAVPe01783 SKVAGQSGRMEFFWTILK 18 m4 /Asn4 Synthetic construct(derived from influenza viral HA) No entry found None Influenza A virus Orthomyxoviridae Infection assay [Ref.27623031]Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(>70% inhibition at 30 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe01783.cif Linear Free Free None L HA receptor binding domain (RBD) Block the HA–cell interactions by binding to the influenza host cell receptor sialyllactose and thus inhibit the viral entry. 2085.45 C96H149N25O25S CDHNPY FGKS 9.99 3 1 2 5 7 -8.33 -1953 1.9 hour >20 hour >10 hour 65 5500 323.53 27623031 ACS Infect Dis. 2016 Mar 11;2(3):187-93 "Chen Q, Guo Y" Influenza Viral Hemagglutinin Peptide Inhibits Influenza Viral Entry by Shielding the Host Receptor 10.1021/acsinfecdis.5b00139 Anti-Anti-Influenza A virus DRAVPe01782 SKANGQSGRMEFFWTILK 18 m3 /Val3 Synthetic construct(derived from influenza viral HA) No entry found None Influenza A virus Orthomyxoviridae Infection assay [Ref.27623031]Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(>50% inhibition at 30 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe01782.cif Linear Free Free None L HA receptor binding domain (RBD) Block the HA–cell interactions by binding to the influenza host cell receptor sialyllactose and thus inhibit the viral entry. 2100.42 C95H146N26O26S CDHPVY FGKS 9.99 3 1 2 6 6 -51.11 -3021 1.9 hour >20 hour >10 hour 48.89 5500 323.53 27623031 ACS Infect Dis. 2016 Mar 11;2(3):187-93 "Chen Q, Guo Y" Influenza Viral Hemagglutinin Peptide Inhibits Influenza Viral Entry by Shielding the Host Receptor 10.1021/acsinfecdis.5b00139 Anti-Anti-Influenza A virus DRAVPe01781 SAVNGQSGRMEFFWTILK 18 m2 /Arg2 Synthetic construct(derived from influenza viral HA) No entry found None Influenza A virus Orthomyxoviridae Infection assay [Ref.27623031]Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(~20% inhibition at 30 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe01781.cif Linear Free Free None L HA receptor binding domain (RBD) Block the HA–cell interactions by binding to the influenza host cell receptor sialyllactose and thus inhibit the viral entry. 2071.38 C94H143N25O26S CDHPY FGS 8.46 2 1 1 6 7 -6.11 -2062 1.9 hour >20 hour >10 hour 65 5500 323.53 27623031 ACS Infect Dis. 2016 Mar 11;2(3):187-93 "Chen Q, Guo Y" Influenza Viral Hemagglutinin Peptide Inhibits Influenza Viral Entry by Shielding the Host Receptor 10.1021/acsinfecdis.5b00139 Anti-Anti-Influenza A virus DRAVPe01780 AKVNGQSGRMEFFWTILK 18 m1 /Ser1 Synthetic construct(derived from influenza viral HA) No entry found None Influenza A virus Orthomyxoviridae Infection assay [Ref.27623031]Pseudovirus influenza A virus(HA(VN/04)/HIV): inhibition of virus entry into Madin Darby canine kidney (MDCK) cells(>20% inhibition at 30 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe01780.cif Linear Free Free None L HA receptor binding domain (RBD) Block the HA–cell interactions by binding to the influenza host cell receptor sialyllactose and thus inhibit the viral entry. 2112.48 C97H150N26O25S CDHPY FGK 9.99 3 1 2 5 7 -23.33 -2277 4.4 hour >20 hour >10 hour 65 5500 323.53 27623031 ACS Infect Dis. 2016 Mar 11;2(3):187-93 "Chen Q, Guo Y" Influenza Viral Hemagglutinin Peptide Inhibits Influenza Viral Entry by Shielding the Host Receptor 10.1021/acsinfecdis.5b00139 Anti-Anti-Influenza A virus DRAVPe01779 PxTXXLPX 8 "Plitidepsin, Aplidine" Synthetic construct No entry found None SARS-CoV-2 Coronaviridae antiviral assay "[Ref.33495306]SARS-CoV-2:inhibition of replication In Vero E6 cells(IC50=0.70 nM,IC90=1.76 nM);inhibition of replication In hACE2-HEK293T cells(IC50=0.73 nM,IC90=0.88 nM);inhibition of replication In pneumocyte-like cells(IC50=1.62 nM,IC90=3.14 nM).##[Ref.35231500]SARS-CoV-2 D614G:inhibition of replication in Vero E6 cells(IC50=5.2 nM);##SARS-CoV-2 Delta:inhibition of replication in Vero E6 cells(IC50=3.9 nM);##SARS-CoV-2 Omicron:inhibition of replication in Vero E6 cells(IC50=4.3 nM)." No hemolysis information or data found in the reference(s) presented in this entry "[Ref.33495306]Vero E6 cells:CC10=0.36 nM,CC50=1.99 nM;hACE2-293T cells:CC10=2.00 nM,CC50>200 nM;pneumocyte-like cells:CC10=20.88 nM,CC50=65.43 nM." DRAVPe01779.cif Linear Pyruvoyl Free "The 'X' at position 2 is N-methylleucine,position 4 is 4-amino-3-hydroxy-5-methyl-Heptanoic acid, position 5 is Hydroxyisovalerylpropionyl, and position 8 is N-methyl-4-methyl-tyrosine.There is a Sidechain-Mainchain Bond between position 3 and 8." Mixed(D-meth-Leu2) Not found The antiviral activity of plitidepsin against SARS-CoV-2 is mediated through inhibition of the known target eEF1A (eukaryotic translation elongation factor 1A). 871.84 C20H26N4O2 ACDEFGHIKMNQRSVWY X 5.96 0 0 0 1 1 -1.25 235 >20 hour >20 hour ? 48.75 0 0 35231500##33495306 Antiviral Res. 2022 Apr;200:105270.##Science. 2021 Feb 26;371(6532):926-931. "Sachse M, Tenorio R, Fernández de Castro I, Muñoz-Basagoiti J, Perez-Zsolt D, Raïch-Regué D, Rodon J, Losada A, Avilés P, Cuevas C, Paredes R, Segalés J, Clotet B, Vergara-Alert J, Izquierdo-Useros N, Risco C.##White KM, Rosales R, Yildiz S, Kehrer T, Miorin L, Moreno E, Jangra S, Uccellini MB, Rathnasinghe R, Coughlan L, Martinez-Romero C, Batra J, Rojc A, Bouhaddou M, Fabius JM, Obernier K, Dejosez M, Guillén MJ, Losada A, Avilés P, Schotsaert M, Zwaka T, Vignuzzi M, Shokat KM, Krogan NJ, Garc" Unraveling the antiviral activity of plitidepsin against SARS-CoV-2 by subcellular and morphological analysis.##Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A. 10.1016/j.antiviral.2022.105270##10.1126/science.abf4058 Anti-SARS-CoV-2 DRAVPe01778 XxXVXAaXXXX 11 "Alisporivir, Debio-025" Synthetic construct No entry found None SARS-CoV-2 Coronaviridae plaque assay "[Ref.32376613]SARS-CoV-2:Inhibition of infection in Vero E6 cells(EC50=0.46±0.04 µM,E90=3.10±1.40 μM).##[Ref.32568027]SARS-CoV-2:Inhibition of infection in Vero E6 cells(EC50=4.9±1.3 µM);##SARS-CoV:Inhibition of infection in Vero E6 cells(EC50=4.3±1.0 µM)." No hemolysis information or data found in the reference(s) presented in this entry [Ref.32376613]Vero E6 cells:CC50>20µM. DRAVPe01778.cif Cyclic No specific N-terminal No specific C-terminal "The 'X' at position 1 is alpha-aminobutyric acid,position 2 is N-methylalanine,the 'V' at position 3 is N-methylalanine,the 'X' at position 5,8,9 are N-methylleucine,the 'X' at position 10 is N-methylvaline and position 11 is N-methyl-(4R)-4-[(E)-but-2-enyl]-4-methyl-L-threonyl" "Mixed(D-Ala7,D-meth-Ala2)" Not found Comment: No comments found on DRAMP database 0 C8H-2N2O-6 CDEFGHIKLMNPQRSTWY X 0 0 0 0 0 2 54.55 585 35.45 0 0 32376613##32568027 Antimicrob Agents Chemother. 2020 Jun 23;64(7):e00876-20. ##J Gen Virol. 2020 Sep;101(9):925-940. "Softic L, Brillet R, Berry F, Ahnou N, Nevers Q, Morin-Dewaele M, Hamadat S, Bruscella P, Fourati S, Pawlotsky JM, Ahmed-Belkacem A.##Ogando NS, Dalebout TJ, Zevenhoven-Dobbe JC, Limpens RWAL, van der Meer Y, Caly L, Druce J, de Vries JJC, Kikkert M, Bárcena M, Sidorov I, Snijder EJ." "Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025).##SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology." 10.1128/AAC.00876-20##10.1099/jgv.0.001453 Anti-SARS-CoV-2 DRAVPe01777 ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL 35 P3 Synthetic construct No entry found None SARS-CoV-2 Coronaviridae Neutralizing assay [Ref.32482145]HCoV-19:inhibition of HCoV-19 S mediated cell–cell fusion(EC50=0.72 μM);neutralizing activities against pseudotype HCoV-19 virus(EC50=0.32 μM);inhibition of authentic HCoV-19 virus infection in Vero E6 cells(EC50=0.58 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01777.cif Linear Free Free None L Not found Comment: No comments found on DRAMP database 3893.41 C168H287N47O58 CFHMPTWY ILN 4.36 3 6 -3 9 15 -8.29 -5930 20 hour 30 min >10 hour 142 0 0 32482145 Emerg Microbes Infect. 2020 Dec;9(1):1238-1241. "Sun H, Li Y, Liu P, Qiao C, Wang X, Wu L, Liu K, Hu Y, Su C, Tan S, Zou S, Wu G, Yan J, Gao GF, Qi J, Wang Q. " Structural basis of HCoV-19 fusion core and an effective inhibition peptide against virus entry. 10.1080/22221751.2020.1770631 Anti-SARS-CoV-2 DRAVPe01776 RGAHIKGRWKSRCHRF 16 FBP Synthetic construct No entry found None SARS-CoV-2 Coronaviridae Plaque reduction assay "[Ref.35259078]A(H1N1)(IC50 = 3.9 μg/ml);A(H3N2)(IC50 = 1.6 μg/ml);FluB (IC50 = 7.1 μg/ml);##SARS-CoV-2 (HKU001a):inhibition of infection in Vero-E6 cells(IC50=2.9 μg/ml);##SARS-CoV-2 (B.1.1.63, D614G):inhibition of infection in Vero-E6 cells(IC50=3.0 μg/ml);##SARS-CoV-2(Delta):inhibition of infection in Vera-E6 cells(IC50=3.9 μg/ml)." [Ref.35259078]No significant hemolysis against Turkey red blood cells (RBC). [Ref.35259078]No significant cytotoxicity was detected in MDCK(Madin Darby canine kidney) cells at 1 mg/ml(TC50 > 1 mg/ml). DRAVPe01776.cif Linear Free Free None L membrane The fusion-inhibition peptide FBP could broadly inhibit influenza virus and SARS-CoV-2 by interfering the viral fusion by the endocytic pathway and showed potently antiviral activity against the influenza virus in mice and SARS-CoV-2 variants in hamsters. 1995.34 C87H139N35O18S DELMNPQTVY R 12.01 8 0 8 4 4 -144.38 -6830 1 hour 2 min 2 min 30.63 5500 366.67 35259078 Emerg Microbes Infect. 2022 Dec;11(1):926-937. "Zhao H, Meng X, Peng Z, Lam H, Zhang C, Zhou X, Chan JF, Kao RYT, To KK, Yuen KY." "Fusion-inhibition peptide broadly inhibits influenza virus and SARS-CoV-2, including Delta and Omicron variants." 10.1080/22221751.2022.2051753 Anti-SARS-CoV-2 DRAVPe01775 SALEEQYKTFLDKFMHELEDLLYQLAL 27 P10 Synthetic construct No entry found None SARS-CoV-2 Coronaviridae plaque assay [Ref.33580154]SARS-CoV-2:95% inhibition of replication in Vero-E6 cells at 10 μM;inhibition of replication in Calu-3 cells(IC50=42 nM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.33580154]The peptide proved to be devoid of cell toxicity on Vero-E6 and Calu-3 cells. DRAVPe01775.cif Linear Free Amidation None L Not found "The peptide was designed mimicking the N-terminal helix of hACE2 protein,which could prevent the SARS-CoV-2 from infecting human cells, blocking the interaction between hACE2 and the virus spike protein." 3288.76 C152H231N33O46S CGINPRVW L 4.35 3 6 -3 4 11 -20 -3140 1.9 hour >20 hour >10 hour 108.52 2980 114.62 33580154 Commun Biol. 2021 Feb 12;4(1):197. "Karoyan P, Vieillard V, Gómez-Morales L, Odile E, Guihot A, Luyt CE, Denis A, Grondin P, Lequin O." Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection. 10.1038/s42003-021-01736-8 Anti-SARS-CoV-2 DRAVPe01774 SALEEQYKTFLDKFMHELEDLLYQLSL 27 P9 Synthetic construct No entry found None SARS-CoV-2 Coronaviridae plaque assay [Ref.33580154]SARS-CoV-2:93% inhibition of replication in Vero-E6 cells at 10 μM;inhibition of replication in Calu-3 cells(IC50=53 nM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.33580154]The peptide proved to be devoid of cell toxicity on Vero-E6 and Calu-3 cells. DRAVPe01774.cif Linear Free Amidation None L Not found "The peptide was designed mimicking the N-terminal helix of hACE2 protein,which could prevent the SARS-CoV-2 from infecting human cells, blocking the interaction between hACE2 and the virus spike protein." 3304.76 C152H231N33O47S CGINPRVW L 4.35 3 6 -3 5 10 -29.63 -3661 1.9 hour >20 hour >10 hour 104.81 2980 114.62 33580154 Commun Biol. 2021 Feb 12;4(1):197. "Karoyan P, Vieillard V, Gómez-Morales L, Odile E, Guihot A, Luyt CE, Denis A, Grondin P, Lequin O." Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection. 10.1038/s42003-021-01736-8 Anti-SARS-CoV-2 DRAVPe01773 SALEEQLKTFLDKFMHELEDLLYQLAL 27 P8 Synthetic construct No entry found None SARS-CoV-2 Coronaviridae plaque assay [Ref.33580154]SARS-CoV-2:91% inhibition of replication in Vero-E6 cells at 10 μM;inhibition of replication in Calu-3 cells(IC50=46 nM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.33580154]The peptide proved to be devoid of cell toxicity on Vero-E6 and Calu-3 cells. DRAVPe01773.cif Linear Free Amidation None L Not found "The peptide was designed mimicking the N-terminal helix of hACE2 protein,which could prevent the SARS-CoV-2 from infecting human cells, blocking the interaction between hACE2 and the virus spike protein." 3238.74 C149H233N33O45S CGINPRVW L 4.35 3 6 -3 3 12 -1.11 -2634 1.9 hour >20 hour >10 hour 122.96 1490 57.31 33580154 Commun Biol. 2021 Feb 12;4(1):197. "Karoyan P, Vieillard V, Gómez-Morales L, Odile E, Guihot A, Luyt CE, Denis A, Grondin P, Lequin O." Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection. 10.1038/s42003-021-01736-8 Anti-SARS-CoV-2 DRAVPe01772 SALEEQYKTFLDKFLHELEDLLYQLALAL 29 P7 Synthetic construct No entry found None SARS-CoV-2 Coronaviridae plaque assay [Ref.33580154]SARS-CoV-2:54% inhibition of replication in Vero-E6 cells at 10 μM;inhibition of replication in Calu-3 cells(IC50>1 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01772.cif Linear Free Amidation None L Not found "The peptide was designed mimicking the N-terminal helix of hACE2 protein,which could prevent the SARS-CoV-2 from infecting human cells, blocking the interaction between hACE2 and the virus spike protein." 3454.96 C162H249N35O48 CGIMNPRVW L 4.35 3 6 -3 4 14 7.24 -2210 1.9 hour >20 hour >10 hour 131.38 2980 106.43 33580154 Commun Biol. 2021 Feb 12;4(1):197. "Karoyan P, Vieillard V, Gómez-Morales L, Odile E, Guihot A, Luyt CE, Denis A, Grondin P, Lequin O." Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection. 10.1038/s42003-021-01736-8 Anti-SARS-CoV-2 DRAVPe01771 RFDGKGLGIYQYMEEIEHAASRFAYFFYQHLA 32 Covid_extented_1 Synthetic construct No entry found None SARS-CoV-2 Coronaviridae virus neutralization assay [Ref.34624194]SARS-CoV-2:inhibition of infection in Vero cells(IC50=5.76 ± 1.65 μM);##SARS-CoV-2 variants B.1.1.7:inhibition of infection in Vero cells(IC50=5.57 ± 4.04 μM);##SARS-CoV-2 variants B.1.351:inhibition of infection in Vero cells(IC50=7.37 ± 1.80 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01771.cif Linear Acylation Amidation None D Not found The peptide acts as an inhibitor of the RBD–ACE2 interaction 3859.33 C181H253N45O48S CNPTVW AFY 6.03 5 4 1 8 12 -33.13 -4489 1 hour 2 min 2 min 61.25 5960 192.26 34624194 J Med Chem. 2021 Oct 28;64(20):14955-14967. "Valiente PA, Wen H, Nim S, Lee J, Kim HJ, Kim J, Perez-Riba A, Paudel YP, Hwang I, Kim KD, Kim S, Kim PM. " Computational Design of Potent D-Peptide Inhibitors of SARS-CoV-2. 10.1021/acs.jmedchem.1c00655 Anti-SARS-CoV-2 DRAVPe01770 LQTALYALMEEIHIAALEKTWTALRHQYT 29 Covid3 Synthetic construct No entry found None SARS-CoV-2 Coronaviridae virus neutralization assay [Ref.34624194]SARS-CoV-2:inhibition of infection in Vero cells(IC50=6.56 ± 2.14 μM);##SARS-CoV-2 variants B.1.1.7:inhibition of infection in Vero cells(IC50=33.40 ± 10.75 μM);##SARS-CoV-2 variants B.1.351:inhibition of infection in Vero cells(IC50=11.13 ± 3.82 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01770.cif Linear Acylation Amidation None D Not found The peptide acts as an inhibitor of the RBD–ACE2 interaction 3415.95 C156H244N40O44S CDFGNPSV AL 6.02 4 3 1 6 13 1.03 -2369 5.5 hour 3 min 2 min 111.38 8480 302.86 34624194 J Med Chem. 2021 Oct 28;64(20):14955-14967. "Valiente PA, Wen H, Nim S, Lee J, Kim HJ, Kim J, Perez-Riba A, Paudel YP, Hwang I, Kim KD, Kim S, Kim PM. " Computational Design of Potent D-Peptide Inhibitors of SARS-CoV-2. 10.1021/acs.jmedchem.1c00655 Anti-SARS-CoV-2 DRAVPe01769 RVKR 4 CMK Synthetic construct No entry found None SARS-CoV-2 Coronaviridae Plaque assay "[Ref.33007239]SARS-CoV-2:inhibition of virus production in Vero E6 cells(IC50=0.057 µM).##[Ref.31683742]Virus:Zika virus (ZIKV):inhibition of virus release in Vero cells(IC50=18.59 µM);Japanese encephalitis virus (JEV):inhibition of virus release in BHK-21 cells(IC50=19.91 µM).##[Ref.23617302]Hepatitis B virus (HBV):Inhibition of HBeAg secretion in HepG2.2.15 cells(26±11% inhibition at 20 µM,21±13% Inhibition at 100 µM)." No hemolysis information or data found in the reference(s) presented in this entry [Ref.31683742]Vero cells:CC50=712.9 µM.##[Ref.33007239]Vero E6 cells:IC50=318.2 µM. DRAVPe01769.cif Linear Decanoyl(C10) chloromethylketone(CMK) None L Not found "CMK blocks virus entry, but it further suppresses cleavage of spikes and the syncytium." 557.7 C23H47N11O5 ACDEFGHILMNPQSTWY R 12.01 3 0 3 0 1 -217.5 -3135 1 hour 2 min 2 min 72.5 0 0 23617302##31683742##33007239 Liver Int. 2013 Sep;33(8):1230-8. ##Viruses. 2019 Oct 31;11(11):1011.##Cell Rep. 2020 Oct 13;33(2):108254. "Pang YJ, Tan XJ, Li DM, Zheng ZH, Lei RX, Peng XM.##Imran M, Saleemi MK, Chen Z, Wang X, Zhou D, Li Y, Zhao Z, Zheng B, Li Q, Cao S, Ye J.##Cheng YW, Chao TL, Li CL, Chiu MF, Kao HC, Wang SH, Pang YH, Lin CH, Tsai YM, Lee WH, Tao MH, Ho TC, Wu PY, Jang LT, Chen PJ, Chang SY, Yeh SH." Therapeutic potential of furin inhibitors for the chronic infection of hepatitis B virus.##Decanoyl-Arg-Val-Lys-Arg-Chloromethylketone: An Antiviral Compound That Acts against Flaviviruses through the Inhibition of Furin-Mediated prM Cleavage.##Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects. 10.1111/liv.12185##10.3390/v11111011##10.1016/j.celrep.2020.108254 Anti-SARS-CoV-2 DRAVPe01768 PHSCN 5 ATN-161 Synthetic construct No entry found None SARS-CoV-2 Coronaviridae ELISA [Ref.33102950]SARS-CoV-2:inhibition of virus replication In VeroE6 cells(IC50=3.16 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01768.cif Linear Acylation Amidation None L Not found The peptide inhibits the spike protein interaction with α5β1 integrin and the interaction between α5β1 integrin and ACE2. 556.59 C21H32N8O8S ADEFGIKLMQRTVWY CHNPS 7.12 1 0 1 3 0 -132 -1342 >20 hour >20 hour ? 0 0 0 33102950 JACC Basic Transl Sci. 2021 Jan;6(1):1-8. "Beddingfield BJ, Iwanaga N, Chapagain PP, Zheng W, Roy CJ, Hu TY, Kolls JK, Bix GJ." "The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection." 10.1016/j.jacbts.2020.10.003 Anti-SARS-CoV-2 DRAVPe01767 ANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQ 42 SARS-CoV-2 HR1P Synthetic construct P0DTC2 None SARS-CoV-2 Coronaviridae Cell-cell fusion assay "[Ref.32047258]SARS-CoV-2(No inhibition of cell-cell fusion up to 40 µM in Huh-7 cells,No inhibition of infection up to 40 µM in 293T/ACE2 cells)" No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01767.cif Linear Free Free None L Not found The peptide acted as a fusion inhibitor which against SARS-CoV-2 S protein-mediated membrane fusion and pseudovirus infection. 4386.89 C187H314N56O65 CEHMPRWY AQ 8.54 3 2 1 14 17 -21.9 -6039 4.4 hour >20 hour >10 hour 100 0 0 32047258 Cell Mol Immunol. 2020 Jul;17(7):765-767. "Xia S, Zhu Y, Liu M, Lan Q, Xu W, Wu Y, Ying T, Liu S, Shi Z, Jiang S, Lu L." Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. 10.1038/s41423-020-0374-2 Anti-SARS-CoV-2 DRAVPe01766 SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSGC 42 EK1-GSGSGC Synthetic construct Q8BB25 None SARS-CoV-2 Coronaviridae "Cell-cell fusion assay,infectivity assay" "[Ref.33082259]SARS-CoV-2:ihibition of cell-cell fusion in 293T cells(IC50=293±60 nM,IC90>900 nM),inhibition of infection in Vero E6 cells(IC50~ 41 nM);##SARS-CoV-2_D614G:ihibition of cell-cell fusion in 293T cells(IC50=261±136 nM,IC90=892±100 nM);##SARS-CoV-2_S943P:ihibition of cell-cell fusion in 293T cells(IC50=286±104 nM,IC90>1000 nM);##SARS-CoV-2_S247R:ihibition of cell-cell fusion in 293T cells(IC50=194±107 nM,IC90=893±77 nM);##MERS-CoV:ihibition of cell-cell fusion in 293T cells(IC50>1000 nM,IC90>1000 nM),inhibition of infection in Vero E6 cells(IC50~ 2 nM);##SARS-CoV-1:ihibition of cell-cell fusion in 293T cells(IC50=36±5 nM,IC90>1000 nM)." No hemolysis information or data found in the reference(s) presented in this entry [Ref.33082259]Human embryonic kidney HEK293T cells:<5% Cytotoxicity at 10 µM;Vero E6 cells:18% Cytotoxicity at 10 µM. DRAVPe01766.cif Linear Free Free None L membrane The lipopeptide is derived from the C-terminal heptad repeat (HRC) domain of SARS-CoV-2 S that potently inhibits infection by SARS-CoV-2. 4780.43 C211H341N49O72S2 HPRW EL 4.36 5 10 -5 12 13 -37.86 -6573 1.9 hour >20 hour >10 hour 102.14 2980 72.68 33082259 mBio. 2020 Oct 20;11(5):e01935-20. "Outlaw VK, Bovier FT, Mears MC, Cajimat MN, Zhu Y, Lin MJ, Addetia A, Lieberman NAP, Peddu V, Xie X, Shi PY, Greninger AL, Gellman SH, Bente DA, Moscona A, Porotto M." Inhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain. 10.1128/mBio.01935-20 Anti-SARS-CoV-2 DRAVPe01765 SLTQINTTLLDLTYEMLSLQQVVKALNESYIDLKELGSGSGC 42 MERS-CoV-HR2P-GSGSGC Synthetic construct "R9UQ53,K9N5Q8" None SARS-CoV-2 Coronaviridae "Cell-cell fusion assay,infectivity assay" "[Ref.33082259]SARS-CoV-2:ihibition of cell-cell fusion in 293T cells(IC50>650 nM,IC90>1000 nM),inhibition of infection in Vero E6 cells(IC50~ 36 nM);##SARS-CoV-2_D614G:ihibition of cell-cell fusion in 293T cells(IC50=1000 nM,IC90>1000 nM);##SARS-CoV-2_S943P:ihibition of cell-cell fusion in 293T cells(IC50>1000,IC90>1000 nM);##SARS-CoV-2_S247R:ihibition of cell-cell fusion in 293T cells(IC50>700 nM,IC90>1000 nM);##MERS-CoV:ihibition of cell-cell fusion in 293T cells(IC50=417±180 nM,IC90>1000 nM),inhibition of infection in Vero E6 cells(IC50~ 4 nM);##SARS-CoV-1:ihibition of cell-cell fusion in 293T cells(IC50=40±34 nM,IC90>700 nM)." No hemolysis information or data found in the reference(s) presented in this entry [Ref.33082259]Human embryonic kidney HEK293T cells:<10% Cytotoxicity at 10 µM;Vero E6 cells:12% Cytotoxicity at 10 µM. DRAVPe01765.cif Linear Free Free None L membrane The lipopeptide is derived from the C-terminal heptad repeat (HRC) domain of SARS-CoV-2 S that potently inhibits infection by SARS-CoV-2. 4590.23 C200H331N49O69S2 FHPRW L 4.18 2 5 -3 17 14 10.48 -3597 1.9 hour >20 hour >10 hour 118.33 2980 72.68 33082259 mBio. 2020 Oct 20;11(5):e01935-20. "Outlaw VK, Bovier FT, Mears MC, Cajimat MN, Zhu Y, Lin MJ, Addetia A, Lieberman NAP, Peddu V, Xie X, Shi PY, Greninger AL, Gellman SH, Bente DA, Moscona A, Porotto M." Inhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain. 10.1128/mBio.01935-20 Anti-SARS-CoV-2 DRAVPe01764 DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGSGSGC 42 SARS-CoV-2-S(1168–1203)-GSGSGC Synthetic construct P0DTC2 None SARS-CoV-2 Coronaviridae "Cell-cell fusion assay,infectivity assay" "[Ref.33082259]SARS-CoV-2:ihibition of cell-cell fusion in 293T cells(IC50=10±8 nM,IC90=98±57 nM),inhibition of infection in Vero E6 cells(IC50~ 6 nM);##SARS-CoV-2_D614G:ihibition of cell-cell fusion in 293T cells(IC50=8±4 nM,IC90=96±50 nM);##SARS-CoV-2_S943P:ihibition of cell-cell fusion in 293T cells(IC50=6±4 nM,IC90=75±42 nM);##SARS-CoV-2_S247R:ihibition of cell-cell fusion in 293T cells(IC50=9±7 nM,IC90=78±59 nM);##MERS-CoV:ihibition of cell-cell fusion in 293T cells(IC50=35±10 nM,IC90>1000 nM),inhibition of infection in Vero E6 cells(IC50~ 3 nM);##SARS-CoV-1:ihibition of cell-cell fusion in 293T cells(IC50=7±5 nM,IC90=43±6 nM)." No hemolysis information or data found in the reference(s) presented in this entry "[Ref.33082259]Human embryonic kidney HEK293T cells:18% Cytotoxicity at 10 µM;Vero E6 cells:12% Cytotoxicity at 1 µM,30% Cytotoxicity at 10 µM;Human airway epithelial cells:25% Cytotoxicity at 1 µM." DRAVPe01764.cif Linear Free Free None L membrane The lipopeptide is derived from the C-terminal heptad repeat (HRC) domain of SARS-CoV-2 S that potently inhibits infection by SARS-CoV-2. 4456.95 C187H316N54O69S FHMPTWY ILNS 4.2 3 7 -4 15 15 -15.95 -7072 1.1 hour 3 min >10 hour 118.33 0 0 33082259##33597220 mBio. 2020 Oct 20;11(5):e01935-20.##Science. 2021 Mar 26;371(6536):1379-1382. "Outlaw VK, Bovier FT, Mears MC, Cajimat MN, Zhu Y, Lin MJ, Addetia A, Lieberman NAP, Peddu V, Xie X, Shi PY, Greninger AL, Gellman SH, Bente DA, Moscona A, Porotto M.##de Vries RD, Schmitz KS, Bovier FT, Predella C, Khao J, Noack D, Haagmans BL, Herfst S, Stearns KN, Drew-Bear J, Biswas S, Rockx B, McGill G, Dorrello NV, Gellman SH, Alabi CA, de Swart RL, Moscona A, Porotto M." Inhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain.##Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets. 10.1128/mBio.01935-20##10.1126/science.abf4896 Anti-SARS-CoV-2 DRAVPe01763 NGAICWGPCPTAFRQIGNCGRFRVRCCRIR 30 8P9R(branched P9R) Synthetic construct No entry found None SARS-CoV-2 Coronaviridae Plaque reduction assay [Ref.33750821]SARS-CoV-2:inhibition of replication in high salt condition(IC50 = 0.3 μg/ml) [Ref.33750821]No obvious hemolysis was observed when turkey red blood cells were treated at 200 μg/ml. [Ref.33750821]Vero-E6 cells:the cytotoxicity indicated that TC50 of 8P9R was higher than 200 μg/ml. DRAVPe01763.cif Branched Free Free None L Not found Have dual-antiviral mechanisms of cross-linking viruses to stop viral entry (mediated by TMPRSS2 for SARS-CoV-2) and of reducing endosomal acidification to inhibit viral entry through endocytic pathway. 3412.05 C144H232N52O35S5 DEHKLMSY R 10.46 6 0 6 12 9 -15 -7004 1.4 hour 3 min >10 hour 55.33 5750 198.28 33750821 Nat Commun. 2021 Mar 9;12(1):1517. "Zhao H, To KKW, Lam H, Zhou X, Chan JF, Peng Z, Lee ACY, Cai J, Chan WM, Ip JD, Chan CC, Yeung ML, Zhang AJ, Chu AWH, Jiang S, Yuen KY." Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2. 10.1038/s41467-021-21825-w Anti-SARS-CoV-2 DRAVPe01762 NGAICWGPCPTAFRQIGNCGRFRVRCCRIR 30 "MBD-4 (11-40) (P9 [H21R,K23R,K28R], P9R)" Synthetic construct P82019 6M56 SARS-CoV-2 Coronaviridae Plaque reduction assay [Ref.32843628]SARS-CoV-2:Inhibition of infection in Vero E6 cells(IC50=0.9 µg/ml);##SARS-CoV:Inhibition of infection in Vero E6 cells(IC50=4.2 µg/ml);##MERS-CoV:Inhibition of infection in Vero E6 cells(IC50=22 µg/ml);##Human rhinovirus (HRV):inhibition of infection in RD cells(IC50=5.7 µg/ml);##Human parainfluenza virus 3:Inhibition of infection in LLC-MK2 cells(IC50>25 µg/ml);##Human Influenza A Virus H1N1:Inhibition of infection In MDCK cells(IC50=0.6 µg/ml);##Human Influenza A Virus H7N9:Inhibition of infection In MDCK cells(IC50=0.9 µg/ml). [Ref.32843628]P9R did not cause the hemolysis of Chicken red blood cells. "[Ref.32843628]The CC50 of P9R was >300 μg/ml for MDCK, VeroE6 and A549 cells." DRAVPe01762.cif Linear Free Free None L Not found Mechanistic studies show that positively charged P9R broadly inhibits viral replication by binding to different viruses and then inhibits virus–host endosomal acidification to prevent the endosomal release of pH-dependent viruses. 3412.05 C144H232N52O35S5 DEHKLMSY R 10.46 6 0 6 12 9 -15 -7004 1.4 hour 3 min >10 hour 55.33 5750 198.28 32843628 Nat Commun. 2020 Aug 25;11(1):4252. "Zhao H, To KKW, Sze KH, Yung TT, Bian M, Lam H, Yeung ML, Li C, Chu H, Yuen KY." A broad-spectrum virus- and host-targeting peptide against respiratory viruses including influenza virus and SARS-CoV-2. 10.1038/s41467-020-17986-9 Anti-SARS-CoV-2 DRAVPe01761 NGAICWGPCPTAFRQIGNCGHFKVRCCKIR 30 MBD-4 (11-40)(P9) Synthetic construct P82019 6M56 SARS-CoV-2 Coronaviridae Plaque reduction assay [Ref.32843628]SARS-CoV-2:Inhibition of infection in Vero E6 cells(IC50=2.4 µg/ml);##SARS-CoV:Inhibition of infection in Vero E6 cells(IC50=6.2 µg/ml);##MERS-CoV:Inhibition of infection in Vero E6 cells(IC50=8.8 µg/ml);##Human rhinovirus (HRV):inhibition of infection in RD cells(IC50=34 µg/ml);##Human parainfluenza virus 3:Inhibition of infection in LLC-MK2 cells(IC50>25 µg/ml);##Human Influenza A Virus H1N1:Inhibition of infection In MDCK cells(IC50=1.6 µg/ml);##Human Influenza A Virus H7N9:Inhibition of infection In MDCK cells(IC50=3.3 µg/ml).##[Ref.26911565]Human Influenza A Virus H1N1(IC50=1.2 µg/ml);Human Influenza A Virus H3N2(IC50=1.2 µg/ml);Human Influenza A Virus H5N1(IC50=2.4 µg/ml);Human Influenza A Virus H7N7(IC50=0.8 µg/ml);Human Influenza A Virus H7N9(IC50=4.6 µg/ml);MERS-CoV(IC50=4.8 µg/ml);SARS-CoV(IC50=4.8 µg/ml) No hemolysis information or data found in the reference(s) presented in this entry [Ref.26911565]Cytotoxicity against Madin-Darby canine kidney cells(TC50=380 μg/ml). DRAVPe01761.cif Linear Free Free None L Not found Mechanistic studies show that positively charged P9 broadly inhibits viral replication by binding to different viruses and then inhibits virus–host endosomal acidification to prevent the endosomal release of pH-dependent viruses. 3336.98 C144H227N47O35S5 DELMSY C 9.41 6 0 6 12 9 -6.67 -4104 1.4 hour 3 min >10 hour 55.33 5750 198.28 26911565##32843628 Sci Rep. 2016 Feb 25;6:22008. ##Nat Commun. 2020 Aug 25;11(1):4252. "Zhao H, Zhou J, Zhang K, Chu H, Liu D, Poon VK, Chan CC, Leung HC, Fai N, Lin YP, Zhang AJ, Jin DY, Yuen KY, Zheng BJ.##Zhao H, To KKW, Sze KH, Yung TT, Bian M, Lam H, Yeung ML, Li C, Chu H, Yuen KY." A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses. ##A broad-spectrum virus- and host-targeting peptide against respiratory viruses including influenza virus and SARS-CoV-2. 10.1038/srep22008##10.1038/s41467-020-17986-9 Anti-SARS-CoV-2 DRAVPe01760 DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL 36 "2019-nCoV-HR2P(SARS-CoV-2-S(1168-1203),SARS-HR2P)" Synthetic construct Q5DIC5 None SARS-CoV-2 Coronaviridae Cell-cell fusion assay "[Ref.32047258]SARS-CoV-2:ihibition of cell-cell fusion in Huh-7 cells(IC50=0.18 µM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=0.98 µM).##[Ref.30989115]SARS-CoV:ihibition of cell-cell fusion in Huh-7 cells(IC50=0.52±0.11 µM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=2.81 µM);##MERS-CoV:ihibition of cell-cell fusion in Huh-7 cells(IC50>5 µM);##HCoV-OC43:ihibition of cell-cell fusion in Huh-7 cells(IC50>5 µM);##HCoV-229E:ihibition of cell-cell fusion in Huh-7 cells(IC50>5 µM);##HCoV-NL63:ihibition of cell-cell fusion in Huh-7 cells(IC50>5 µM);##CoV-WIV1:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=2.73 µM);##CoV-Rs3367:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=3.05 µM)." No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01760.cif Linear Free Free None L membrane 2019-nCoV HR1 and HR2 regions are able to interact with each other to form 6-HB and suggest that 2019-nCoV-HR2P may inhibit 2019-nCoV fusion with and entry into the target cell. 4008.5 C172H292N48O61 CFHMPTWY ILN 4.2 3 7 -4 9 15 -17.78 -6802 1.1 hour 3 min >10 hour 138.06 0 0 30989115##32047258 Sci Adv. 2019 Apr 10;5(4):eaav4580.##Cell Mol Immunol. 2020 Jul;17(7):765-767. "Xia S, Yan L, Xu W, Agrawal AS, Algaissi A, Tseng CK, Wang Q, Du L, Tan W, Wilson IA, Jiang S, Yang B, Lu L.##Xia S, Zhu Y, Liu M, Lan Q, Xu W, Wu Y, Ying T, Liu S, Shi Z, Jiang S, Lu L." A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike.##Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. 10.1126/sciadv.aav4580##10.1038/s41423-020-0374-2 Anti-SARS-CoV-2 DRAVPe01758 AWDFGSLGGVFTSIGKALHQVFGAIYGAA 29 DENV2 Ep (419-447) Synthetic construct Q9WDA6 None DENV-2 Flaviviridae Plaque assay [Ref.20881042]DENV2(dengue virus type 2): Inhibition of DENV-2 infection in BHK-21 cells (IC90~250µM) No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01758.cif Linear Free Free None L low-pH endosome "an initial, nonspecific interaction of the hydrophobicC terminus of the peptide inhibitor with the viral membranecarries it with the virion into the endosome, allowing aspecific interaction of the peptide with domain II as theprotein reconfigures, inhibiting the final zipping of thestem" 2941.34 C139H202N34O37 CEMNPR G 6.79 2 1 1 10 15 73.79 1974 4.4 hour >20 hour >10 hour 91.03 6990 249.64 20881042 J Virol. 2010 Dec;84(24):12549-54. "Schmidt AG, Yang PL, Harrison SC." Peptide inhibitors of flavivirus entry derived from the E protein stem. 10.1128/JVI.01440-10 Anti-Anti-DENV-2 DRAVPe01759 GDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELG 38 SARS-CoV-S (1149–1186) Synthetic construct P59594 None SARS-CoV Coronaviridae Fusion inhibition assay "[Ref.15158473]SARS-CoV: inhibition of SARS-CoV cytopathic effect in Vero E6 cells ( synthetic HR2-38 IC50=0.5-5nM, GST-HR2-38 IC50=66.2nM)" No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01759.cif Linear Free Free None L GST as GST-fusion polypeptide 4122.6 C176H298N50O63 CFHMPTWY ILN 4.2 3 7 -4 11 15 -18.95 -6614 30 hour >20 hour >10 hour 130.79 0 0 15158473 Biochem Biophys Res Commun. 2004 Jun 18;319(1):283-8. "Zhu J, Xiao G, Xu Y, Yuan F, Zheng C, Liu Y, Yan H, Cole DK, Bell JI, Rao Z, Tien P, Gao GF." Following the rule: formation of the 6-helix bundle of the fusion core from severe acute respiratory syndrome coronavirus spike protein and identification of potent peptide inhibitors. 10.1016/j.bbrc.2004.04.141 Anti-SARS-CoV DRAVPe01757 AWDFGSLGGVFTSIGKALHQVFGGAFGAA 29 "DENV2 Ep (419-447)[A24G,I25A,Y26F]" Synthetic construct Q9WDA6 None DENV-2 Flaviviridae Plaque assay [Ref.20881042]DENV2(dengue virus type 2): Inhibition of DENV-2 infection in BHK-21 cells (IC90~2µM) No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01757.cif Linear Free Free None L low-pH endosome "an initial, nonspecific interaction of the hydrophobicC terminus of the peptide inhibitor with the viral membranecarries it with the virion into the endosome, allowing aspecific interaction of the peptide with domain II as theprotein reconfigures, inhibiting the final zipping of thestem" 2869.23 C135H194N34O36 CEMNPRY G 6.79 2 1 1 10 15 71.03 1888 4.4 hour >20 hour >10 hour 77.59 5500 196.43 20881042 J Virol. 2010 Dec;84(24):12549-54. "Schmidt AG, Yang PL, Harrison SC." Peptide inhibitors of flavivirus entry derived from the E protein stem. 10.1128/JVI.01440-10 Anti-Anti-DENV-2 DRAVPe01756 ALNCYWPLNDYGFYTTTGIGYQPYRVVVLSFEL 33 SARS-CoV Sgp (471-503) Synthetic construct P59594 None SARS-CoV Coronaviridae Plaque reduction assay [Ref.16153058]SARS-CoV(Severe acute respiratory syndrome): inhibition of SARS-CoV infction in Vero cells (EC50=41.6µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01756.cif Linear Free Free None L not found "block the binding between the RBD and angiotensin-convertingenzyme 2, resulting in the inhibition of SARS-CoV entrance into host cells in vitro" 3864.39 C184H260N40O50S HKM Y 4.37 1 2 -1 15 12 16.67 -1016 4.4 hour >20 hour >10 hour 88.48 12950 404.69 16153058 J Comb Chem. 2005 Sep-Oct;7(5):648-56. "Hu H, Li L, Kao RY, Kou B, Wang Z, Zhang L, Zhang H, Hao Z, Tsui WH, Ni A, Cui L, Fan B, Guo F, Rao S, Jiang C, Li Q, Sun M, He W, Liu G." Screening and identification of linear B-cell epitopes and entry-blocking peptide of severe acute respiratory syndrome (SARS)-associated coronavirus using synthetic overlapping peptide library. 10.1021/cc0500607 Anti-SARS-CoV DRAVPe01755 SLTQINTTLLDLEYEMRSLQQVVKALNESYIDLKEL 36 "MERS-CoV-HR2P [T1263E,L1267R]" Synthetic construct K9N5Q8 None MERS-CoV Coronaviridae Cell–cell fusion [Ref.24473083]MERS-COV(Middle East respiratory syndrome coronavirus): inhibition of cell–cell fusion infection in Huh-7 and 293T/MERS/EGFP cells (IC50=0.93±0.15µM); inhibition of MERS-CoV infection in Vero cells (IC50=0.6µM); inhibition of MERS-CoV infection in Calu-3 cells (IC50=0.6µM); inhibition of MERS-CoV infection in HFL cells (IC50=13.9µM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.24473083]HR2P has low or no in vitro toxic effect. DRAVPe01755.cif Linear Free Free None L HR1 domain "interact with the viral HR1 domain to form heterologous 6-HB and block viral fusion coreformation, resulting in inhibition of MERS-CoV S protein-mediated membrane fusion." 4212.82 C186H308N46O62S CFGHPW L 4.36 3 6 -3 10 13 -17.78 -5735 1.9 hour >20 hour >10 hour 127.22 2980 85.14 24473083 Nat Commun. 2014;5:3067. "Lu L, Liu Q, Zhu Y, Chan KH, Qin L, Li Y, Wang Q, Chan JF, Du L, Yu F, Ma C, Ye S, Yuen KY, Zhang R, Jiang S." Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. 10.1038/ncomms4067 Anti-MERS-CoV DRAVPe01754 LTQINTTLLDLTYEMLSLQQVVKALNESYIDLKEL 35 MERS-S (1252-1286) Synthetic construct K9N5Q8##R9UQ53 None MERS-CoV PsV Coronaviridae pseudovirus entry inhibition assay [Ref.24067982]MERS-COV(Middle East respiratory syndrome coronavirus): inhibition of MERS-CoV PsV infection in 293T/Huh7 cells (EC50~3.013µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01754.cif Linear Free Free None L membrane inhibit MERS-CoV fusion and entry by using a pseudotyped-virus system 4054.71 C182H302N42O59S CFGHPRW L 4.18 2 5 -3 10 14 15.71 -2987 5.5 hour 3 min 2 min 142 2980 87.65 24067982 J Virol. 2013 Dec;87(24):13134-40. "Gao J, Lu G, Qi J, Li Y, Wu Y, Deng Y, Geng H, Li H, Wang Q, Xiao H, Tan W, Yan J, Gao GF." Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus. 10.1128/JVI.02433-13 Anti-MERS-CoV DRAVPe01753 RIQQIEQKIHHIEQRIQQIEQRISGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL 59 T21N36 Synthetic construct A1YNW7 None HIV-1 Retroviridae Cell-cell fusion assay [Ref.31932193]HIV-1(human immunodeficiency virus 1): inhiition of cell-cell fusion between TZM-bl cells and HL2/3 cells(IC50=81.8±5.69nM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01753.cif Linear Acetylation Free None L gp41 function as potent inhibitors of viral infection by forming a coiled-coil structure covalently stabilized by interchain disulfide bonds 7070.23 C312H526N100O87 CDFMPY Q 10.78 10 4 6 6 24 -45.25 -12299 1 hour 2 min 2 min 133.9 5500 94.83 31932193 Bioorg Med Chem. 2020 Feb 15;28(4):115214. "Lai W, Wang C, Yan J, Liu H, Zhang W, Lin B, Xi Z." Suitable fusion of N-terminal heptad repeats to achieve covalently stabilized potent N-peptide inhibitors of HIV-1 infection. 10.1016/j.bmc.2019.115214 Anti-HIV-1 DRAVPe01752 RIQQIEQKIHHIEQRIQQIEQRAIEAQQHLLQLTVWGIKQLQARIL 46 T21N23 Synthetic construct None None HIV-1 Retroviridae Cell-cell fusion assay [Ref.31932193]HIV-1(human immunodeficiency virus 1): inhiition of cell-cell fusion between TZM-bl cells and HL2/3 cells(IC50=38.9±35.8nM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01752.cif Linear Acetylation Free None L gp41 function as potent inhibitors of viral infection by forming a coiled-coil structure covalently stabilized by interchain disulfide bonds 5605.54 C249H417N79O68 CDFMNPSY Q 9.97 9 4 5 2 19 -52.83 -9943 1 hour 2 min 2 min 131.52 5500 122.22 31932193 Bioorg Med Chem. 2020 Feb 15;28(4):115214. "Lai W, Wang C, Yan J, Liu H, Zhang W, Lin B, Xi Z." Suitable fusion of N-terminal heptad repeats to achieve covalently stabilized potent N-peptide inhibitors of HIV-1 infection. 10.1016/j.bmc.2019.115214 Anti-HIV-1 DRAVPe01751 RIQQIEQKIHHIEQRIQQIEQLLQLTVWGIKQLQARIL 38 T21N17 Synthetic construct None None HIV-1 Retroviridae Cell-cell fusion assay [Ref.31932193]HIV-1(human immunodeficiency virus 1): inhiition of cell-cell fusion between TZM-bl cells and HL2/3 cells(IC50=251±41.1nM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01751.cif Linear Acetylation Free None L gp41 function as potent inhibitors of viral infection by forming a coiled-coil structure covalently stabilized by interchain disulfide bonds 4671.52 C210H354N64O56 CDFMNPSY Q 9.98 7 3 4 2 16 -37.37 -7050 1 hour 2 min 2 min 143.68 5500 148.65 31932193 Bioorg Med Chem. 2020 Feb 15;28(4):115214. "Lai W, Wang C, Yan J, Liu H, Zhang W, Lin B, Xi Z." Suitable fusion of N-terminal heptad repeats to achieve covalently stabilized potent N-peptide inhibitors of HIV-1 infection. 10.1016/j.bmc.2019.115214 Anti-HIV-1 DRAVPe01750 LHQNIVDVQYMYGLS 15 "HCV gp (696–710), E2-79" Synthetic construct Q99IB8 None HCV Flaviviridae HCV infection assay [Ref.28638089]HCV(Hepatitis C virus): inhibition of HCVcc infection in Huh7.5/CD81 cells (IC50=1~5nM) No hemolysis information or data found in the reference(s) presented in this entry [Ref.28638089]have no effect on the viability of Huh7.5-CD81 cells at concentrations of 10 nM DRAVPe01750.cif Linear Free Free None L Envelope protein "Inhibits HCV entry at the post-attachment step and block cell-to-cell transmission, inhibit the late steps of HCV life cycle, such as HCV package and release." 1780.03 C80H122N20O24S ACEFKPRTW LQVY 5.08 1 1 0 5 5 9.33 -865 5.5 hour 3 min 2 min 116.67 2980 212.86 28638089 A screen for inhibitory peptides of hepatitis C virus identifies a novel entry inhibitor targeting E1 and E2. "Yin P, Zhang L, Ye F, Deng Y, Lu S, Li YP, Zhang L, Tan W." A screen for inhibitory peptides of hepatitis C virus identifies a novel entry inhibitor targeting E1 and E2. 10.1038/s41598-017-04274-8 Anti-HCV DRAVPe01749 GLLHLHQNIVDVQYM 15 "HCV gp (692–706), E2-78" Synthetic construct Q99IB8 None HCV Flaviviridae HCV infection assay [Ref.28638089]HCV(Hepatitis C virus): inhibition of HCVcc infection in Huh7.5/CD81 cells (IC50=1~5nM) No hemolysis information or data found in the reference(s) presented in this entry [Ref.28638089]have no effect on the viability of Huh7.5-CD81 cells at concentrations of 10 nM DRAVPe01749.cif Linear Free Free None L Envelope protein "Inhibits HCV entry at the post-attachment step and block cell-to-cell transmission, inhibit the late steps of HCV life cycle, such as HCV package and release." 1780.07 C80H126N22O22S ACEFKPRSTW L 5.97 2 1 1 3 6 27.33 -485 30 hour >20 hour >10 hour 142.67 1490 106.43 28638089 A screen for inhibitory peptides of hepatitis C virus identifies a novel entry inhibitor targeting E1 and E2. "Yin P, Zhang L, Ye F, Deng Y, Lu S, Li YP, Zhang L, Tan W." A screen for inhibitory peptides of hepatitis C virus identifies a novel entry inhibitor targeting E1 and E2. 10.1038/s41598-017-04274-8 Anti-HCV DRAVPe01748 FGCTWMNSTGFTKTC 15 "HCV gp (552–566), E2-43" Synthetic construct Q99IB8 None HCV Flaviviridae HCV infection assay [Ref.28638089]HCV(Hepatitis C virus): inhibition of HCVcc infection in Huh7.5/CD81 cells (IC50=1~5nM) No hemolysis information or data found in the reference(s) presented in this entry [Ref.28638089]have no effect on the viability of Huh7.5-CD81 cells at concentrations of 10 nM DRAVPe01748.cif Linear Free Free None L Envelope protein "Inhibits HCV entry at the post-attachment step and block cell-to-cell transmission, inhibit the late steps of HCV life cycle, such as HCV package and release." 1683.93 C73H106N18O22S3 ADEHILPQRVY T 8.06 1 0 1 10 3 -1.33 -1079 1.1 hour 3 min 2 min 0 5625 401.79 28638089 A screen for inhibitory peptides of hepatitis C virus identifies a novel entry inhibitor targeting E1 and E2. "Yin P, Zhang L, Ye F, Deng Y, Lu S, Li YP, Zhang L, Tan W." A screen for inhibitory peptides of hepatitis C virus identifies a novel entry inhibitor targeting E1 and E2. 10.1038/s41598-017-04274-8 Anti-HCV DRAVPe01747 QGSWFGCTWMNSTGF 18 "HCV gp (548–562), E2-42" Synthetic construct Q99IB8 None HCV Flaviviridae HCV infection assay [Ref.28638089]HCV(Hepatitis C virus): inhibition of HCVcc infection in Huh7.5/CD81 cells (IC50=1~5nM) No hemolysis information or data found in the reference(s) presented in this entry [Ref.28638089]have no effect on the viability of Huh7.5-CD81 cells at concentrations of 10 nM DRAVPe01747.cif Linear Free Free None L Envelope protein "Inhibits HCV entry at the post-attachment step and block cell-to-cell transmission, inhibit the late steps of HCV life cycle, such as HCV package and release." 1708.88 C77H101N19O22S2 ADEHIKLPRVY G 5.52 0 0 0 9 4 -20 -705 0.8 hour 10 min >10 hour 0 11000 785.71 28638089 A screen for inhibitory peptides of hepatitis C virus identifies a novel entry inhibitor targeting E1 and E2. "Yin P, Zhang L, Ye F, Deng Y, Lu S, Li YP, Zhang L, Tan W." A screen for inhibitory peptides of hepatitis C virus identifies a novel entry inhibitor targeting E1 and E2. 10.1038/s41598-017-04274-8 Anti-HCV DRAVPe01746 VEPGQLKLNWFKK 13 P7(DENV-2 gp (662-674)) Synthetic construct P14340 None "DENV-1, DENV-2" Flaviviridae Plaque assay "[Ref.29709564]DENV-2(dengue virus serotype 2): inhibition of virus entry in HUVECs(human umbilical vein endothelial cells)(65 ± 6% inhibition at 40 μM,55± 12% inhibition at 20 μM,41± 13% inhibition at 10 μM,IC50=12.86±5.96µM);##DENV-1(dengue virus serotype 1): inhibition of virus entry in HUVECs(human umbilical vein endothelial cells)(65 ± 12% inhibition at 40 μM)." No hemolysis information or data found in the reference(s) presented in this entry [Ref.29709564]No toxic effect on HUVEC(Human umbilical vein endothelial cells) at concentrations up to 100 µM DRAVPe01746.cif Linear Free Free None L β3 integrin might be involved in blocking viral entry via occupying the binding site in the receptor on the host cell(β3 integrin). 1586.9 C76H119N19O18 ACDHIMRSTY K 9.7 3 1 2 2 5 -80.77 -1551 100 hour >20 hour >10 hour 82.31 5500 458.33 29709564 Antiviral Res. 2018 Jul;155:20-27. "Cui X, Wu Y, Fan D, Gao N, Ming Y, Wang P, An J." Peptides P4 and P7 derived from E protein inhibit entry of dengue virus serotype 2 via interacting with β3 integrin. 10.1016/j.antiviral.2018.04.018 "Anti-Anti-DENV-1, Anti-Anti-DENV-2" DRAVPe01745 CKIPFEIMDLEKRHV 15 P4(DENV-2 gp (613-627)) Synthetic construct P14340 None DENV-2 Flaviviridae Plaque assay "[Ref.29709564]DENV-2(dengue virus serotype 2): inhibition of virus entry in HUVECs(human umbilical vein endothelial cells)(70 ± 9% inhibition at 40 μM,44 ± 10% inhibition at 20 μM,40± 6% inhibition at 10 μM,IC50=19.08±2.52µM)." No hemolysis information or data found in the reference(s) presented in this entry [Ref.29709564]No toxic effect on HUVEC(Human umbilical vein endothelial cells) at concentrations up to 100 µM DRAVPe01745.cif Linear Free Free None L β3 integrin might be involved in blocking viral entry via occupying the binding site in the receptor on the host cell(β3 integrin). 1858.25 C83H136N22O22S2 AGNQSTWY EIK 6.75 4 3 1 1 5 -22.67 -2761 1.2 hour >20 hour >10 hour 97.33 0 0 29709564 Antiviral Res. 2018 Jul;155:20-27. "Cui X, Wu Y, Fan D, Gao N, Ming Y, Wang P, An J." Peptides P4 and P7 derived from E protein inhibit entry of dengue virus serotype 2 via interacting with β3 integrin. 10.1016/j.antiviral.2018.04.018 Anti-Anti-DENV-2 DRAVPe01733 GNHILSLVQNAPYGLYFIHFSW 22 MHV (1096–1117)[Y1117W] Synthetic construct P11224 None MHV Plaque reduction assay [Ref.16616792]MHV(murine hepatitis virus): inhibition of virus infection in L2 cells(22% inhibition at 30 μM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.16616792]No cytotoxic at a concentration of 30 μM on L2 cells DRAVPe01733.cif Linear Free Free None L cell membrane inhibits viral entry through coiled coil interactions. 2576.94 C125H174N30O30 CDEKMRT L 6.92 2 0 2 8 10 34.55 540 30 hour >20 hour >10 hour 106.36 8480 403.81 16616792 Virus Res. 2006 Sep;120(1-2):146-55. "Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF." Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein. 10.1016/j.virusres.2006.03.001 Anti-MHV DRAVPe01734 GYFVQDDGEWKFTGSSYYY 19 MHV (1144–1162) Synthetic construct P11224 None MHV Plaque reduction assay "[Ref.16616792]MHV(murine hepatitis virus): inhibition of virus infection in L2 cells(98% inhibition at 30 Μm, IC50=4 μM)." No hemolysis information or data found in the reference(s) presented in this entry [Ref.16616792]No cytotoxic at a concentration of 30 μM on L2cells DRAVPe01734.cif Linear Free Free None L cell membrane inhibits viral entry through coiled coil interactions. 2312.43 C110H138N22O34 ACHILMNPR Y 4.03 1 3 -2 10 4 -93.16 -3012 30 hour >20 hour >10 hour 15.26 11460 636.67 16616792 Virus Res. 2006 Sep;120(1-2):146-55. "Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF." Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein. 10.1016/j.virusres.2006.03.001 Anti-MHV DRAVPe01732 AACEVAKNLNESLIDLQELGKYEQYIKW 28 AAC-SARS-CoV (1170–1194) Synthetic construct Q19QX0 None SARS-CoV Coronaviridae Plaque reduction assay [Ref.16616792]SARS-CoV: inhibition of virus infection in Vero-E6 cells(42% inhibition at 30 μM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.16616792]No cytotoxic at a concentration of 30 μM on Vero-E6 cells DRAVPe01732.cif Linear Free Free None L cell membrane inhibits viral entry through coiled coil interactions. 3269.72 C147H230N36O46S FHMPRT EL 4.59 3 5 -2 7 11 -41.43 -3711 4.4 hour >20 hour >10 hour 104.64 8480 314.07 16616792 Virus Res. 2006 Sep;120(1-2):146-55. "Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF." Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein. 10.1016/j.virusres.2006.03.001 Anti-SARS-CoV DRAVPe01731 GVFVFNGTSWFITQRNFFS 19 SARS-CoV (1075–1093) Synthetic construct Q19QX0 None SARS-CoV Coronaviridae Plaque reduction assay "[Ref.16616792]SARS-CoV: inhibition of virus infection in Vero-E6 cells(83% inhibition at 30 μM,IC50~2 μM)." No hemolysis information or data found in the reference(s) presented in this entry [Ref.16616792]No cytotoxic at a concentration of 30 μM on Vero-E6 cells DRAVPe01731.cif Linear Free Free None L cell membrane inhibits viral entry through coiled coil interactions. 2254.53 C109H148N26O27 ACDEHKLMPY F 9.75 1 0 1 8 9 37.89 -1357 30 hour >20 hour >10 hour 51.05 5500 305.56 16616792 Virus Res. 2006 Sep;120(1-2):146-55. "Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF." Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein. 10.1016/j.virusres.2006.03.001 Anti-SARS-CoV DRAVPe01730 GYHLMSFPQAAP-HGVVFLHVTW 22 SARS-CoV (1028–1049)[Y1049W] Synthetic construct Q19QX0 None SARS-CoV Coronaviridae Plaque reduction assay "[Ref.16616792]SARS-CoV: inhibition of virus infection in Vero-E6 cells(90% inhibition at 30 μM,IC50~2 μM)." No hemolysis information or data found in the reference(s) presented in this entry [Ref.16616792]No cytotoxic at a concentration of 30 μM on Vero-E6 cells DRAVPe01730.cif Linear Free Free None L cell membrane inhibits viral entry through coiled coil interactions. 2607.98 C120H166N30O26S CDEIKNR HV 7.02 3 0 3 5 10 45.65 1247 30 hour >20 hour >10 hour 80.43 6990 317.73 16616792 Virus Res. 2006 Sep;120(1-2):146-55. "Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF." Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein. 10.1016/j.virusres.2006.03.001 Anti-SARS-CoV DRAVPe01729 ATAGWTFGAGAALQIPFAMQMAY 23 SARS-CoV (864-886) Synthetic construct Q19QX0 None SARS-CoV Coronaviridae Plaque reduction assay [Ref.16616792]SARS-CoV: inhibition of virus infection in Vero-E6 cells(39% inhibition at 30 μM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.16616792]No cytotoxic at a concentration of 30 μM on Vero-E6 cells DRAVPe01729.cif Linear Free Free None L cell membrane inhibits viral entry through coiled coil interactions. 2374.76 C110H160N26O29S2 CDEHKNRSV A 5.57 0 0 0 6 12 73.48 2196 4.4 hour >20 hour >10 hour 64.35 6990 317.73 16616792 Virus Res. 2006 Sep;120(1-2):146-55. "Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF." Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein. 10.1016/j.virusres.2006.03.001 Anti-SARS-CoV DRAVPe01727 TLKPIFKLPLGINITNFR 18 "SARS-CoV-S (215-232), peptide 9626" Synthetic construct P59594 None SARS-CoV PsV Coronaviridae western blot [Ref.19853613]SARS-COV: inhibition of SARS-CoV/HIV PsV virus infection in 293T/ACE2 cells (IC50=11µM); inhibition of SARS-CoV/HIV PsV virus entry in 293T/ACE2 cells(80% at 50µM) No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01727.cif Linear Free Free None L not found "Presumably inhibit virus entry by binding to Spike protein, hACE2, or an unknown co-receptor." 2085.56 C100H165N25O23 ACDEHMQSVWY IL 11.17 3 0 3 5 8 34.44 -802 7.2 hour >20 hour >10 hour 130 0 0 19853613 J Mol Biol. 2009 Dec 11;394(4):600-5. "Guo Y, Tisoncik J, McReynolds S, Farzan M, Prabhakar BS, Gallagher T, Rong L, Caffrey M." Identification of a new region of SARS-CoV S protein critical for viral entry. 10.1016/j.jmb.2009.10.032 Anti-SARS-CoV PsV DRAVPe01728 MWKTPTLKYFGGFNFSQIL 19 SARS-CoV (770-788)[Y771W] Synthetic construct Q19QX0 None SARS-CoV Coronaviridae Plaque reduction assay [Ref.16616792]SARS-CoV: inhibition of virus infection in Vero-E6 cells(58% inhibition at 30 μM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.16616792]No cytotoxic at a concentration of 30 μM on Vero-E6 cells DRAVPe01728.cif Linear Free Free None L cell membrane inhibits viral entry through coiled coil interactions. 2278.7 C111H160N24O26S ACDEHRV F 9.7 2 0 2 7 7 4.21 -170 30 hour >20 hour >10 hour 61.58 6990 388.33 16616792 Virus Res. 2006 Sep;120(1-2):146-55. "Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF." Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein. 10.1016/j.virusres.2006.03.001 Anti-SARS-CoV DRAVPe01726 QNQSANQFQKEISQINEVLTTTNTSLGKLQDDVNQNNQSLNTLQKE 46 "N46eg(SARS-CoV (902-947)[K2N,I4S,N9Q,A11E,Q16N,S18V,S23N,A25S,V32D,A37N,A39S,V44Q,Q46E])" Synthetic construct P59594 None SARS-CoV Coronaviridae cell fusion inhibition assay [Ref.18983873]SARS-CoV:inhibition of cell fusion in Hela cells (IC50=5.07 ± 0.17 μM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.18983873]No discernable cytotoxicity on HeLa or VeroE6 cells at the concentrations of 25 μM. DRAVPe01726.cif Linear Free Free None L membrane "Binding to the HR2 region and blocking the formation of a 6-helix bundle during the fusion step of virus entry, thus inhibiting virus entry." 5205.59 C216H356N66O83 CHMPRWY Q 4.51 3 5 -2 18 11 -119.13 -13570 0.8 hour 10 min >10 hour 74.13 0 0 18983873 Antiviral Res. 2009 Jan;81(1):82-7. "Liu IJ, Kao CL, Hsieh SC, Wey MT, Kan LS, Wang WK." Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors. 10.1016/j.antiviral.2008.10.001 Anti-SARS-CoV DRAVPe01725 QKQIANQFNKAISQIQESLTTTSTALGKLQDVVNQNAQALNTLVKQ 46 N46(SARS-CoV (902-947)) Synthetic construct P59594 None SARS-CoV Coronaviridae cell fusion inhibition assay [Ref.18983873]SARS-CoV:inhibition of cell fusion in Hela cells (IC50=3.97 ± 1.40 μM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.18983873]No discernable cytotoxicity on HeLa or VeroE6 cells at the concentrations of 25 μM. DRAVPe01725.cif Linear Free Free None L membrane "Binding to the HR2 region and blocking the formation of a 6-helix bundle during the fusion step of virus entry, thus inhibiting virus entry." 5027.67 C216H366N64O73 CHMPRWY Q 9.53 4 2 2 14 17 -45.65 -7939 0.8 hour 10 min >10 hour 97.61 0 0 18983873 Antiviral Res. 2009 Jan;81(1):82-7. "Liu IJ, Kao CL, Hsieh SC, Wey MT, Kan LS, Wang WK." Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors. 10.1016/j.antiviral.2008.10.001 Anti-SARS-CoV DRAVPe01723 GINASVVNIQKEIDRLNEVAKNLNESLIDL 30 P4(SARS-CoV (1153–1182)) Synthetic construct P59594 None SARS-CoV Coronaviridae cell fusion inhibition assay [Ref.18983873]SARS-CoV:inhibition of cell fusion in Hela cells (IC50=0.80 ± 0.21 μM);inhibition of SARS-CoV infection in Vero-E6 cells (IC50=3.17 ± 0.24 μM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.18983873]No discernable cytotoxicity on HeLa or VeroE6 cells at the concentrations of 25 μM. DRAVPe01723.cif Linear Free Free None L membrane "Binding to the HR1 region and blocking the formation of a 6-helix bundle during the fusion step of virus entry, thus inhibiting virus entry." 3322.76 C143H245N41O49 CFHMPTWY N 4.51 3 5 -2 8 13 -11.33 -5339 30 hour >20 hour >10 hour 139.67 0 0 18983873 Antiviral Res. 2009 Jan;81(1):82-7. "Liu IJ, Kao CL, Hsieh SC, Wey MT, Kan LS, Wang WK." Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors. 10.1016/j.antiviral.2008.10.001 Anti-SARS-CoV DRAVPe01724 GINASVVNIQKEIDRLNEVAKNL 23 P6(SARS-CoV (1153–1175)) Synthetic construct P59594 None SARS-CoV Coronaviridae cell fusion inhibition assay [Ref.18983873]SARS-CoV:inhibition of cell fusion in Hela cells (IC50=1.04 ± 0.22 μM); inhibition of SARS-CoV infection in Vero-E6 cells (IC50=2.28 ± 0.81 μM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.18983873]No discernable cytotoxicity on HeLa or VeroE6 cells at the concentrations of 25 μM. DRAVPe01724.cif Linear Free Free None L membrane "Binding to the HR1 region and blocking the formation of a 6-helix bundle during the fusion step of virus entry, thus inhibiting virus entry." 2537.9 C109H189N33O36 CFHMPTWY N 6.18 3 3 0 6 10 -18.26 -4258 30 hour >20 hour >10 hour 131.3 0 0 18983873 Antiviral Res. 2009 Jan;81(1):82-7. "Liu IJ, Kao CL, Hsieh SC, Wey MT, Kan LS, Wang WK." Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors. 10.1016/j.antiviral.2008.10.001 Anti-SARS-CoV DRAVPe01722 GINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE 37 P1(SARS-CoV (1153-1189)) Synthetic construct P59594 None SARS-CoV Coronaviridae cell fusion inhibition assay [Ref.18983873]SARS-CoV:inhibition of cell fusion in Hela cells (IC50=0.62 ± 0.20 μM);inhibition of SARS-CoV infection in Vero-E6 cells (IC50=3.04 ± 0.06 μM).##[Ref.15043961]SARS-CoV:inhibition of the cytopathic effect in Vero E6 cells(IC50~19 μM/L). No hemolysis information or data found in the reference(s) presented in this entry [Ref.18983873]No discernable cytotoxicity on HeLa or VeroE6 cells at the concentrations of 25 μM. DRAVPe01722.cif Linear Free Free None L membrane "Binding to the HR1 region and blocking the formation of a 6-helix bundle during the fusion step of virus entry, thus inhibiting virus entry." 4170.69 C181H302N50O62 CFHMPTW ELN 4.49 4 7 -3 10 14 -42.43 -7238 30 hour >20 hour >10 hour 123.78 1490 41.39 18983873##15043961 Antiviral Res. 2009 Jan;81(1):82-7.##Lancet. 2004 Mar 20;363(9413):938-47. "Liu IJ, Kao CL, Hsieh SC, Wey MT, Kan LS, Wang WK.##Liu S, Xiao G, Chen Y, He Y, Niu J, Escalante CR, Xiong H, Farmar J, Debnath AK, Tien P, Jiang S." Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors.##Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. 10.1093/infdis/jiv325.##10.1016/j.antiviral.2008.10.001.##10.1016/S0140-6736(04)15788-7. Anti-SARS-CoV DRAVPe01721 AWDFGSVGGVFNSLGKGIHQIFGAAFKSL 29 ZIKV Ep (424-452) Synthetic construct Q32ZE1 None ZIKV Flaviviridae "qRT-PCR, western blotting, the plaque assay" [Ref.28232248]Zika virus (ZIKV):inhibition of Zika virus (ZIKV) infection in Vero cells (IC50=1.32μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01721.cif Linear Free Free None L membrane Peptide derived from protein E stem may inhibit virus infection by blocking virus entry. 3011.43 C142H208N36O37 CEMPRTY G 8.64 3 1 2 10 14 49.66 622 4.4 hour >20 hour >10 hour 84.14 5500 196.43 28232248 Antiviral Res. 2017 May;141:140-149. "Chen L, Liu Y, Wang S, Sun J, Wang P, Xin Q, Zhang L, Xiao G, Wang W." Antiviral activity of peptide inhibitors derived from the protein E stem against Japanese encephalitis and Zika viruses. 10.1016/j.antiviral.2017.02.009 Anti-ZIKV DRAVPe01719 AWDFGSIGGVFNSIGRAVHQVFGGAFRTL 29 JEV Ep (424–452) Synthetic construct P0DOH7 None JEV Flaviviridae "qRT-PCR, western blotting, the plaque assay" [Ref.28232248]Japanese encephalitis virus (JEV):inhibition of JEV infection in BHK-21 (baby hamster kidney) cells (IC50=7.66 nM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01719.cif Linear Free Free None L membrane Peptide derived from protein E stem may inhibit virus infection by blocking virus entry. 3067.46 C142H208N40O37 CEKMPY G 9.65 3 1 2 10 14 47.24 -1257 4.4 hour >20 hour >10 hour 80.69 5500 196.43 28232248 Antiviral Res. 2017 May;141:140-149. "Chen L, Liu Y, Wang S, Sun J, Wang P, Xin Q, Zhang L, Xiao G, Wang W." Antiviral activity of peptide inhibitors derived from the protein E stem against Japanese encephalitis and Zika viruses. 10.1016/j.antiviral.2017.02.009 Anti-JEV DRAVPe01720 AWDFGSIGGVFNSIGRAVHQVF 22 JEV Ep (424–445) Synthetic construct P0DOH7 None "JEV, ZIKV" Flaviviridae "qRT-PCR, western blotting, the plaque assay" [Ref.28232248]Japanese encephalitis virus (JEV):inhibition of JEV infection in BHK-21 (baby hamster kidney) cells (IC50=3.93 nM);##Zika virus (ZIKV):inhibition of Zika virus (ZIKV) infection in Vero cells (IC50=3.27μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01720.cif Linear Free Free None L membrane "The peptide prevented JEV infection in mice by reducing viral load and the inflammatory response in the brain, thereby improving the survival rate." 2364.65 C110H158N30O29 CEKLMPTY G 6.79 2 1 1 7 11 51.36 -667 4.4 hour >20 hour >10 hour 84.09 5500 261.9 28232248 Antiviral Res. 2017 May;141:140-149. "Chen L, Liu Y, Wang S, Sun J, Wang P, Xin Q, Zhang L, Xiao G, Wang W." Antiviral activity of peptide inhibitors derived from the protein E stem against Japanese encephalitis and Zika viruses. 10.1016/j.antiviral.2017.02.009 "Anti-JEV, Anti-ZIKV" DRAVPe01718 AALGDTAWDFGSIGGVFNSIGRAVHQVFGGAFRTL 35 JEV Ep (418–452) Synthetic construct P0DOH7 None JEV Flaviviridae "qRT-PCR, western blotting, the plaque assay" [Ref.28232248]Japanese encephalitis virus (JEV):inhibition of JEV infection in BHK-21 (baby hamster kidney) cells (IC50=58.07 nM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01718.cif Linear Free Free None L membrane Peptide derived from protein E stem may inhibit virus infection by blocking virus entry. 3596.02 C164H244N46O46 CEKMPY G 6.79 3 2 1 12 17 47.14 -1438 4.4 hour >20 hour >10 hour 83.71 5500 161.76 28232248 Antiviral Res. 2017 May;141:140-149. "Chen L, Liu Y, Wang S, Sun J, Wang P, Xin Q, Zhang L, Xiao G, Wang W." Antiviral activity of peptide inhibitors derived from the protein E stem against Japanese encephalitis and Zika viruses. 10.1016/j.antiviral.2017.02.009 Anti-JEV DRAVPe01717 SIGGVFNSIGRAVHQVFGGAFRTL 24 JEV Ep (428–452) Synthetic construct P0DOH7 None JEV Flaviviridae "qRT-PCR, western blotting, the plaque assay" [Ref.28232248]Japanese encephalitis virus (JEV):inhibition of JEV infection in BHK-21 (baby hamster kidney) cells (IC50=94.10 nM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01717.cif Linear Free Free None L membrane Peptide derived from protein E stem may inhibit virus infection by blocking virus entry. 2490.85 C113H176N34O30 CDEKMPWY G 12 3 0 3 9 11 57.92 -1191 1.9 hour >20 hour >10 hour 93.33 0 0 28232248 Antiviral Res. 2017 May;141:140-149. "Chen L, Liu Y, Wang S, Sun J, Wang P, Xin Q, Zhang L, Xiao G, Wang W." Antiviral activity of peptide inhibitors derived from the protein E stem against Japanese encephalitis and Zika viruses. 10.1016/j.antiviral.2017.02.009 Anti-JEV DRAVPe01716 STLGKAFSTTLKGAQRLAALGDTAWDFG 28 JEV Ep (401–428) Synthetic construct P0DOH7 None JEV Flaviviridae "qRT-PCR, western blotting, the plaque assay, immunofluorescence analysis" [Ref.28232248]Japanese encephalitis virus (JEV):inhibition of JEV infection in BHK-21 (baby hamster kidney) cells (IC50=3790.71 nM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01716.cif Linear Free Free None L membrane Peptide derived from protein E stem may inhibit virus infection by blocking virus entry. 2884.24 C129H203N35O40 CEHIMNPVY A 8.31 3 2 1 10 12 0.36 -2530 1.9 hour >20 hour >10 hour 73.57 5500 203.7 28232248 Antiviral Res. 2017 May;141:140-149. "Chen L, Liu Y, Wang S, Sun J, Wang P, Xin Q, Zhang L, Xiao G, Wang W." Antiviral activity of peptide inhibitors derived from the protein E stem against Japanese encephalitis and Zika viruses. 10.1016/j.antiviral.2017.02.009 Anti-JEV DRAVPe01714 LDLSDEMAMLLQEVVKQLNDSYIDLKELGNYTYYNKW 37 HKU4-HR2P3 Synthetic construct No entry found None MERS-CoV Coronaviridae Cell–Cell Fusion Assay [Ref.30646495]MERS-CoV:inhibition of cell-cell fusion between 293T cells and Huh-7 cells(IC50=0.55 μM);##MERS-CoV Q1020:inhibition of Pseudovirus Infection in Huh-7 cells(IC50=0.48 μM);##MERS-CoV Q1020H:inhibition of Pseudovirus Infection in Huh-7 cells(IC50=0.52 μM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.30646495]No cytotoxicity against Huh-7 cells up to 100 μM. DRAVPe01714.cif Linear Free Free None L membrane The peptide bind with HR1 of MERS-CoV and thus disrupting the process of MERS-6HB formation can inhibit virus–cell membrane fusion and abolish viral infection. 4457.05 C201H308N46O64S2 CFHPR L 4.14 3 7 -4 11 12 -47.03 -5567 5.5 hour 3 min 2 min 102.7 11460 318.33 30646495 Viruses. 2019 Jan 14;11(1):56. doi: 10.3390/v11010056 "Xia S, Lan Q, Pu J, Wang C, Liu Z, Xu W, Wang Q, Liu H, Jiang S, Lu L." Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4. 10.3390/v11010056 Anti-MERS-CoV DRAVPe01715 GGGSLTQINTTLLDLTYEMLSLQQVVKALNESYIDLKEL 39 MERS-HR2P Synthetic construct No entry found None MERS-CoV Coronaviridae Cell–Cell Fusion Assay [Ref.30646495]MERS-CoV:inhibition of cell-cell fusion between 293T cells and Huh-7 cells(IC50=1.07 μM);##MERS-CoV Q1020:inhibition of Pseudovirus Infection in Huh-7 cells(IC50=1.14 μM);##MERS-CoV Q1020H:inhibition of Pseudovirus Infection in Huh-7 cells(IC50=1.71 μM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.30646495]No cytotoxicity against Huh-7 cells up to 100 μM. DRAVPe01715.cif Linear Free Free None L membrane The peptide bind with HR1 of MERS-CoV and thus disrupting the process of MERS-6HB formation can inhibit virus–cell membrane fusion and abolish viral infection. 4312.94 C191H316N46O64S CFHPRW L 4.18 2 5 -3 14 14 8.97 -3045 30 hour >20 hour >10 hour 127.44 2980 78.42 30646495 Viruses. 2019 Jan 14;11(1):56. doi: 10.3390/v11010056 "Xia S, Lan Q, Pu J, Wang C, Liu Z, Xu W, Wang Q, Liu H, Jiang S, Lu L." Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4. 10.3390/v11010056 Anti-MERS-CoV DRAVPe01713 EISKINTTLLDLSDEMAMLLQEVVKQLNDSYIDLKEL 37 HKU4-HR2P2 Synthetic construct No entry found None MERS-CoV Coronaviridae Cell–Cell Fusion Assay [Ref.30646495]MERS-CoV:inhibition of cell-cell fusion between 293T cells and Huh-7 cells(IC50=0.38 μM);##MERS-CoV Q1020:inhibition of Pseudovirus Infection in Huh-7 cells(IC50=0.34 μM);##MERS-CoV Q1020H:inhibition of Pseudovirus Infection in Huh-7 cells(IC50=0.44 μM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.30646495]No cytotoxicity against Huh-7 cells up to 100 μM. DRAVPe01713.cif Linear Free Free None L membrane The peptide bind with HR1 of MERS-CoV and thus disrupting the process of MERS-6HB formation can inhibit virus–cell membrane fusion and abolish viral infection. 4266.93 C187H314N44O64S2 CFGHPRW L 4.07 3 8 -5 8 14 -2.43 -4990 1 hour 30 min >10 hour 134.32 1490 41.39 30646495 Viruses. 2019 Jan 14;11(1):56. doi: 10.3390/v11010056 "Xia S, Lan Q, Pu J, Wang C, Liu Z, Xu W, Wang Q, Liu H, Jiang S, Lu L." Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4. 10.3390/v11010056 Anti-MERS-CoV DRAVPe01712 GPNFAEISKINTTLLDLSDEMAMLLQEVVKQLNDSYI 37 HKU4-HR2P1 Synthetic construct No entry found None MERS-CoV Coronaviridae Cell–Cell Fusion Assay [Ref.30646495]MERS-CoV:inhibition of cell-cell fusion between 293T cells and Huh-7 cells(IC50=1.09 μM);##MERS-CoV Q1020:inhibition of Pseudovirus Infection in Huh-7 cells(IC50=2.15 μM);##MERS-CoV Q1020H:inhibition of Pseudovirus Infection in Huh-7 cells(IC50=2.72 μM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.30646495]No cytotoxicity against Huh-7 cells up to 100 μM. DRAVPe01712.cif Linear Free Free None L membrane The peptide bind with HR1 of MERS-CoV and thus disrupting the process of MERS-6HB formation can inhibit virus–cell membrane fusion and abolish viral infection. 4154.76 C183H298N44O61S2 CHRW L 4.02 2 6 -4 10 14 4.05 -3957 30 hour >20 hour >10 hour 115.95 1490 41.39 30646495 Viruses. 2019 Jan 14;11(1):56. doi: 10.3390/v11010056 "Xia S, Lan Q, Pu J, Wang C, Liu Z, Xu W, Wang Q, Liu H, Jiang S, Lu L." Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4. 10.3390/v11010056 Anti-MERS-CoV DRAVPe01711 ISLTPLLVCVAALLLLEQ 18 E1P52-2 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01711.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 1909.4 C89H157N19O24S DFGHKMNRWY L 4 0 1 -1 3 12 197.22 3402 20 hour 30 min >10 hour 216.67 0 0 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01709 GVISLTPLLVCVAALLLL 18 E1P52 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=55.7± 5.7 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01709.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 1808.34 C86H154N18O21S DEFHKMNQRWY L 5.52 0 0 0 4 13 257.22 5135 30 hour >20 hour >10 hour 232.78 0 0 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01710 VISLTPLLVCVAALLLLE 18 E1P52-1 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01710.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 1880.4 C89H158N18O23S DFGHKMNQRWY L 4 0 1 -1 3 13 240 4360 100 hour >20 hour >10 hour 232.78 0 0 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01708 RGVISLTPLLVCVAALLL 18 E1P51-2 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01708.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 1851.36 C86H155N21O21S DEFHKMNQWY L 8.25 1 0 1 4 12 211.11 3151 1 hour 2 min 2 min 211.11 0 0 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01707 WRGVISLTPLLVCVAALL 18 E1P51-1 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01707.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 1924.42 C91H154N22O21S DEFHKMNQY L 8.25 1 0 1 4 12 185 2892 2.8 hour 3 min 2 min 189.44 5500 323.53 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01705 DFWRGVISLTPLLVCVAA 18 E1P50-2 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01705.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 1960.36 C92H146N22O23S EHKMNQY LV 5.83 1 1 0 4 11 138.89 1334 1.1 hour 3 min >10 hour 146.11 5500 323.53 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01706 FWRGVISLTPLLVCVAAL 18 E1P51 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01706.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 1958.44 C94H152N22O21S DEHKMNQY L 8.25 1 0 1 4 12 179.44 2698 1.1 hour 3 min 2 min 167.78 5500 323.53 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01704 FDFWRGVISLTPLLVCVA 18 E1P50-1 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01704.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 2036.46 C98H150N22O23S EHKMNQY LV 5.83 1 1 0 4 11 144.44 1451 1.1 hour 3 min 2 min 140.56 5500 323.53 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01703 PFDFWRGVISLTPLLVCV 18 E1P50 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01703.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 2062.5 C100H152N22O23S AEHKMNQY LV 6.22 1 1 0 4 10 125.56 1270 >20 hour >20 hour ? 135 5500 323.53 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01702 VPFDFWRGVISLTPLLVC 18 E1P49-2 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01702.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 2062.5 C100H152N22O23S AEHKMNQY LV 5.8 1 1 0 4 10 125.56 1270 100 hour >20 hour >10 hour 135 5500 323.53 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01701 KVPFDFWRGVISLTPLLV 18 E1P49-1 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=63.3 ± 5.8 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01701.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 2087.54 C103H159N23O23 ACEHMNQY LV 8.75 2 1 1 3 10 90 587 1.3 hour 3 min 2 min 135 5500 323.53 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01699 LWKVPFDFWRGVISLTPL 18 E1P48-2 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=14.7 ± 0.6 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01699.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 2174.62 C109H160N24O23 ACEHMNQY L 8.75 2 1 1 3 10 61.67 416 5.5 hour 3 min 2 min 118.89 11000 647.06 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01700 WKVPFDFWRGVISLTPLL 18 E1P49 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=17.3 ± 3.2 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01700.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 2174.62 C109H160N24O23 ACEHMNQY L 8.75 2 1 1 3 10 61.67 416 2.8 hour 3 min 2 min 118.89 11000 647.06 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01697 EYLWKVPFDFWRGVISLT 18 E1P48 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=44.7 ± 3.2 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01697.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 2256.63 C112H158N24O26 ACHMNQ FLVW 6.17 2 2 0 4 9 22.78 -771 1 hour 30 min >10 hour 97.22 12490 734.71 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01698 YLWKVPFDFWRGVISLTP 18 E1P48-1 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=70.7 ±9.5 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01698.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 2224.63 C112H158N24O24 ACEHMNQ FLPVW 8.59 2 1 1 4 9 33.33 -90 2.8 hour 10 min 2 min 97.22 12490 734.71 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01695 ILEYLWKVPFDFWRGVIS 18 E1P47-1 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=5.4 ± 0.0 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01695.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 2268.69 C114H162N24O25 ACHMNQT FILVW 6.07 2 2 0 3 10 51.67 -22 20 hour 30 min >10 hour 118.89 12490 734.71 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01696 LEYLWKVPFDFWRGVISL 18 E1P47-2 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=6.6± 0.6 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01696.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 2268.69 C114H162N24O25 ACHMNQT L 6.07 2 2 0 3 10 47.78 -22 5.5 hour 3 min 2 min 118.89 12490 734.71 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01694 WILEYLWKVPFDFWRGVI 18 E1P47 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=2.7 ± 0.3 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01694.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 2367.82 C122H167N25O24 ACHMNQST W 6.07 2 2 0 2 11 51.11 551 2.8 hour 3 min 2 min 118.89 17990 1058.24 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01692 NYWILEYLWKVPFDFWRG 18 E1P46-1 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=12.3 ± 0.6 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01692.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 2432.81 C124H162N26O26 ACHMQST W 6.07 2 2 0 4 9 -23.89 -1023 1.4 hour 3 min >10 hour 81.11 19480 1145.88 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01693 YWILEYLWKVPFDFWRGV 18 E1P46-2 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=32.3 ± 11.0 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01693.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 2417.84 C125H165N25O25 ACHMNQST W 6.07 2 2 0 3 10 18.89 45 2.8 hour 10 min 2 min 97.22 19480 1145.88 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01691 SNYWILEYLWKVPFDFWR 18 E1P46 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=19.7 ± 8.1 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01691.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 2462.84 C125H164N26O27 ACGHMQT W 5.79 2 2 0 4 9 -26.11 -1457 1.9 hour >20 hour >10 hour 81.11 19480 1145.88 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01690 ASNYWILEYLWKVPFDFW 18 E1P45-2 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=11.3 ± 3.8 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01690.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 2377.73 C122H157N23O27 CGHMQRT W 4.37 1 2 -1 4 10 8.89 216 4.4 hour >20 hour >10 hour 86.67 19480 1145.88 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01689 LASNYWILEYLWKVPFDF 18 E1P45-1 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=12.7 ±1.2 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01689.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 2304.67 C117H158N22O27 CGHMQRT L 4.37 1 2 -1 4 10 35 475 5.5 hour 3 min 2 min 108.33 13980 822.35 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01688 QLASNYWILEYLWKVPFD 18 E1P45 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=27.7 ±5.8 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01688.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 2285.63 C113H157N23O28 CGHMRT L 4.37 1 2 -1 4 9 0 -377 0.8 hour 10 min >10 hour 108.33 13980 822.35 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01686 TEQLASNYWILEYLWKVP 18 E1P44-1 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01686.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 2253.58 C109H157N23O29 CDFGHMR L 4.53 1 2 -1 5 8 -19.44 -741 7.2 hour >20 hour >10 hour 108.33 13980 822.35 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01687 EQLASNYWILEYLWKVPF 18 E1P44-2 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=90.3 ± 15.3 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01687.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 2299.65 C114H159N23O28 CDGHMRT L 4.53 1 2 -1 4 9 0 -186 1 hour 30 min >10 hour 108.33 13980 822.35 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01685 WTEQLASNYWILEYLWKV 18 E1P44 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01685.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 2342.68 C115H160N24O29 CDFGHMPR LW 4.53 1 2 -1 5 9 -15.56 -508 2.8 hour 3 min 2 min 108.33 19480 1145.88 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01684 RWTEQLASNYWILEYLWK 18 E1P43-2 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=19.7 ± 9.1 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01684.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 2399.73 C116H163N27O29 CDFGHMPV LW 6.14 2 2 0 5 8 -63.89 -2404 1 hour 2 min 2 min 92.22 19480 1145.88 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01683 WRWTEQLASNYWILEYLW 18 E1P43-1 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=6.8 ± 0.3 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01683.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 2457.77 C121H161N27O29 CDFGHKMPV W 4.53 1 2 -1 5 9 -47.22 -1616 2.8 hour 3 min 2 min 92.22 24980 1469.41 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01682 FWRWTEQLASNYWILEYL 18 E1P43 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=43.0 ± 10.8 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01682.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 2418.74 C119H160N26O29 CDGHKMPV LW 4.53 1 2 -1 5 9 -26.67 -1551 1.1 hour 3 min 2 min 92.22 19480 1145.88 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01680 SEFWRWTEQLASNYWILE 18 E1P42-1 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=31.0 ± 3.5 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01680.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 2358.59 C112H152N26O31 CDGHKMPV EW 4.25 1 3 -2 5 8 -64.44 -3050 1.9 hour >20 hour >10 hour 70.56 17990 1058.24 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01681 EFWRWTEQLASNYWILEY 18 E1P42-2 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01681.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 2434.69 C118H156N26O31 CDGHKMPV EW 4.25 1 3 -2 5 8 -67.22 -2724 1 hour 30 min >10 hour 70.56 19480 1145.88 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01679 ESEFWRWTEQLASNYWIL 18 E1P42 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=50.0 ± 8.7 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01679.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 2358.59 C112H152N26O31 CDGHKMPV EW 4.25 1 3 -2 5 8 -64.44 -3050 1 hour 30 min >10 hour 70.56 17990 1058.24 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01677 KWESEFWRWTEQLASNYW 18 E1P41-1 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=66.7 ± 20.2 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01677.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 2446.66 C117H152N28O31 CDGHIMPV W 4.79 2 3 -1 5 7 -137.22 -4356 1.3 hour 3 min 2 min 27.22 23490 1381.76 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01678 WESEFWRWTEQLASNYWI 18 E1P41-2 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=22.0 ± 0.0 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01678.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 2431.65 C117H151N27O31 CDGHKMPV W 4.25 1 3 -2 5 8 -90.56 -3309 2.8 hour 3 min 2 min 48.89 23490 1381.76 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01676 LKWESEFWRWTEQLASNY 18 E1P41 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01676.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 2373.61 C112H153N27O31 CDGHIMPV EW 4.79 2 3 -1 5 7 -111.11 -4097 5.5 hour 3 min 2 min 48.89 17990 1058.24 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01675 ELKWESEFWRWTEQLASN 18 E1P40-2 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01675.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 2339.55 C108H151N27O32 CDGHIMPVY E 4.49 2 4 -2 4 7 -123.33 -4764 1 hour 30 min >10 hour 48.89 16500 970.59 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01674 CELKWESEFWRWTEQLAS 18 E1P40-1 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=34.0 ± 15.4 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01674.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 2328.58 C107H150N26O31S DGHIMNPVY E 4.49 2 4 -2 4 7 -90 -3972 1.2 hour >20 hour >10 hour 48.89 16500 970.59 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01673 ACELKWESEFWRWTEQLA 18 E1P40 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01673.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 2312.58 C107H150N26O30S DGHIMNPVY E 4.49 2 4 -2 3 8 -75.56 -3451 4.4 hour >20 hour >10 hour 54.44 16500 970.59 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01671 AVACELKWESEFWRWTEQ 18 E1P39-1 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=44.0 ± 13.9 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01671.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 2298.56 C106H148N26O30S DGHIMNPY E 4.49 2 4 -2 3 8 -73.33 -3539 4.4 hour >20 hour >10 hour 48.89 16500 970.59 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01672 VACELKWESEFWRWTEQL 18 E1P39-2 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=37.7 ± 7.0 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01672.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 2340.64 C109H154N26O30S DGHIMNPY E 4.49 2 4 -2 3 8 -62.22 -3228 100 hour >20 hour >10 hour 65 16500 970.59 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01670 CAVACELKWESEFWRWTE 18 E1P39 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=11.3 ± 1.5 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01670.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 2273.57 C104H145N25O29S2 DGHIMNPQY E 4.49 2 4 -2 4 8 -40 -2857 1.2 hour >20 hour >10 hour 48.89 16625 977.94 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01668 LTCAVACELKWESEFWRW 18 E1P38-1 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01668.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 2257.61 C105H149N25O27S2 DGHIMNPQY EW 4.79 2 3 -1 4 9 0.56 -1684 5.5 hour 3 min 2 min 70.56 16625 977.94 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01669 TCAVACELKWESEFWRWT 18 E1P38-2 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01669.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 2245.56 C103H145N25O28S2 DGHIMNPQY EW 4.78 2 3 -1 5 8 -24.44 -2433 7.2 hour >20 hour >10 hour 48.89 16625 977.94 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01667 NLTCAVACELKWESEFWR 18 E1P38 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50>125 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01667.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 2185.5 C98H145N25O28S2 DGHIMPQY E 4.79 2 3 -1 5 8 -13.89 -2581 1.4 hour 3 min >10 hour 70.56 11125 654.41 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01665 VPNLTCAVACELKWESEF 18 E1P37-1 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=80.0 ± 62.4 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01665.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 2039.35 C91H139N21O28S2 DGHIMQRY E 4.25 1 3 -2 5 8 30.56 -918 100 hour >20 hour >10 hour 86.67 5625 330.88 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01666 PNLTCAVACELKWESEFR 18 E1P37-2 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=99.0 ± 22.5 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01666.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 2096.4 C92H142N24O28S2 DGHIMQY E 4.79 2 3 -1 5 7 -17.78 -2814 >20 hour >20 hour ? 70.56 5625 330.88 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01664 PVPNLTCAVACELKWESE 18 E1P37 Synthetic construct No entry found None HIV Retroviridae Fluorescence resonance energy transfer (FRET) assay [Ref.26905802]HIV-1 NL4-3:inhibition of virus infection in TZM-bl cells(IC50=41.0 ± 8.7 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01664.cif Linear Free Free None L gp41 The peptide inhibits HIV-1 Env-mediated cell fusion thus inhibits virus infection. 1989.29 C87H137N21O28S2 DFGHIMQRY E 4.25 1 3 -2 5 7 6.11 -1216 >20 hour >20 hour ? 86.67 5625 330.88 26905802 Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. "Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I." Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. 10.1016/j.bbagen.2016.02.008 Anti-HIV DRAVPe01663 yAIIXYNKYXNC 12 compound 6 Synthetic construct No entry found None "ZIKV,DENV,WNV" Flaviviridae protease enzymatic inhibition assay [Ref.30783498]Zika Virus(ZIKV):inhibition of flaviviral Protease(Zika virus NS2B-NS3 protease) activity in Huh-7 cells(IC50=3.2 ± 0.4 μM);##Dengue virus serotype 2:inhibition of flaviviral Protease(Zika virus NS2B-NS3 protease) activity in Huh-7 cells(IC50>20 μM);##West Nile virus:inhibition of flaviviral Protease(West Nile virus NS2B-NS3 protease) activity in Huh-7 cells(IC50>20 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01663.cif Linear Thioether-acyl moiety (−S-Ac−)(forms a macrocycle through the side chain of the underlined cysteine residue) Amidation "The 'X' at position 5 indicates N-methyl-4-O-methyl-tyrosine, position 10 indicates N-methyl-leucine." Mixed(D-Tyr1) NS2B-NS3 protease No machanism information found in the reference(s) presented in this entry 1487.12 C50H70N12O11S DEFGHLMPQRSTVW INYX 8.15 1 0 1 5 3 -1.67 -618 73.33 2980 270.91 30783498 ACS Med Chem Lett. 2019 Jan 4;10(2):168-174. "Nitsche C, Passioura T, Varava P, Mahawaththa MC, Leuthold MM, Klein CD, Suga H, Otting G. " De Novo Discovery of Nonstandard Macrocyclic Peptides as Noncompetitive Inhibitors of the Zika Virus NS2B-NS3 Protease. 10.1021/acsmedchemlett.8b00535 "Anti-ZIKV,Anti-DENV,Anti-WNV" DRAVPe01662 YTLPFHNXTFFC 12 compound 5 Synthetic construct No entry found None "ZIKV,DENV,WNV" Flaviviridae protease enzymatic inhibition assay [Ref.30783498]Zika Virus(ZIKV):inhibition of flaviviral Protease(Zika virus NS2B-NS3 protease) activity in Huh-7 cells(IC50≥50 μM);##Dengue virus serotype 2:inhibition of flaviviral Protease(Zika virus NS2B-NS3 protease) activity in Huh-7 cells(IC50>10 μM);##West Nile virus:inhibition of flaviviral Protease(West Nile virus NS2B-NS3 protease) activity in Huh-7 cells(IC50>10 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01662.cif Linear Thioether-acyl moiety (−S-Ac−)(forms a macrocycle through the side chain of the underlined cysteine residue) Amidation The 'X' at position 8 indicates N-methyl-glycine. L NS2B-NS3 protease No machanism information found in the reference(s) presented in this entry 1500.92 C68H86N14O15S ADEGIKMQRSVW F 6.73 1 0 1 5 4 30.83 -144 2.8 hour 10 min 2 min 32.5 1490 135.45 30783498 ACS Med Chem Lett. 2019 Jan 4;10(2):168-174. "Nitsche C, Passioura T, Varava P, Mahawaththa MC, Leuthold MM, Klein CD, Suga H, Otting G. " De Novo Discovery of Nonstandard Macrocyclic Peptides as Noncompetitive Inhibitors of the Zika Virus NS2B-NS3 Protease. 10.1021/acsmedchemlett.8b00535 "Anti-ZIKV,Anti-DENV,Anti-WNV" DRAVPe01661 YXIAKYNXXIPC 12 compound 4 Synthetic construct No entry found None "ZIKV,DENV,WNV" Flaviviridae protease enzymatic inhibition assay [Ref.30783498]Zika Virus(ZIKV):inhibition of flaviviral Protease(Zika virus NS2B-NS3 protease) activity in Huh-7 cells(IC50=4.6 ± 0.3 μM);##Dengue virus serotype 2:inhibition of flaviviral Protease(Zika virus NS2B-NS3 protease) activity in Huh-7 cells(IC50≥20 μM);##West Nile virus:inhibition of flaviviral Protease(West Nile virus NS2B-NS3 protease) activity in Huh-7 cells(IC50≥20 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01661.cif Linear Thioether-acyl moiety (−S-Ac−)(forms a macrocycle through the side chain of the underlined cysteine residue) Amidation "The 'X' at position 2 indicates N-methyl-glycine, position 8 and 9 indicates N-methyl-4-O-methyl-tyrosine." L NS2B-NS3 protease No machanism information found in the reference(s) presented in this entry 1418.29 C51H71N11O10S DEFGHLMQRSTVW X 8.18 1 0 1 4 3 14.17 46 2.8 hour 10 min 2 min 73.33 2980 270.91 30783498 ACS Med Chem Lett. 2019 Jan 4;10(2):168-174. "Nitsche C, Passioura T, Varava P, Mahawaththa MC, Leuthold MM, Klein CD, Suga H, Otting G. " De Novo Discovery of Nonstandard Macrocyclic Peptides as Noncompetitive Inhibitors of the Zika Virus NS2B-NS3 Protease. 10.1021/acsmedchemlett.8b00535 "Anti-ZIKV,Anti-DENV,Anti-WNV" DRAVPe01660 YTNFYLYPYXFC 12 compound 3 Synthetic construct No entry found None "ZIKV,DENV,WNV" Flaviviridae protease enzymatic inhibition assay [Ref.30783498]Zika Virus(ZIKV):inhibition of flaviviral Protease(Zika virus NS2B-NS3 protease) activity in Huh-7 cells(IC50=2.2 ± 0.1 μM);##Dengue virus serotype 2:inhibition of flaviviral Protease(Zika virus NS2B-NS3 protease) activity in Huh-7 cells(IC50>20 μM);##West Nile virus:inhibition of flaviviral Protease(West Nile virus NS2B-NS3 protease) activity in Huh-7 cells(IC50>20 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01660.cif Linear Thioether-acyl moiety (−S-Ac−)(forms a macrocycle through the side chain of the underlined cysteine residue) Amidation The 'X' at position 10 indicates MeYMe(N-methyl-4-O-methyl-tyrosine). L NS2B-NS3 protease No machanism information found in the reference(s) presented in this entry 1605.03 C76H90N12O17S ADEGHIKMQRSVW Y 5.52 0 0 0 7 3 7.5 239 2.8 hour 10 min 2 min 32.5 5960 541.82 30783498 ACS Med Chem Lett. 2019 Jan 4;10(2):168-174. "Nitsche C, Passioura T, Varava P, Mahawaththa MC, Leuthold MM, Klein CD, Suga H, Otting G. " De Novo Discovery of Nonstandard Macrocyclic Peptides as Noncompetitive Inhibitors of the Zika Virus NS2B-NS3 Protease. 10.1021/acsmedchemlett.8b00535 "Anti-ZIKV,Anti-DENV,Anti-WNV" DRAVPe01659 YXKXKXXKXXKC 12 compound 2 Synthetic construct No entry found None "ZIKV,DENV,WNV" Flaviviridae protease enzymatic inhibition assay [Ref.30783498]Zika Virus(ZIKV):inhibition of flaviviral Protease(Zika virus NS2B-NS3 protease) activity in Huh-7 cells(IC50=0.25 ± 0.01 μM);##Dengue virus serotype 2:inhibition of flaviviral Protease(Zika virus NS2B-NS3 protease) activity in Huh-7 cells(IC50=1.7 ± 0.1 μM);##West Nile virus:inhibition of flaviviral Protease(West Nile virus NS2B-NS3 protease) activity in Huh-7 cells(IC50=3.9 ± 0.4 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01659.cif Linear Thioether-acyl moiety (−S-Ac−)(forms a macrocycle through the side chain of the underlined cysteine residue) Amidation "The 'X' at position 2,7,9 and 10 indicates MeYMe(N-methyl-4-O-methyl-tyrosine), position 4 indicates MeF(N-methyl-phenylalanine), position 6 indicates MeS(N-methyl-serine)." L NS2B-NS3 protease No machanism information found in the reference(s) presented in this entry 1465.01 C36H52N10O2S ADEFGHILMNPQRSTVW X 9.87 4 0 4 2 0 -120 -2106 2.8 hour 10 min 2 min 0 1490 135.45 30783498 ACS Med Chem Lett. 2019 Jan 4;10(2):168-174. "Nitsche C, Passioura T, Varava P, Mahawaththa MC, Leuthold MM, Klein CD, Suga H, Otting G. " De Novo Discovery of Nonstandard Macrocyclic Peptides as Noncompetitive Inhibitors of the Zika Virus NS2B-NS3 Protease. 10.1021/acsmedchemlett.8b00535 "Anti-ZIKV,Anti-DENV,Anti-WNV" DRAVPe01658 YWKIXNTLVNIC 12 compound 1 Synthetic construct No entry found None "ZIKV,DENV,WNV" Flaviviridae protease enzymatic inhibition assay [Ref.30783498]Zika Virus(ZIKV):inhibition of flaviviral Protease(Zika virus NS2B-NS3 protease) activity in Huh-7 cells(IC50=1.5 ± 0.1 μM);##Dengue virus serotype 2:inhibition of flaviviral Protease(Zika virus NS2B-NS3 protease) activity in Huh-7 cells(IC50>10 μM);##West Nile virus: inhibition of flaviviral Protease(West Nile virus NS2B-NS3 protease) activity in Huh-7 cells(IC50>10 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01658.cif Linear Thioether-acyl moiety (−S-Ac−)(forms a macrocycle through the side chain of the underlined cysteine residue) Amidation The 'X' at position 4 indicates MeYMe(N-methyl-4-O-methyl-tyrosine). L NS2B-NS3 protease No machanism information found in the reference(s) presented in this entry 1477.97 C64H97N15O15S ADEFGHMPQRS IN 8.2 1 0 1 5 5 47.5 87 2.8 hour 10 min 2 min 121.67 6990 635.45 30783498 ACS Med Chem Lett. 2019 Jan 4;10(2):168-174. "Nitsche C, Passioura T, Varava P, Mahawaththa MC, Leuthold MM, Klein CD, Suga H, Otting G. " De Novo Discovery of Nonstandard Macrocyclic Peptides as Noncompetitive Inhibitors of the Zika Virus NS2B-NS3 Protease. 10.1021/acsmedchemlett.8b00535 "Anti-ZIKV,Anti-DENV,Anti-WNV" DRAVPe01657 GVLV 4 Peptide 6 Synthetic construct No entry found None "SARS-CoV-2,HCMV,VZV" "Coronaviridae, Herpesviridae" Cytopathic effect assay [Ref.34502335]SARS-CoV-2 UC-1074:inhibition of virus activity in Vero cells(EC50≥20 μM);##SARS-CoV-2 UC-1075:inhibition of virus activity in Vero cells(EC50>20 μM);##cytomegalovirus (HCMV) AD-169 Strain:inhibition of virus activity in human embryonic lung (HEL) cells(EC50>4 µM);##cytomegalovirus (HCMV) Davis strain:inhibition of virus activity in human embryonic lung (HEL) cells(EC50>20 µM);##varicella-zoster virus (VZV) TK+ VZV Strain OKA:inhibition of virus activity in human embryonic lung (HEL) cells(EC50>20 µM);##varicella-zoster virus (VZV) TK-VZV Strain 07–1:inhibition of virus activity in human embryonic lung (HEL) cells(EC50>20 µM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.34502335]Vero cell:CC50=77.4 ±0.7 µM. DRAVPe01657.cif Linear Acylation Methyl amidation None L Main protease No machanism information found in the reference(s) presented in this entry 386.49 C18H34N4O5 ACDEFHIKMNPQRSTWY V 5.52 0 0 0 1 3 295 1394 30 hour >20 hour >10 hour 242.5 0 0 34502335 Int J Mol Sci. 2021 Aug 30;22(17):9427. "Di Micco S, Musella S, Sala M, Scala MC, Andrei G, Snoeck R, Bifulco G, Campiglia P, Fasano A." "Peptide Derivatives of the Zonulin Inhibitor Larazotide (AT1001) as Potential Anti SARS-CoV-2: Molecular Modelling, Synthesis and Bioactivity Evaluation." 10.3390/ijms22179427 "Anti-SARS-CoV-2,Anti-HCMV,Anti-VZV" DRAVPe01656 GVLVQ 5 Peptide 5 Synthetic construct No entry found None "SARS-CoV-2,HCMV,VZV" "Coronaviridae, Herpesviridae" Cytopathic effect assay [Ref.34502335]SARS-CoV-2 UC-1074:inhibition of virus activity in Vero cells(EC50≥20 μM);##SARS-CoV-2 UC-1075:inhibition of virus activity in Vero cells(EC50>20 μM);##cytomegalovirus (HCMV) AD-169 Strain:inhibition of virus activity in human embryonic lung (HEL) cells(EC50>20 µM);##cytomegalovirus (HCMV) Davis strain:inhibition of virus activity in human embryonic lung (HEL) cells(EC50>100 µM);##varicella-zoster virus (VZV) TK+ VZV Strain OKA:inhibition of virus activity in human embryonic lung (HEL) cells(EC50=59.80 µM);##varicella-zoster virus (VZV) TK-VZV Strain 07–1:inhibition of virus activity in human embryonic lung (HEL) cells(EC50>100 µM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.34502335]Vero cell:CC50=75.0 ±2.2 µM. DRAVPe01656.cif Linear Acylation Methyl amidation None L Main protease No machanism information found in the reference(s) presented in this entry 514.62 C23H42N6O7 ACDEFHIKMNPRSTWY V 5.52 0 0 0 1 3 166 840 30 hour >20 hour >10 hour 194 0 0 34502335 Int J Mol Sci. 2021 Aug 30;22(17):9427. "Di Micco S, Musella S, Sala M, Scala MC, Andrei G, Snoeck R, Bifulco G, Campiglia P, Fasano A." "Peptide Derivatives of the Zonulin Inhibitor Larazotide (AT1001) as Potential Anti SARS-CoV-2: Molecular Modelling, Synthesis and Bioactivity Evaluation." 10.3390/ijms22179427 "Anti-SARS-CoV-2,Anti-HCMV,Anti-VZV" DRAVPe01655 GGVLVQPG 8 Peptide 4 Synthetic construct No entry found None "SARS-CoV-2,HCMV,VZV" "Coronaviridae, Herpesviridae" Cytopathic effect assay [Ref.34502335]SARS-CoV-2 UC-1074:inhibition of virus activity in Vero cells(EC50≥20 μM);##SARS-CoV-2 UC-1075:inhibition of virus activity in Vero cells(EC50>20 μM);##cytomegalovirus (HCMV) AD-169 Strain:inhibition of virus activity in human embryonic lung (HEL) cells(EC50>20 µM);##cytomegalovirus (HCMV) Davis strain:inhibition of virus activity in human embryonic lung (HEL) cells(EC50=100 µM);##varicella-zoster virus (VZV) TK+ VZV Strain OKA:inhibition of virus activity in human embryonic lung (HEL) cells(EC50=78.20 µM);##varicella-zoster virus (VZV) TK-VZV Strain 07–1:inhibition of virus activity in human embryonic lung (HEL) cells(EC50>100 µM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.34502335]Vero cell:CC50=74.9 ± 4.9 µM. DRAVPe01655.cif Linear Pivaloylation Methyl amidation None L Main protease No machanism information found in the reference(s) presented in this entry 725.84 C32H55N9O10 ACDEFHIKMNRSTWY G 5.52 0 0 0 3 3 73.75 1028 30 hour >20 hour >10 hour 121.25 0 0 34502335 Int J Mol Sci. 2021 Aug 30;22(17):9427. "Di Micco S, Musella S, Sala M, Scala MC, Andrei G, Snoeck R, Bifulco G, Campiglia P, Fasano A." "Peptide Derivatives of the Zonulin Inhibitor Larazotide (AT1001) as Potential Anti SARS-CoV-2: Molecular Modelling, Synthesis and Bioactivity Evaluation." 10.3390/ijms22179427 "Anti-SARS-CoV-2,Anti-HCMV,Anti-VZV" DRAVPe01653 GGVLVQPG 8 Peptide 2 Synthetic construct No entry found None "SARS-CoV-2,HCMV,VZV" "Coronaviridae, Herpesviridae" Cytopathic effect assay [Ref.34502335]SARS-CoV-2 UC-1074:inhibition of virus activity in Vero cells(EC50≥17.6 ± 2.4 μM);##SARS-CoV-2 UC-1075:inhibition of virus activity in Vero cells(EC50>20 μM);##cytomegalovirus (HCMV) AD-169 Strain:inhibition of virus activity in human embryonic lung (HEL) cells(EC50>20 µM);##cytomegalovirus (HCMV) Davis strain:inhibition of virus activity in human embryonic lung (HEL) cells(EC50>20 µM);##varicella-zoster virus (VZV) TK+ VZV Strain OKA:inhibition of virus activity in human embryonic lung (HEL) cells(EC50=50.05 µM);##varicella-zoster virus (VZV) TK-VZV Strain 07–1:inhibition of virus activity in human embryonic lung (HEL) cells(EC50=48.42 µM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.34502335]Vero cell:CC50=83.0 ± 17.0 µM. DRAVPe01653.cif Linear Acylation Amidation None L Main protease No machanism information found in the reference(s) presented in this entry 725.84 C32H55N9O10 ACDEFHIKMNRSTWY G 5.52 0 0 0 3 3 73.75 1028 30 hour >20 hour >10 hour 121.25 0 0 34502335 Int J Mol Sci. 2021 Aug 30;22(17):9427. "Di Micco S, Musella S, Sala M, Scala MC, Andrei G, Snoeck R, Bifulco G, Campiglia P, Fasano A." "Peptide Derivatives of the Zonulin Inhibitor Larazotide (AT1001) as Potential Anti SARS-CoV-2: Molecular Modelling, Synthesis and Bioactivity Evaluation." 10.3390/ijms22179427 "Anti-SARS-CoV-2,Anti-HCMV,Anti-VZV" DRAVPe01654 GGVLVQPG 8 Peptide 3 Synthetic construct No entry found None "SARS-CoV-2,HCMV,VZV" "Coronaviridae, Herpesviridae" Cytopathic effect assay [Ref.34502335]SARS-CoV-2 UC-1074:inhibition of virus activity in Vero cells(EC50>20 μM);##SARS-CoV-2 UC-1075:inhibition of virus activity in Vero cells(EC50>20 μM);##cytomegalovirus (HCMV) AD-169 Strain:inhibition of virus activity in human embryonic lung (HEL) cells(EC50>20 µM);##cytomegalovirus (HCMV) Davis strain:inhibition of virus activity in human embryonic lung (HEL) cells(EC50>100 µM);##varicella-zoster virus (VZV) TK+ VZV Strain OKA:inhibition of virus activity in human embryonic lung (HEL) cells(EC50=58.09 µM);##varicella-zoster virus (VZV) TK-VZV Strain 07–1:inhibition of virus activity in human embryonic lung (HEL) cells(EC50=81.09 µM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.34502335]Vero cell:CC50=81.8 ± 2.1 µM. DRAVPe01654.cif Linear Acylation Methyl amidation None L Main protease No machanism information found in the reference(s) presented in this entry 725.84 C32H55N9O10 ACDEFHIKMNRSTWY G 5.52 0 0 0 3 3 73.75 1028 30 hour >20 hour >10 hour 121.25 0 0 34502335 Int J Mol Sci. 2021 Aug 30;22(17):9427. "Di Micco S, Musella S, Sala M, Scala MC, Andrei G, Snoeck R, Bifulco G, Campiglia P, Fasano A." "Peptide Derivatives of the Zonulin Inhibitor Larazotide (AT1001) as Potential Anti SARS-CoV-2: Molecular Modelling, Synthesis and Bioactivity Evaluation." 10.3390/ijms22179427 "Anti-SARS-CoV-2,Anti-HCMV,Anti-VZV" DRAVPe01652 SAHS 4 Ac-SAHS-NH2 Synthetic construct No entry found None Influenza virus Orthomyxoviridae Neutralization assay [Ref.34681184]A/Roma-ISS/02/08 H1N1:inhibition of virus replication in MDCK cells(EC50=5.77 ± 0.01 × 10−7 μM);##A/Parma/24/09 H1N1:inhibition of virus replication in MDCK cells(EC50=4.3 ± 0.3 × 10−10 μM);##A/Parma0/5/06 H3N2:inhibition of virus replication in MDCK cells(EC50=9.36 ± 0.1 × 10−7 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01652.cif Linear Acylation Amidation None L hemagglutinin (HA) "Hemagglutinin is the major glycoprotein component of the viral envelope along with neuraminidase (NA), peptide derived from Lactoferrin binds Influenza A virus hemagglutinin (HA) inhibiting the hemagglutination and infection of major virus subtypes." 400.39 C15H24N6O7 CDEFGIKLMNPQRTVWY S 6.46 1 0 1 2 1 -75 -965 1.9 hour >20 hour >10 hour 25 0 0 34681184 Pharmaceuticals (Basel). 2021 Sep 23;14(10):959.  "Scala MC, Agamennone M, Pietrantoni A, Di Sarno V, Bertamino A, Superti F, Campiglia P, Sala M." "Discovery of a Novel Tetrapeptide against Influenza A Virus: Rational Design, Synthesis, Bioactivity Evaluation and Computational Studies." 10.3390/ph14100959 Anti-Influenza virus DRAVPe01651 SKHS 4 Peptide 17(lactoferrin 418–421) Synthetic construct P24627 None Influenza virus Orthomyxoviridae Neutralization assay [Ref.28878220]A/Roma-ISS/02/08 H1N1:inhibition of virus replication in MDCK cells(EC50=3 ± 0.61 pM);##A/Parma/24/09 H1N1:inhibition of virus replication in MDCK cells(EC50=0.048 ± 0.0012 pM);##A/Parma0/5/06 H3N2:inhibition of virus replication in MDCK cells(EC50=5.0 ± 0.02 pM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01651.cif Linear Acylation Amidation None L hemagglutinin (HA) "Hemagglutinin is the major glycoprotein component of the viral envelope along with neuraminidase (NA), peptide derived from Lactoferrin binds Influenza A virus hemagglutinin (HA) inhibiting the hemagglutination and infection of major virus subtypes." 457.49 C18H31N7O7 ACDEFGILMNPQRTVWY S 8.49 2 0 2 2 0 -217.5 -1701 1.9 hour >20 hour >10 hour 0 0 0 28878220##34681184 Sci Rep. 2017 Sep 6;7(1):10593.##Pharmaceuticals (Basel). 2021 Sep 23;14(10):959. "Scala MC, Sala M, Pietrantoni A, Spensiero A, Di Micco S, Agamennone M, Bertamino A, Novellino E, Bifulco G, Gomez-Monterrey IM, Superti F, Campiglia P.##Scala MC, Agamennone M, Pietrantoni A, Di Sarno V, Bertamino A, Superti F, Campiglia P, Sala M." "Lactoferrin-derived Peptides Active towards Influenza: Identification of Three Potent Tetrapeptide Inhibitors.##Discovery of a Novel Tetrapeptide against Influenza A Virus: Rational Design, Synthesis, Bioactivity Evaluation and Computational Studies." 10.1038/s41598-017-10492-x##10.3390/ph14100959 Anti-Influenza virus DRAVPe01650 SLDC 4 Peptide 15(lactoferrin 422-425) Synthetic construct P24627 None Influenza virus Orthomyxoviridae Neutralization assay [Ref.28878220]A/Roma-ISS/02/08 H1N1:inhibition of virus replication in MDCK cells(EC50=0.5 ± 0.001 pM);##A/Parma/24/09 H1N1:inhibition of virus replication in MDCK cells(EC50=4.6 ± 0.05 pM);##A/Parma0/5/06 H3N2:inhibition of virus replication in MDCK cells(EC50=4.3 ± 0.03 pM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01650.cif Linear Acylation Amidation None L hemagglutinin (HA) "Hemagglutinin is the major glycoprotein component of the viral envelope along with neuraminidase (NA), peptide derived from Lactoferrin binds Influenza A virus hemagglutinin (HA) inhibiting the hemagglutination and infection of major virus subtypes." 436.48 C16H28N4O8S AEFGHIKMNPQRTVWY CDLS 3.8 0 1 -1 2 1 50 -592 1.9 hour >20 hour >10 hour 97.5 0 0 28878220##34681184 Sci Rep. 2017 Sep 6;7(1):10593.##Pharmaceuticals (Basel). 2021 Sep 23;14(10):959. "Scala MC, Sala M, Pietrantoni A, Spensiero A, Di Micco S, Agamennone M, Bertamino A, Novellino E, Bifulco G, Gomez-Monterrey IM, Superti F, Campiglia P.##Scala MC, Agamennone M, Pietrantoni A, Di Sarno V, Bertamino A, Superti F, Campiglia P, Sala M." "Lactoferrin-derived Peptides Active towards Influenza: Identification of Three Potent Tetrapeptide Inhibitors.##Discovery of a Novel Tetrapeptide against Influenza A Virus: Rational Design, Synthesis, Bioactivity Evaluation and Computational Studies." 10.1038/s41598-017-10492-x##10.3390/ph14100959 Anti-Influenza virus DRAVPe01649 SKHSSLDC 8 Peptide 16(lactoferrin 418-425) Synthetic construct P24627 None Influenza virus Orthomyxoviridae Neutralization assay [Ref.28878220]A/Roma-ISS/02/08 H1N1:inhibition of virus replication in MDCK cells(EC50=80 ± 0.19 pM);##A/Parma/24/09 H1N1:inhibition of virus replication in MDCK cells(EC50=0.1 ± 0.001 pM);##A/Parma0/5/06 H3N2:inhibition of virus replication in MDCK cells(EC50=5.0 ± 0.45 pM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01649.cif Linear Free Free None L hemagglutinin (HA) "Hemagglutinin is the major glycoprotein component of the viral envelope along with neuraminidase (NA), peptide derived from Lactoferrin binds Influenza A virus hemagglutinin (HA) inhibiting the hemagglutination and infection of major virus subtypes." 875.95 C34H57N11O14S AEFGIMNPQRTVWY S 6.46 2 1 1 4 1 -83.75 -2293 1.9 hour >20 hour >10 hour 48.75 0 0 28878220 Sci Rep. 2017 Sep 6;7(1):10593. "Scala MC, Sala M, Pietrantoni A, Spensiero A, Di Micco S, Agamennone M, Bertamino A, Novellino E, Bifulco G, Gomez-Monterrey IM, Superti F, Campiglia P." Lactoferrin-derived Peptides Active towards Influenza: Identification of Three Potent Tetrapeptide Inhibitors. 10.1038/s41598-017-10492-x Anti-Influenza virus DRAVPe01648 VLRP 4 Peptide 14(lactoferrin 426–429) Synthetic construct P24627 3IB0 Influenza virus Orthomyxoviridae Neutralization assay [Ref.28878220]A/Roma-ISS/02/08 H1N1:inhibition of virus replication in MDCK cells(EC50=0.45 ± 0.1 pM);##A/Parma/24/09 H1N1:inhibition of virus replication in MDCK cells(EC50=1 ± 0.05 pM);##A/Parma0/5/06 H3N2:inhibition of virus replication in MDCK cells(EC50=250 ± 0.42 pM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01648.cif Linear Free Free None L hemagglutinin (HA) "Hemagglutinin is the major glycoprotein component of the viral envelope along with neuraminidase (NA), peptide derived from Lactoferrin binds Influenza A virus hemagglutinin (HA) inhibiting the hemagglutination and infection of major virus subtypes." 483.61 C22H41N7O5 ACDEFGHIKMNQSTWY LPRV 9.72 1 0 1 0 2 47.5 -596 100 hour >20 hour >10 hour 170 0 0 28878220 Sci Rep. 2017 Sep 6;7(1):10593. "Scala MC, Sala M, Pietrantoni A, Spensiero A, Di Micco S, Agamennone M, Bertamino A, Novellino E, Bifulco G, Gomez-Monterrey IM, Superti F, Campiglia P." Lactoferrin-derived Peptides Active towards Influenza: Identification of Three Potent Tetrapeptide Inhibitors. 10.1038/s41598-017-10492-x Anti-Influenza virus DRAVPe01647 SLDCVLRP 8 Peptide 13(lactoferrin 422–429) Synthetic construct P24627 3IB0 Influenza virus Orthomyxoviridae Neutralization assay [Ref.28878220]A/Roma-ISS/02/08 H1N1:inhibition of virus replication in MDCK cells(EC50=0.3 ± 0.5 pM);##A/Parma/24/09 H1N1:inhibition of virus replication in MDCK cells(EC50=2.5± 0.37 pM);##A/Parma0/5/06 H3N2:inhibition of virus replication in MDCK cells(EC50=300± 0.2 pM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01647.cif Linear Free Free None L hemagglutinin (HA) "Hemagglutinin is the major glycoprotein component of the viral envelope along with neuraminidase (NA), peptide derived from Lactoferrin binds Influenza A virus hemagglutinin (HA) inhibiting the hemagglutination and infection of major virus subtypes." 902.08 C38H67N11O12S AEFGHIKMNQTWY L 5.55 1 1 0 2 3 48.75 -1188 1.9 hour >20 hour >10 hour 133.75 0 0 28878220 Sci Rep. 2017 Sep 6;7(1):10593. "Scala MC, Sala M, Pietrantoni A, Spensiero A, Di Micco S, Agamennone M, Bertamino A, Novellino E, Bifulco G, Gomez-Monterrey IM, Superti F, Campiglia P." Lactoferrin-derived Peptides Active towards Influenza: Identification of Three Potent Tetrapeptide Inhibitors. 10.1038/s41598-017-10492-x Anti-Influenza virus DRAVPe01646 KSETKN 6 Peptide 8(lactoferrin 633-638) Synthetic construct P24627 3IB0 Influenza virus Orthomyxoviridae Neutralization assay [Ref.28878220]A/Roma-ISS/02/08 H1N1:inhibition of virus replication in MDCK cells(EC50=0.5 ± 0.01 pM);##A/Parma/24/09 H1N1:inhibition of virus replication in MDCK cells(EC50=500 ± 0.46 pM);##A/Parma0/5/06 H3N2:inhibition of virus replication in MDCK cells(EC50=400.000 ± 210 pM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01646.cif Linear Free Free None L hemagglutinin (HA) "Hemagglutinin is the major glycoprotein component of the viral envelope along with neuraminidase (NA), peptide derived from Lactoferrin binds Influenza A virus hemagglutinin (HA) inhibiting the hemagglutination and infection of major virus subtypes." 705.77 C28H51N9O12 ACDFGHILMPQRVWY K 8.59 2 1 1 3 0 -271.67 -3052 1.3 hour 3 min 2 min 0 0 0 28878220 Sci Rep. 2017 Sep 6;7(1):10593. "Scala MC, Sala M, Pietrantoni A, Spensiero A, Di Micco S, Agamennone M, Bertamino A, Novellino E, Bifulco G, Gomez-Monterrey IM, Superti F, Campiglia P." Lactoferrin-derived Peptides Active towards Influenza: Identification of Three Potent Tetrapeptide Inhibitors. 10.1038/s41598-017-10492-x Anti-Influenza virus DRAVPe01645 TNGESTADWAKN 12 Peptide 6(lactoferrin 552-563) Synthetic construct P24627 3IB0 Influenza virus Orthomyxoviridae Neutralization assay [Ref.28878220]A/Roma-ISS/02/08 H1N1:inhibition of virus replication in MDCK cells(EC50=400 ±0.02 pM);##A/Parma/24/09 H1N1:inhibition of virus replication in MDCK cells(EC50=50.000 ± 230 pM);##A/Parma0/5/06 H3N2:inhibition of virus replication in MDCK cells(EC50=10.000± 120 pM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01645.cif Linear Free Free None L hemagglutinin (HA) "Hemagglutinin is the major glycoprotein component of the viral envelope along with neuraminidase (NA), peptide derived from Lactoferrin binds Influenza A virus hemagglutinin (HA) inhibiting the hemagglutination and infection of major virus subtypes." 1293.31 C53H80N16O22 CFHILMPQRVY ANT 4.37 1 2 -1 6 3 -148.33 -3601 7.2 hour >20 hour >10 hour 16.67 5500 500 28878220 Sci Rep. 2017 Sep 6;7(1):10593. "Scala MC, Sala M, Pietrantoni A, Spensiero A, Di Micco S, Agamennone M, Bertamino A, Novellino E, Bifulco G, Gomez-Monterrey IM, Superti F, Campiglia P." Lactoferrin-derived Peptides Active towards Influenza: Identification of Three Potent Tetrapeptide Inhibitors. 10.1038/s41598-017-10492-x Anti-Influenza virus DRAVPe01644 KANEGLTWNSLKDK 14 Peptide 4(lactoferrin 441–454) Synthetic construct P24627 3IB0 Influenza virus Orthomyxoviridae Neutralization assay [Ref.28878220]A/Roma-ISS/02/08 H1N1:inhibition of virus replication in MDCK cells(EC50=1± 0.15 pM);##A/Parma/24/09 H1N1:inhibition of virus replication in MDCK cells(EC50=50.000 ± 250 pM);##A/Parma0/5/06 H3N2:inhibition of virus replication in MDCK cells(EC50=1.000 ± 360 pM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01644.cif Linear Free Free None L hemagglutinin (HA) "Hemagglutinin is the major glycoprotein component of the viral envelope along with neuraminidase (NA), peptide derived from Lactoferrin binds Influenza A virus hemagglutinin (HA) inhibiting the hemagglutination and infection of major virus subtypes." 1603.8 C70H114N20O23 CFHIMPQRVY K 8.5 3 2 1 5 4 -136.43 -3651 1.3 hour 3 min 2 min 62.86 5500 423.08 28878220 Sci Rep. 2017 Sep 6;7(1):10593. "Scala MC, Sala M, Pietrantoni A, Spensiero A, Di Micco S, Agamennone M, Bertamino A, Novellino E, Bifulco G, Gomez-Monterrey IM, Superti F, Campiglia P." Lactoferrin-derived Peptides Active towards Influenza: Identification of Three Potent Tetrapeptide Inhibitors. 10.1038/s41598-017-10492-x Anti-Influenza virus DRAVPe01643 SKHSSLDCVLRP 12 Peptide 1(lactoferrin 418–429) Synthetic construct P24627 3IB0 Influenza virus Orthomyxoviridae Neutralization assay [Ref.28878220]A/Roma-ISS/02/08 H1N1:inhibition of virus replication in MDCK cells(EC50=4 ± 0.37 pM);##A/Parma/24/09 H1N1:inhibition of virus replication in MDCK cells(EC50=3.1 ± 0.12 pM);##A/Parma0/5/06 H3N2:inhibition of virus replication in MDCK cells(EC50=5.8 ± 0.7 pM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information found in the reference(s) presented DRAVPe01643.cif Linear Free Free None L hemagglutinin (HA) "Hemagglutinin is the major glycoprotein component of the viral envelope along with neuraminidase (NA), peptide derived from Lactoferrin binds Influenza A virus hemagglutinin (HA) inhibiting the hemagglutination and infection of major virus subtypes." 1341.55 C56H96N18O18S AEFGIMNQTWY S 7.97 3 1 2 4 3 -40 -2889 1.9 hour >20 hour >10 hour 89.17 0 0 28878220 Sci Rep. 2017 Sep 6;7(1):10593. "Scala MC, Sala M, Pietrantoni A, Spensiero A, Di Micco S, Agamennone M, Bertamino A, Novellino E, Bifulco G, Gomez-Monterrey IM, Superti F, Campiglia P." Lactoferrin-derived Peptides Active towards Influenza: Identification of Three Potent Tetrapeptide Inhibitors. 10.1038/s41598-017-10492-x Anti-Influenza virus DRAVPe01642 AGVSGHGQHGVHG 13 Alloferon-1 [H1A] Synthetic construct P83412 None "HHV,CBV2" "Herpesviridae, Picornaviridae" Antiviral assay(cytopathic effect) [Ref.21766388]Coxsackie virus 971 PT(971 PT CVB2):inhibition of virus replication in LLC-MK2 cells(IC50=358.00 µg/ml). No hemolysis information or data found in the reference(s) presented in this entry "[Ref.21766388]No cytotoxicity against Vero cells,LLC-MK2 cells and Hep-2 cells up to 187.50 µg/ml." DRAVPe01642.cif Linear Free Free None L Not found The peptide may inhibit the replication of DNA and RNA viruses. 1199.25 C49H74N20O16 CDEFIKLMNPRTWY G 7.06 3 0 3 6 3 -43.85 -833 4.4 hour >20 hour >10 hour 52.31 0 0 21766388 J Pept Sci. 2011 Nov;17(11):715-9. "Kuczer M, Midak-Siewirska A, Zahorska R, Luczak M, Konopińska D." Further studies on the antiviral activity of alloferon and its analogues. 10.1002/psc.1388 "Anti-HHV,Anti-CBV2" DRAVPe01641 RGVSGHGQHGVHG 13 Alloferon-1 [H1R] Synthetic construct P83412 None "HHV,CBV2" "Herpesviridae, Picornaviridae" Antiviral assay(cytopathic effect) [Ref.21766388]HHV-1 McIntyre strain:inhibition of virus replication in Vero cells(IC50=321.10 µg/ml);##HHV-1:inhibition of virus replication in Vero cells(IC50=277.50 µg/ml);inhibition of virus replication in HEp-2 cells(IC50=602.18 µg/ml);##Coxsackie virus 971 PT(971 PT CVB2):inhibition of virus replication in LLC-MK2 cells(IC50=577.73 µg/ml);inhibition of virus replication in Hep-2 cells(IC50=167.71 µg/ml);##CVB2:inhibition of virus replication in LLC-MK2 cells(IC50=355.18 µg/ml). No hemolysis information or data found in the reference(s) presented in this entry "[Ref.21766388]No cytotoxicity against Vero cells,LLC-MK2 cells and Hep-2 cells up to 143.75 µg/ml." DRAVPe01641.cif Linear Free Free None L Not found The peptide may inhibit the replication of DNA and RNA viruses. 1284.36 C52H81N23O16 ACDEFIKLMNPTWY G 9.77 4 0 4 6 2 -92.31 -2506 1 hour 2 min 2 min 44.62 0 0 21766388 J Pept Sci. 2011 Nov;17(11):715-9. "Kuczer M, Midak-Siewirska A, Zahorska R, Luczak M, Konopińska D." Further studies on the antiviral activity of alloferon and its analogues. 10.1002/psc.1388 "Anti-HHV,Anti-CBV2" DRAVPe01640 KGVSGHGQHGVHG 13 Alloferon-1 [H1K] Synthetic construct P83412 None "HHV,CBV2" "Herpesviridae, Picornaviridae" Antiviral assay(cytopathic effect) [Ref.21766388]HHV-1 McIntyre strain:inhibition of virus replication in Vero cells(IC50=147.09 µg/ml);inhibition of virus replication in Hep-2 cells(IC50=241.90 µg/ml);##HHV-1:inhibition of virus replication in Vero cells(IC50=9.19 µg/ml);inhibition of virus replication in HEp-2 cells(IC50=12.98 µg/ml);##Coxsackie virus 971 PT(971 PT CVB2):inhibition of virus replication in LLC-MK2 cells(IC50=157.73 µg/ml);inhibition of virus replication in Hep-2 cells(IC50=107.04 µg/ml);##CVB2:inhibition of virus replication in LLC-MK2 cells(IC50=190.67 µg/ml);inhibition of virus replication in Hep-2 cells(IC50=74.00 µg/ml). No hemolysis information or data found in the reference(s) presented in this entry "[Ref.21766388]No cytotoxicity against Vero cells,LLC-MK2 cells and Hep-2 cells up to 218.75 µg/ml." DRAVPe01640.cif Linear Free Free None L Not found The peptide may inhibit the replication of DNA and RNA viruses. 1256.35 C52H81N21O16 ACDEFILMNPRTWY G 8.77 4 0 4 6 2 -87.69 -1569 1.3 hour 3 min 2 min 44.62 0 0 21766388 J Pept Sci. 2011 Nov;17(11):715-9. "Kuczer M, Midak-Siewirska A, Zahorska R, Luczak M, Konopińska D." Further studies on the antiviral activity of alloferon and its analogues. 10.1002/psc.1388 "Anti-HHV,Anti-CBV2" DRAVPe01639 GQGKAHNGRLITANP 15 DENV Envelope glycoprotein (340 – 354) Synthetic construct(derived from DENV Envelope glycoprotein) Q5UB51##P17763 None DENV Flaviviridae Focus-forming assay (FFA) "[Ref.30508603]DENV-1:inhibition of virus infection in Vero cells(83%±3.72% inhibition at 50 μM,IC50=33 μM);##DENV-2:inhibition of virus infection in Vero cells(IC50=10 μM);##DENV-3:inhibition of virus infection in Vero cells(60% inhibition at 20μM);##DENV-4:inhibition of virus infection in Vero cells(55% inhibition at 20μM)." No hemolysis information or data found in the reference(s) presented in this entry [Ref.30508603]<20% cytotoxicity against Vero and C6/36 cells at 200 μM. DRAVPe01639.cif Linear Free Free None L E protein "The peptide acts as inhibitors by binding to the E protein, suppressing its conformational changes, and preventing its binding to the cellular receptor, thereby inhibiting viral entry." 1533.71 C64H108N24O20 CDEFMSVWY G 11 3 0 3 6 4 -91.33 -3024 30 hour >20 hour >10 hour 65.33 0 0 30508603 Virus Res. 2019 Jan 15;260:142-150. "John AM, Jittmittraphap A, Chattanadee S, Alwin Prem Anand A, Shenbagarathai R, Leaungwutiwong P." In vitro analysis of synthetic peptides in blocking the entry of dengue virus. 10.1016/j.virusres.2018.11.016 Anti-DENV DRAVPe01638 DRGWGNGCGLFG 12 DENV Envelope glycoprotein (98-109) Synthetic construct(derived from DENV Envelope glycoprotein) Q5UB51##P17763 None DENV Flaviviridae Focus-forming assay (FFA) "[Ref.30508603]DENV-1:inhibition of virus infection in Vero cells(88%±3.89% inhibition at 50 μM,IC50=10 μM);##DENV-2:inhibition of virus infection in Vero cells(IC50=10 μM);##DENV-3:inhibition of virus infection in Vero cells(60% inhibition at 20μM);##DENV-4:inhibition of virus infection in Vero cells(55% inhibition at 20μM)." No hemolysis information or data found in the reference(s) presented in this entry [Ref.30508603]<20% cytotoxicity against Vero and C6/36 cells at 200 μM. DRAVPe01638.cif Linear Free Free None L E protein "The peptide acts as inhibitors by binding to the E protein, suppressing its conformational changes, and preventing its binding to the cellular receptor, thereby inhibiting viral entry." 1238.34 C53H75N17O16S AEHIKMPQSTVY G 5.83 1 1 0 7 3 -44.17 -1407 1.1 hour 3 min >10 hour 32.5 5500 500 30508603 Virus Res. 2019 Jan 15;260:142-150. "John AM, Jittmittraphap A, Chattanadee S, Alwin Prem Anand A, Shenbagarathai R, Leaungwutiwong P." In vitro analysis of synthetic peptides in blocking the entry of dengue virus. 10.1016/j.virusres.2018.11.016 Anti-DENV DRAVPe01637 LEHGSCVTTMAKDKPTL 17 DENV Envelope glycoprotein (25-41) Synthetic construct(derived from DENV Envelope glycoprotein) Q5UB51##P17763 None DENV Flaviviridae Focus-forming assay (FFA) "[Ref.30508603]DENV-1:inhibition of virus infection in Vero cells(58%±2.55% inhibition at 50 μM,IC50=10 μM);##DENV-2:inhibition of virus infection in Vero cells(IC50=10 μM);##DENV-3:inhibition of virus infection in Vero cells(60% inhibition at 20μM);##DENV-4:inhibition of virus infection in Vero cells(55% inhibition at 20μM)." No hemolysis information or data found in the reference(s) presented in this entry [Ref.30508603]<20% cytotoxicity against Vero and C6/36 cells at 200 μM. DRAVPe01637.cif Linear Free Free None L E protein "The peptide acts as inhibitors by binding to the E protein, suppressing its conformational changes, and preventing its binding to the cellular receptor, thereby inhibiting viral entry." 1831.13 C77H131N21O26S2 FINQRWY T 6.74 3 2 1 6 4 -28.82 -2214 5.5 hour 3 min 2 min 68.82 0 0 30508603 Virus Res. 2019 Jan 15;260:142-150. "John AM, Jittmittraphap A, Chattanadee S, Alwin Prem Anand A, Shenbagarathai R, Leaungwutiwong P." In vitro analysis of synthetic peptides in blocking the entry of dengue virus. 10.1016/j.virusres.2018.11.016 Anti-DENV DRAVPe01636 RRRRRRRXPLSPPLRNTHPQAMQWNSTTF 29 7R-Ahx-HBV Large envelope protein (96-116) Synthetic construct P03138 None HBV Hepadnaviridae FQ-PCR [Ref.21144865]HBV:inhibition of cell proliferation in HepG2.2.15 cells(EC50=6.5 ± 1.5 μM;EC90=41.4 ±8.7 μM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.21144865]HepG2.2.15:LC50=515.9± 43.8 μM. DRAVPe01636.cif Linear Free Free The 'X' at position 8 is 6-aminocaproic acid. L DNA The peptide can efficiently enter cells and inhibit the envelopment of HBV nucleocapsids and subsequent secretion of viral particles. 3628.37 C150H245N59O37S CDEGIKVY R 12.85 9 0 9 7 5 -172.76 -14358 1 hour 2 min 2 min 30.34 5500 196.43 21144865 Antiviral Res. 2011 Jan;89(1):109-14. "Pan XB, Wei L, Han JC, Ma H, Deng K, Cong X." Artificial recombinant cell-penetrating peptides interfere with envelopment of hepatitis B virus nucleocapsid and viral production. 10.1016/j.antiviral.2010.12.001 Anti-HBV DRAVPe01635 RRRRRRRXLDPAFR 14 7R-Ahx-HBV Large envelope protein (19-24) Synthetic construct P03138 None HBV Hepadnaviridae FQ-PCR [Ref.21144865]HBV:inhibition of cell proliferation in HepG2.2.15 cells(EC50=3.0 ± 1.0 μM;EC90=10.9 ± 3.4 μM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.21144865]No cytotoxicity was observed at 1mM of peptide concentration against HepG2.2.15. DRAVPe01635.cif Linear Free Free The 'X' at position 8 is 6-aminocaproic acid. L DNA The peptide can efficiently enter cells and inhibit the envelopment of HBV nucleocapsids and subsequent secretion of viral particles. 1922.47 C75H133N37O15 CEGHIKMNQSTVWY R 12.48 8 1 7 0 3 -233.57 -11837 1 hour 2 min 2 min 35 0 0 21144865 Antiviral Res. 2011 Jan;89(1):109-14. "Pan XB, Wei L, Han JC, Ma H, Deng K, Cong X." Artificial recombinant cell-penetrating peptides interfere with envelopment of hepatitis B virus nucleocapsid and viral production. 10.1016/j.antiviral.2010.12.001 Anti-HBV DRAVPe01633 RRRRRRRXPTSNHSPTSCPPTCPGYRWMCLRRF 33 7R-Ahx-HBV Large envelope protein (219-243) Synthetic construct P03138 None HBV Hepadnaviridae FQ-PCR [Ref.21144865]HBV:inhibition of cell proliferation in HepG2.2.15 cells(EC50=12.8 ± 2.0 μM;EC90=85.6 ± 9.5 μM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.21144865]HepG2.2.15:LC50=457.9 ± 41.0 μM. DRAVPe01633.cif Linear Free Free The 'X' at position 8 is 6-aminocaproic acid. L DNA The peptide can efficiently enter cells and inhibit the envelopment of HBV nucleocapsids and subsequent secretion of viral particles. 4099.99 C167H270N66O40S4 ADEIKQV R 12 11 0 11 12 3 -153.94 -16119 1 hour 2 min 2 min 11.82 7115 222.34 21144865 Antiviral Res. 2011 Jan;89(1):109-14. "Pan XB, Wei L, Han JC, Ma H, Deng K, Cong X." Artificial recombinant cell-penetrating peptides interfere with envelopment of hepatitis B virus nucleocapsid and viral production. 10.1016/j.antiviral.2010.12.001 Anti-HBV DRAVPe01634 RRRRRRRXGSLLGRMKGA 18 7R-Ahx-P3 Synthetic construct None None HBV Hepadnaviridae FQ-PCR [Ref.21144865]HBV:inhibition of cell proliferation in HepG2.2.15 cells(EC50=2.5 ±1.0 μM;EC90=8.6± 3.2 μM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.21144865]HepG2.2.15:LC50=828.7 ± 50.3 μM. DRAVPe01634.cif Linear Free Free The 'X' at position 8 is 6-aminocaproic acid. L DNA The peptide can efficiently enter cells and inhibit the envelopment of HBV nucleocapsids and subsequent secretion of viral particles. 2193.84 C83H158N42O18S CDEFHINPQTVWY R 12.85 9 0 9 4 3 -170 -11149 1 hour 2 min 2 min 48.89 0 0 21144865 Antiviral Res. 2011 Jan;89(1):109-14. "Pan XB, Wei L, Han JC, Ma H, Deng K, Cong X." Artificial recombinant cell-penetrating peptides interfere with envelopment of hepatitis B virus nucleocapsid and viral production. 10.1016/j.antiviral.2010.12.001 Anti-HBV DRAVPe01632 EEQAKTFLDKFNHEAEDLFYQSSGLGKGDFR 31 P6(ACE2 (4-26)-G-ACE2 (333-339)) Synthetic construct(derived from angiotensin-converting enzyme 2) Q9BYF1 None SARS-CoV Coronaviridae Pseudovirus infection assay [Ref.16510163]SARS-CoV:inhibition of pseudovirus infection in HeLa cells(IC50=0.1 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe01632.cif Linear Free Free None L spike glycoprotein "Virus entry into cells is mediated through interactions between spike (S) glycoprotein and angiotensin-converting enzyme 2 (ACE2), peptide derived from ACE2 could bind with spike glycoprotein and inhibits virus entry." 3607.89 C161H236N42O53 CIMPVW EF 4.7 5 7 -2 8 9 -106.45 -8374 1 hour 30 min >10 hour 44.19 1490 49.67 16510163 Virology. 2006 Jun 20;350(1):15-25. "Han DP, Penn-Nicholson A, Cho MW." Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor. 10.1016/j.virol.2006.01.029 Anti-SARS-CoV DRAVPe01631 EEQAKTFLDKFNHEAEDLFYQSSLASWNYNTNITEE 36 P5(ACE2 (4-39)) Synthetic construct(derived from angiotensin-converting enzyme 2) Q9BYF1 None SARS-CoV Coronaviridae Pseudovirus infection assay [Ref.16510163]SARS-CoV:inhibition of pseudovirus infection in HeLa cells(IC50=6 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe01631.cif Linear Free Free None L spike glycoprotein "Virus entry into cells is mediated through interactions between spike (S) glycoprotein and angiotensin-converting enzyme 2 (ACE2), peptide derived from ACE2 could bind with spike glycoprotein and inhibits virus entry." 4313.57 C192H275N47O67 CGMPRV E 4.16 3 8 -5 12 11 -106.39 -9351 1 hour 30 min >10 hour 51.67 8480 242.29 16510163 Virology. 2006 Jun 20;350(1):15-25. "Han DP, Penn-Nicholson A, Cho MW." Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor. 10.1016/j.virol.2006.01.029 Anti-SARS-CoV DRAVPe01630 EEQAKTFLDKFNHEAEDLFYQSS 23 P4(ACE2 (4-26)) Synthetic construct(derived from angiotensin-converting enzyme 2) Q9BYF1 None SARS-CoV Coronaviridae Pseudovirus infection assay [Ref.16510163]SARS-CoV:inhibition of pseudovirus infection in HeLa cells(IC50=50 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe01630.cif Linear Free Free None L spike glycoprotein "Virus entry into cells is mediated through interactions between spike (S) glycoprotein and angiotensin-converting enzyme 2 (ACE2), peptide derived from ACE2 could bind with spike glycoprotein and inhibits virus entry." 2776.95 C124H178N30O43 CGIMPRVW E 4.35 3 6 -3 5 7 -115.22 -6527 1 hour 30 min >10 hour 42.61 1490 67.73 16510163 Virology. 2006 Jun 20;350(1):15-25. "Han DP, Penn-Nicholson A, Cho MW." Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor. 10.1016/j.virol.2006.01.029 Anti-SARS-CoV DRAVPe01629 NHEAEDLFY 9 P3(ACE2 (15-23)) Synthetic construct(derived from angiotensin-converting enzyme 2) Q9BYF1 None SARS-CoV Coronaviridae Pseudovirus infection assay [Ref.16510163]SARS-CoV:inhibition of pseudovirus infection in HeLa cells(30% inhibition at 100 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe01629.cif Linear Free Free None L spike glycoprotein "Virus entry into cells is mediated through interactions between spike (S) glycoprotein and angiotensin-converting enzyme 2 (ACE2), peptide derived from ACE2 could bind with spike glycoprotein and inhibits virus entry." 1137.17 C51H68N12O18 CGIKMPQRSTVW E 4.13 1 3 -2 2 3 -112.22 -2407 1.4 hour 3 min >10 hour 54.44 1490 186.25 16510163 Virology. 2006 Jun 20;350(1):15-25. "Han DP, Penn-Nicholson A, Cho MW." Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor. 10.1016/j.virol.2006.01.029 Anti-SARS-CoV DRAVPe01628 DKFNHEAED 9 P2(ACE2 (12-20)) Synthetic construct(derived from angiotensin-converting enzyme 2) Q9BYF1 None SARS-CoV Coronaviridae Pseudovirus infection assay [Ref.16510163]SARS-CoV:inhibition of pseudovirus infection in HeLa cells(40% inhibition at 100 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe01628.cif Linear Free Free None L spike glycoprotein "Virus entry into cells is mediated through interactions between spike (S) glycoprotein and angiotensin-converting enzyme 2 (ACE2), peptide derived from ACE2 could bind with spike glycoprotein and inhibits virus entry." 1104.1 C46H65N13O19 CGILMPQRSTVWY DE 4.31 2 4 -2 1 2 -222.22 -4312 1.1 hour 3 min >10 hour 11.11 0 0 16510163 Virology. 2006 Jun 20;350(1):15-25. "Han DP, Penn-Nicholson A, Cho MW." Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor. 10.1016/j.virol.2006.01.029 Anti-SARS-CoV DRAVPe01627 EEQAKTFLDK 10 P1(ACE2 (4-13)) Synthetic construct(derived from angiotensin-converting enzyme 2) Q9BYF1 None SARS-CoV Coronaviridae Pseudovirus infection assay [Ref.16510163]SARS-CoV:inhibition of pseudovirus infection in HeLa cells(25% inhibition at 100 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe01627.cif Linear Free Free None L spike glycoprotein "Virus entry into cells is mediated through interactions between spike (S) glycoprotein and angiotensin-converting enzyme 2 (ACE2), peptide derived from ACE2 could bind with spike glycoprotein and inhibits virus entry." 1208.33 C53H85N13O19 CGHIMNPRSVWY EK 4.68 2 3 -1 1 3 -141 -3184 1 hour 30 min >10 hour 49 0 0 16510163 Virology. 2006 Jun 20;350(1):15-25. "Han DP, Penn-Nicholson A, Cho MW." Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor. 10.1016/j.virol.2006.01.029 Anti-SARS-CoV DRAVPe01625 HAKFWW 6 None Synthetic construct No entry found None HIV Retroviridae integrase assay [Ref.8524782]HIV-1:inhibition of integrase-mediated 3'-processing and integration(IC50=30 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe01625.cif Linear Free Amidation None L integrase "The peptide may inhibit integrase-mediated 3'-processing and integration, which is useful for inhibiting virus replication." 874.01 C46H55N11O7 CDEGILMNPQRSTVY W 8.76 2 0 2 0 4 -71.67 -76 3.5 hour 10 min >10 hour 16.67 11000 2200 8524782 Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60. "Puras Lutzke RA, Eppens NA, Weber PA, Houghten RA, Plasterk RH." Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library. 10.1073/pnas.92.25.11456 Anti-HIV DRAVPe01626 HCAFWW 6 None Synthetic construct No entry found None HIV Retroviridae integrase assay [Ref.8524782]HIV-1:inhibition of integrase-mediated 3'-processing and integration(IC50=49 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe01626.cif Linear Free Amidation None L integrase "The peptide may inhibit integrase-mediated 3'-processing and integration, which is useful for inhibiting virus replication." 848.98 C43H48N10O7S DEGIKLMNPQRSTVY W 6.73 1 0 1 1 4 35 607 3.5 hour 10 min >10 hour 16.67 11000 2200 8524782 Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60. "Puras Lutzke RA, Eppens NA, Weber PA, Houghten RA, Plasterk RH." Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library. 10.1073/pnas.92.25.11456 Anti-HIV DRAVPe00001 EEHEKYHSNW 10 NL1 Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>2000 µM);inhibition of strand transfer catalyzed by integrase(IC50>2000 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00001 DRAVPe00001.cif Linear Free Amidation None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1358.39 C60H79N17O20 ACDFGILMPQRTV E 5.33 3 3 0 3 1 -273 -4315 1 hour 30 min >10 hour 0 6990 776.67 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00002 ASCDKCQLKG 10 NL2 Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>2000 µM);inhibition of strand transfer catalyzed by integrase(IC50>2000 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00002 DRAVPe00002.cif Linear Free Amidation None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1052.23 C41H73N13O15S2 EFHIMNPRTVWY CK 8.09 2 1 1 4 2 -54 -1853 4.4 hour >20 hour >10 hour 49 125 13.89 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00003 HGQVDCSPGIWQLDCTH 17 NL3 Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=1000 µM);inhibition of strand transfer catalyzed by integrase(IC50=1000 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00003 DRAVPe00003.cif Linear Free Amidation None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1896.08 C80H118N24O26S2 AEFKMNRY CDGHQ 5.05 2 2 0 6 4 -45.29 -2316 3.5 hour 10 min >10 hour 62.94 5625 351.56 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00004 VHVASGY 7 NL4 Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>2000 µM);inhibition of strand transfer catalyzed by integrase(IC50>2000 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00004 DRAVPe00004.cif Linear Free Amidation None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 731.81 C33H49N9O10 CDEFIKLMNPQRTW V 6.71 1 0 1 3 3 64.29 263 100 hour >20 hour >10 hour 97.14 1490 248.33 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00005 PAETGQET 8 NL5 Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>2000 µM);inhibition of strand transfer catalyzed by integrase(IC50>2000 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00005 DRAVPe00005.cif Linear Free Amidation None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 831.83 C33H53N9O16 CDFHIKLMNRSVWY ET 3.8 0 2 -2 3 1 -151.25 -2155 >20 hour >20 hour ? 12.5 0 0 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00006 TAYFLLKLAGRW 12 NL-6 Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=21±7 µM);inhibition of strand transfer catalyzed by integrase(IC50=2.7±1 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00006 DRAVPe00006.cif Linear Free Amidation None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1438.74 C71H107N17O15 CDEHIMNPQSV L 9.99 2 0 2 3 7 50.83 145 7.2 hour >20 hour >10 hour 114.17 6990 635.45 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00007 GRWPVKT 7 NL7 Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>2000 µM);inhibition of strand transfer catalyzed by integrase(IC50>2000 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00007 DRAVPe00007.cif Linear Free Amidation None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 843 C39H62N12O9 ACDEFHILMNQSY GKPRTVW 11 2 0 2 2 2 -111.43 -1573 30 hour >20 hour >10 hour 41.43 5500 916.67 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00008 HTDNGSNF 8 NL8 Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>2000 µM);inhibition of strand transfer catalyzed by integrase(IC50>2000 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00008 DRAVPe00008.cif Linear Free Amidation None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 890.86 C36H50N12O15 ACEIKLMPQRVWY N 5.08 1 1 0 5 1 -160 -2871 3.5 hour 10 min >10 hour 0 0 0 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00009 ACWWAGIKQEF 11 NL-9 Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=95±9 µM);inhibition of strand transfer catalyzed by integrase(IC50=56±5 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00009 DRAVPe00009.cif Linear Free Amidation None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1338.55 C64H87N15O15S DHLMNPRSTVY AW 6.04 1 1 0 2 6 2.73 50 4.4 hour >20 hour >10 hour 53.64 11000 1100 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00010 FGIPYNPQSQ 10 NL10 Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>1000 µM);inhibition of strand transfer catalyzed by integrase(IC50>1000 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00010 DRAVPe00010.cif Linear Free Amidation None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1150.26 C53H75N13O16 ACDEHKLMRTVW PQ 5.52 0 0 0 4 2 -89 -1242 1.1 hour 3 min 2 min 39 1490 165.56 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00011 ESMNKELKKI 10 NL11 Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>2000 µM);inhibition of strand transfer catalyzed by integrase(IC50>2000 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00011 DRAVPe00011.cif Linear Free Amidation None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1219.46 C52H94N14O17S ACDFGHPQRTVWY K 8.59 3 2 1 2 2 -128 -2812 1 hour 30 min >10 hour 78 0 0 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00012 VRDQAEHLKT 10 NL12 Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>2000 µM);inhibition of strand transfer catalyzed by integrase(IC50>2000 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00012 DRAVPe00012.cif Linear Free Amidation None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1196.33 C50H85N17O17 CFGIMNPSWY ADEHKLQRTV 6.72 3 2 1 1 3 -130 -3800 100 hour >20 hour >10 hour 78 0 0 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00013 FIHNFKRK 8 NL13 Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>2000 µM);inhibition of strand transfer catalyzed by integrase(IC50>2000 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00013 DRAVPe00013.cif Linear Free Amidation None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1089.31 C52H80N16O10 ACDEGLMPQSTVWY FK 11.17 4 0 4 1 3 -111.25 -2644 1.1 hour 3 min 2 min 48.75 0 0 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00014 GYSAGERIVD 10 NL14 Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>2000 µM);inhibition of strand transfer catalyzed by integrase(IC50>2000 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00014 DRAVPe00014.cif Linear Free Amidation None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1066.14 C45H71N13O17 CFHKLMNPQTW G 4.37 1 2 -1 4 3 -39 -2134 30 hour >20 hour >10 hour 78 1490 165.56 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00015 WKGPAKLLWK 10 NL15 Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>1000 µM);inhibition of strand transfer catalyzed by integrase(IC50>1000 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00015 DRAVPe00015.cif Linear Free Amidation None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1226.53 C62H95N15O11 CDEFHIMNQRSTVY K 10.3 3 0 3 1 5 -61 60 2.8 hour 3 min 2 min 88 11000 1222.22 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00016 VPRRKAKI 8 NL16 Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>1000 µM);inhibition of strand transfer catalyzed by integrase(IC50>1000 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00016 DRAVPe00016.cif Linear Free Amidation None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 967.23 C43H82N16O9 CDEFGHLMNQSTWY KR 12.02 4 0 4 0 3 -98.75 -3017 100 hour >20 hour >10 hour 97.5 0 0 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00017 AAYFLLKLAGRW 12 NL6-T1A Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=100±10 µM);inhibition of strand transfer catalyzed by integrase(IC50=47±7 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00017 DRAVPe00017.cif Linear Free Free None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1408.71 C70H105N17O14 CDEHIMNPQSTV AL 9.99 2 0 2 2 8 71.67 583 4.4 hour >20 hour >10 hour 122.5 6990 635.45 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00018 TAAFLLKLAGRW 12 NL6-Y3A Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=193±10 µM);inhibition of strand transfer catalyzed by integrase(IC50=119±11 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00018 DRAVPe00018.cif Linear Free Free None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1346.64 C65H103N17O14 CDEHIMNPQSVY AL 11 2 0 2 2 8 76.67 340 7.2 hour >20 hour >10 hour 122.5 5500 500 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00019 TAYALLKLAGRW 12 NL6-F4A Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>333 µM);inhibition of strand transfer catalyzed by integrase(IC50>333 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00019 DRAVPe00019.cif Linear Free Free None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1362.64 C65H103N17O15 CDEFHIMNPQSV AL 9.99 2 0 2 3 7 42.5 28 7.2 hour >20 hour >10 hour 122.5 6990 635.45 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00020 TAYFALKLAGRW 12 NL6-L5A Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=115±21 µM);inhibition of strand transfer catalyzed by integrase(IC50=51±7 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00020 DRAVPe00020.cif Linear Free Free None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1396.65 C68H101N17O15 CDEHIMNPQSV A 9.99 2 0 2 3 7 34.17 -166 7.2 hour >20 hour >10 hour 90 6990 635.45 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00021 TAYFLAKLAGRW 12 NL6-L6A Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>333 µM);inhibition of strand transfer catalyzed by integrase(IC50>333 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00021 DRAVPe00021.cif Linear Free Free None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1396.65 C68H101N17O15 CDEHIMNPQSV A 9.99 2 0 2 3 7 34.17 -166 7.2 hour >20 hour >10 hour 90 6990 635.45 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00022 TAYFLLALAGRW 12 NL6-K7A Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=113±15 µM);inhibition of strand transfer catalyzed by integrase(IC50=56±7 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00022 DRAVPe00022.cif Linear Free Free None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1381.64 C68H100N16O15 CDEHIKMNPQSV AL 8.41 1 0 1 3 8 98.33 881 7.2 hour >20 hour >10 hour 122.5 6990 635.45 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00023 TAYFLLKAAGRW 12 NL6-L8A Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>333 µM);inhibition of strand transfer catalyzed by integrase(IC50=106±7 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00023 DRAVPe00023.cif Linear Free Free None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1396.65 C68H101N17O15 CDEHIMNPQSV A 9.99 2 0 2 3 7 34.17 -166 7.2 hour >20 hour >10 hour 90 6990 635.45 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00024 TAYFLLKLAARW 12 NL6-G10A Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=118±10 µM);inhibition of strand transfer catalyzed by integrase(IC50=19±6 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00024 DRAVPe00024.cif Linear Free Free None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1452.76 C72H109N17O15 CDEGHIMNPQSV AL 9.99 2 0 2 2 8 69.17 232 7.2 hour >20 hour >10 hour 122.5 6990 635.45 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00025 TAYFLLKLAGAW 12 NL6-R11A Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=83±15 µM);inhibition of strand transfer catalyzed by integrase(IC50=80±8 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00025 DRAVPe00025.cif Linear Free Free None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1353.63 C68H100N14O15 CDEHIMNPQRSV AL 8.26 1 0 1 3 8 103.33 1818 7.2 hour >20 hour >10 hour 122.5 6990 635.45 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00026 TAYFLLKLAGRA 12 NL6-W12A Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>333 µM);inhibition of strand transfer catalyzed by integrase(IC50>333 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00026 DRAVPe00026.cif Linear Free Free None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1323.6 C63H102N16O15 CDEHIMNPQSVW AL 9.99 2 0 2 3 7 73.33 93 7.2 hour >20 hour >10 hour 122.5 1490 135.45 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00027 AAWWAGIKQEF 11 NL9-C2A Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=277±47 µM);inhibition of strand transfer catalyzed by integrase(IC50=311±19 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00027 DRAVPe00027.cif Linear Free Free None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1306.49 C64H87N15O15 CDHLMNPRSTVY A 6.05 1 1 0 1 7 -3.64 103 4.4 hour >20 hour >10 hour 62.73 11000 1100 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00028 ACAWAGIKQEF 11 NL9-W3A Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=33±6 µM);inhibition of strand transfer catalyzed by integrase(IC50=34±8 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00028 DRAVPe00028.cif Linear Free Free None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1223.41 C56H82N14O15S DHLMNPRSTVY A 6.04 1 1 0 2 6 27.27 -2 4.4 hour >20 hour >10 hour 62.73 5500 550 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00029 ACWAAGIKQEF 11 NL9-W4A Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>333 µM);inhibition of strand transfer catalyzed by integrase(IC50>333 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00029 DRAVPe00029.cif Linear Free Free None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1223.41 C56H82N14O15S DHLMNPRSTVY A 6.04 1 1 0 2 6 27.27 -2 4.4 hour >20 hour >10 hour 62.73 5500 550 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00030 ACWWAAIKQEF 11 NL9-G6A Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=90±10 µM);inhibition of strand transfer catalyzed by integrase(IC50=43±7 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00030 DRAVPe00030.cif Linear Free Free None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1352.57 C65H89N15O15S DGHLMNPRSTVY A 6.04 1 1 0 1 7 22.73 137 4.4 hour >20 hour >10 hour 62.73 11000 1100 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00031 ACWWAGAKQEF 11 NL9-I7A Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>333 µM);inhibition of strand transfer catalyzed by integrase(IC50>333 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00031 DRAVPe00031.cif Linear Free Free None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1296.47 C61H81N15O15S DHILMNPRSTVY A 6.04 1 1 0 2 6 -21.82 -261 4.4 hour >20 hour >10 hour 27.27 11000 1100 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00032 ACWWAGIAQEF 11 NL9-K8A Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=62±13 µM);inhibition of strand transfer catalyzed by integrase(IC50=55±7 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00032 DRAVPe00032.cif Linear Free Free None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1281.45 C61H80N14O15S DHKLMNPRSTVY A 4 0 1 -1 2 7 54.55 786 4.4 hour >20 hour >10 hour 62.73 11000 1100 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00033 ACWWAGIKAEF 11 NL9-Q9A Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>333 µM);inhibition of strand transfer catalyzed by integrase(IC50>333 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00033 DRAVPe00033.cif Linear Free Free None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1281.49 C62H84N14O14S DHLMNPQRSTVY A 6.04 1 1 0 2 7 50.91 785 4.4 hour >20 hour >10 hour 62.73 11000 1100 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00034 ACWWAGIKQAF 11 NL9-E10A Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>333 µM);inhibition of strand transfer catalyzed by integrase(IC50>333 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00034 DRAVPe00034.cif Linear Free Free None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1280.51 C62H85N15O13S DEHLMNPRSTVY A 8.27 1 0 1 2 7 50.91 912 4.4 hour >20 hour >10 hour 62.73 11000 1100 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00035 ACWWAGIKQEA 11 NL9-F11A Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=245±13 µM);inhibition of strand transfer catalyzed by integrase(IC50=206±12 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00035 DRAVPe00035.cif Linear Free Free None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1262.45 C58H83N15O15S DFHLMNPRSTVY A 6.04 1 1 0 2 6 -6.36 -67 4.4 hour >20 hour >10 hour 62.73 11000 1100 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00036 TASFLLKLAGRW 12 NL6-1 Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=186±23 µM);inhibition of strand transfer catalyzed by integrase(IC50=11±2 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00036 DRAVPe00036.cif Linear Free Amidation None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1362.64 C65H103N17O15 CDEHIMNPQVY L 11 2 0 2 3 7 55 -181 7.2 hour >20 hour >10 hour 114.17 5500 500 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00037 TAYFLLILAGRW 12 NL6-2 Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=4.1±0.7 µM);inhibition of strand transfer catalyzed by integrase(IC50=3.0±1.0 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00037 DRAVPe00037.cif Linear Free Amidation None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1423.72 C71H106N16O15 CDEHKMNPQSV L 8.41 1 0 1 3 8 120.83 1192 7.2 hour >20 hour >10 hour 146.67 6990 635.45 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00038 TAYFLLKLAGRL 12 NL6-3 Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=315±30 µM);inhibition of strand transfer catalyzed by integrase(IC50=38±2 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00038 DRAVPe00038.cif Linear Free Amidation None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1365.68 C66H108N16O15 CDEHIMNPQSVW L 9.99 2 0 2 3 7 90 404 7.2 hour >20 hour >10 hour 146.67 1490 135.45 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00039 ASWWAGIKQEF 11 NL9-1 Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=294±41 µM);inhibition of strand transfer catalyzed by integrase(IC50=163±15 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00039 DRAVPe00039.cif Linear Free Amidation None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1322.49 C64H87N15O16 CDHLMNPRTVY AW 6.05 1 1 0 2 6 -27.27 -418 4.4 hour >20 hour >10 hour 53.64 11000 1100 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00040 ACGWAGIKQEF 11 NL9-2 Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=46±5 µM);inhibition of strand transfer catalyzed by integrase(IC50=16±2 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00040 DRAVPe00040.cif Linear Free Amidation None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1209.38 C55H80N14O15S DHLMNPRSTVY AG 6.04 1 1 0 3 5 7.27 -89 4.4 hour >20 hour >10 hour 53.64 5500 550 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00041 ACWGAGIKQEF 11 NL9-3 Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>333 µM);inhibition of strand transfer catalyzed by integrase(IC50>333 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00041 DRAVPe00041.cif Linear Free Amidation None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1209.38 C55H80N14O15S DHLMNPRSTVY AG 6.04 1 1 0 3 5 7.27 -89 4.4 hour >20 hour >10 hour 53.64 5500 550 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00042 ACWWAGIRQEF 11 NL9-4 Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>333 µM);inhibition of strand transfer catalyzed by integrase(IC50>333 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00042 DRAVPe00042.cif Linear Free Amidation None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1366.56 C64H87N17O15S DHKLMNPSTVY AW 6.04 1 1 0 2 6 -2.73 -887 4.4 hour >20 hour >10 hour 53.64 11000 1100 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00043 TAYFLL 6 NL6-4 Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=500 µM);inhibition of strand transfer catalyzed by integrase(IC50=500 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00043 DRAVPe00043.cif Linear Free Amidation None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 726.87 C37H54N6O9 CDEGHIKMNPQRSVW L 5.18 0 0 0 2 4 170 1192 7.2 hour >20 hour >10 hour 146.67 1490 298 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00044 YFLLKL 6 NL6-5 Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=20 µM);inhibition of strand transfer catalyzed by integrase(IC50=20 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00044 DRAVPe00044.cif Linear Free Amidation None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 796.02 C42H65N7O8 ACDEGHIMNPQRSTVW L 8.59 1 0 1 1 4 150 1205 2.8 hour 10 min 2 min 195 1490 298 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00045 KLAGRW 6 NL6-6 Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>100 µM);inhibition of strand transfer catalyzed by integrase(IC50>100 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00045 DRAVPe00045.cif Linear Free Amidation None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 729.88 C34H55N11O7 CDEFHIMNPQSTVY AGKLRW 11 2 0 2 1 3 -68.33 -1047 1.3 hour 3 min 2 min 81.67 5500 1100 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00046 ACWWAG 6 NL9-5 Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>100 µM);inhibition of strand transfer catalyzed by integrase(IC50>100 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00046 DRAVPe00046.cif Linear Free Amidation None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 692.79 C33H40N8O7S DEFHIKLMNPQRSTVY AW 5.56 0 0 0 2 4 65 1050 4.4 hour >20 hour >10 hour 33.33 11000 2200 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00047 WAGIKQ 6 NL9-6 Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>100 µM);inhibition of strand transfer catalyzed by integrase(IC50>100 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00047 DRAVPe00047.cif Linear Free Amidation None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 701.82 C33H51N9O8 CDEFHLMNPRSTVY AGIKQW 8.75 1 0 1 1 3 -40 -109 2.8 hour 3 min 2 min 81.67 5500 1100 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00048 IKQEF 5 NL9-7 Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>100 µM);inhibition of strand transfer catalyzed by integrase(IC50>100 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00048 DRAVPe00048.cif Linear Free Amidation None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 663.77 C31H49N7O9 ACDGHLMNPRSTVWY EFIKQ 6 1 1 0 0 2 -72 -1000 20 hour 30 min >10 hour 78 0 0 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00049 tayfllklagrw 12 DNL-6 Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=65±8 µM);inhibition of strand transfer catalyzed by integrase(IC50=13±1 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00049 DRAVPe00049.cif Linear Free Free None D Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1438.74 H-22O-11 ACDEFGHIKLMNPQRSTVWY ACDEFGHIKLMNPQRSTVWY 9.99 0 0 0 0 0 0 0 0 0 0 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00050 WRGALKLLFYAT 12 RNL-6 Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=96±2 µM);inhibition of strand transfer catalyzed by integrase(IC50=16±4 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00050 DRAVPe00050.cif Linear Free Free None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1438.74 C71H107N17O15 CDEHIMNPQSV L 9.99 2 0 2 3 7 50.83 145 2.8 hour 3 min 2 min 114.17 6990 635.45 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00051 wrgalkllfyat 12 RDNL-6 Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=3.5±1 µM);inhibition of strand transfer catalyzed by integrase(IC50=4.0±1 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00051 DRAVPe00051.cif Linear Free Free None D Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1438.74 H-22O-11 ACDEFGHIKLMNPQRSTVWY ACDEFGHIKLMNPQRSTVWY 9.99 0 0 0 0 0 0 0 0 0 0 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00052 acwwagikqef 11 DNL-9 Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>1000 µM);inhibition of strand transfer catalyzed by integrase(IC50>1000 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00052 DRAVPe00052.cif Linear Free Free None D Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1338.55 H-20O-10 ACDEFGHIKLMNPQRSTVWY ACDEFGHIKLMNPQRSTVWY 6.04 0 0 0 0 0 0 0 0 0 0 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00053 FEQKIGAWWCA 11 RNL-9 Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>1000 µM);inhibition of strand transfer catalyzed by integrase(IC50>1000 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00053 DRAVPe00053.cif Linear Free Free None L Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1338.55 C64H87N15O15S DHLMNPRSTVY AW 5.99 1 1 0 2 6 2.73 50 1.1 hour 3 min 2 min 53.64 11000 1100 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00054 feqkigawwca 11 RDNL-9 Synthetic construct(derived from HIV-1 integrase) No entry found None HIV Retroviridae Integrase Assay [Ref.16854053]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>1000 µM);inhibition of strand transfer catalyzed by integrase(IC50>1000 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00054 DRAVPe00054.cif Linear Free Free None D Integrase "HIV-1 integrase (IN) is essential for viral replication. Following reverse transcription of the RNA into DNA by HIV-1 reverse transcriptase, IN integrates the viral DNA into the host genome.The peptide could inbibit integrase(By inhibiting the two steps of IN catalysis: 3′-processing and strand transfer)." 1338.55 H-20O-10 ACDEFGHIKLMNPQRSTVWY ACDEFGHIKLMNPQRSTVWY 5.99 0 0 0 0 0 0 0 0 0 0 16854053 J Med Chem. 2006 Jul 27;49(15):4477-86. "Li HY, Zawahir Z, Song LD, Long YQ, Neamati N." Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme. 10.1021/jm060307u Anti-HIV DRAVPe00055 DFRELNKRTQDFWEVQLGIP 20 4277(derived from DNA-polymerase domain of HIV-1 RT (20-mers)) Synthetic construct(derived from HIV-1 Reverse Transcriptase) No entry found None HIV Retroviridae Dot-blot assay [Ref.15790559]HIV-1:the level of peptide binding to HIV integrase is very low. No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00055 DRAVPe00055.cif Linear Free Free None L Integrase "Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RT DNA polymerase domain inhibits all three integrase-associated activities (3′-end processing, strand transfer, and disintegration) and inhibit virus replication." 2491.79 C113H171N31O33 ACHMSY DEFLQR 4.78 3 4 -1 3 7 -95.5 -5871 1.1 hour 3 min >10 hour 73 5500 289.47 15790559 J Biol Chem. 2005 Jun 10;280(23):21987-96. "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A." Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase. 10.1074/jbc.M414679200 Anti-HIV DRAVPe00056 SPAIFQSSMTKILEPFRKQN 20 4285(derived from DNA-polymerase domain of HIV-1 RT (20-mers)) Synthetic construct(derived from HIV-1 Reverse Transcriptase) No entry found None HIV Retroviridae Dot-blot assay [Ref.15790559]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=35 µM);inhibition of strand transfer catalyzed by integrase(IC50=270 µM);inhibition of disintegration catalyzed by integrase(IC50>100 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00056 DRAVPe00056.cif Linear Free Free None L Integrase "Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RT DNA polymerase domain inhibits all three integrase-associated activities (3′-end processing, strand transfer, and disintegration) and inhibit virus replication." 2322.71 C104H168N28O30S CDGHVWY S 9.99 3 1 2 5 6 -52.5 -3844 1.9 hour >20 hour >10 hour 63.5 0 0 15790559 J Biol Chem. 2005 Jun 10;280(23):21987-96. "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A." Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase. 10.1074/jbc.M414679200 Anti-HIV DRAVPe00057 FRKQNPDIVIYQYMD 15 4286’-1(derived from the DNA-polymerase domain of HIV-1 RT (14-mer) ) Synthetic construct(derived from HIV-1 Reverse Transcriptase) No entry found None HIV Retroviridae Dot-blot assay [Ref.15790559]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=119 µM);inhibition of strand transfer catalyzed by integrase(IC50=97 µM);inhibition of disintegration catalyzed by integrase(IC50>270 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00057 DRAVPe00057.cif Linear Free Free None L Integrase "Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RT DNA polymerase domain inhibits all three integrase-associated activities (3′-end processing, strand transfer, and disintegration) and inhibit virus replication." 1930.21 C88H132N22O25S ACEGHLSTW DIQY 5.96 2 2 0 3 4 -81.33 -3670 1.1 hour 3 min 2 min 71.33 2980 212.86 15790559 J Biol Chem. 2005 Jun 10;280(23):21987-96. "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A." Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase. 10.1074/jbc.M414679200 Anti-HIV DRAVPe00058 KILEPFRKQNPDIVIYQYMD 20 4286(derived from DNA-polymerase domain of HIV-1 RT (20-mers)) Synthetic construct(derived from HIV-1 Reverse Transcriptase) No entry found None HIV Retroviridae Dot-blot assay [Ref.15790559]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=4.8 µM);inhibition of strand transfer catalyzed by integrase(IC50=4.5 µM);inhibition of disintegration catalyzed by integrase(IC50=9.4 µM);##HIV-1:the level of peptide binding to HIV integrase is high. No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00058 DRAVPe00058.cif Linear Free Free None L Integrase "Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RT DNA polymerase domain inhibits all three integrase-associated activities (3′-end processing, strand transfer, and disintegration) and inhibit virus replication." 2510.93 C116H180N28O32S ACGHSTW I 6.12 3 3 0 3 6 -64.5 -3922 1.3 hour 3 min 2 min 92.5 2980 156.84 15790559 J Biol Chem. 2005 Jun 10;280(23):21987-96. "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A." Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase. 10.1074/jbc.M414679200 Anti-HIV DRAVPe00059 PDIVIYQYMDDLYVGSDLEI 20 "4287(derived from DNA-polymerase domain of HIV-1 RT (20-mers)),34(derived from the HIV-1 HXB2 Pol region of the viral genome)" Synthetic construct(derived from HIV-1 Reverse Transcriptase) No entry found None HIV Retroviridae Dot-blot assay "[Ref.15790559]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=22 µM);inhibition of strand transfer catalyzed by integrase(IC50=54 µM);inhibition of disintegration catalyzed by integrase(IC50>120 µM);##HIV-1:the level of peptide binding to HIV integrase is high.##[Ref.16879966]HIV:inhibition of 3′-processing catalyzed by wild-type integrase(IC50=6±1 µM);inhibition of strand transfer catalyzed by wild-type integrase(IC50=10±1 µM);inhibition of 3′-processing catalyzed by soluble mutant integrase(IC50=28±2 µM);inhibition of strand transfer catalyzed by soluble mutant integrase(IC50=23±2 µM);inhibition of 3′-processing catalyzed by C130S integrase(IC50=41±2 µM);inhibition of strand transfer catalyzed by C130S integrase(IC50=2±1 µM);inhibition of 3′-processing catalyzed by C130S integrase(IC50=20 µM);inhibition of strand transfer catalyzed by C130A integrase(IC50=5 µM).##NOTE:soluble mutant,C130S,C130S integrase are mutant IN." No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00059 DRAVPe00059.cif Linear Free Free None L Integrase "Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RT DNA polymerase domain inhibits all three integrase-associated activities (3′-end processing, strand transfer, and disintegration) and inhibit virus replication." 2361.65 C108H161N21O36S ACFHKNRTW D 3.28 0 5 -5 5 7 18.5 -1508 >20 hour >20 hour ? 126.5 4470 235.26 15790559##16879966 J Biol Chem. 2005 Jun 10;280(23):21987-96.##Bioorg Med Chem Lett. 2006 Oct 1;16(19):5199-202. "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.##Zawahir Z, Neamati N." Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.##Inhibition of HIV-1 integrase activity by synthetic peptides derived from the HIV-1 HXB2 Pol region of the viral genome. 10.1074/jbc.M414679200##10.1016/j.bmcl.2006.07.022 Anti-HIV DRAVPe00060 DIQKLVGKLNWASQIYPGIK 20 4295(derived from DNA-polymerase domain of HIV-1 RT (20-mers)) Synthetic construct(derived from HIV-1 Reverse Transcriptase) No entry found None HIV Retroviridae Dot-blot assay [Ref.15790559]HIV-1:the level of peptide binding to HIV integrase is low. No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00060 DRAVPe00060.cif Linear Free Free None L Integrase "Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RT DNA polymerase domain inhibits all three integrase-associated activities (3′-end processing, strand transfer, and disintegration) and inhibit virus replication." 2271.69 C106H171N27O28 CEFHMRT IK 9.53 3 1 2 5 8 -20 -1197 1.1 hour 3 min >10 hour 117 6990 367.89 15790559 J Biol Chem. 2005 Jun 10;280(23):21987-96. "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A." Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase. 10.1074/jbc.M414679200 Anti-HIV DRAVPe00061 IAEIQKQGQGQWTYQIYQEP 20 4302(derived from DNA-polymerase domain of HIV-1 RT (20-mers)) Synthetic construct(derived from HIV-1 Reverse Transcriptase) No entry found None HIV Retroviridae Dot-blot assay [Ref.15790559]HIV-1:the level of peptide binding to HIV integrase is high. No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00061 DRAVPe00061.cif Linear Free Free None L Integrase "Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RT DNA polymerase domain inhibits all three integrase-associated activities (3′-end processing, strand transfer, and disintegration) and inhibit virus replication." 2408.65 C109H162N28O34 CDFHLMNRSV Q 4.53 1 2 -1 5 5 -116 -3448 20 hour 30 min >10 hour 63.5 8480 446.32 15790559 J Biol Chem. 2005 Jun 10;280(23):21987-96. "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A." Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase. 10.1074/jbc.M414679200 Anti-HIV DRAVPe00062 KQLTEAVQKITTEAnti-SIVIWGK 20 "4306(derived from DNA-polymerase domain of HIV-1 RT (20-mers)),53(derived from the HIV-1 HXB2 Pol region of the viral genome)" Synthetic construct(derived from HIV-1 Reverse Transcriptase) No entry found None HIV Retroviridae Dot-blot assay "[Ref.15790559]HIV-1:the level of peptide binding to HIV integrase is high.##[Ref.16879966]HIV:inhibition of 3′-processing catalyzed by wild-type integrase(IC50=7±1 µM);inhibition of strand transfer catalyzed by wild-type integrase(IC50=4±1 µM);inhibition of 3′-processing catalyzed by soluble mutant integrase(IC50=51±7 µM);inhibition of strand transfer catalyzed by soluble mutant integrase(IC50=31±7 µM);inhibition of 3′-processing catalyzed by C130S integrase(IC50=29±1 µM);inhibition of strand transfer catalyzed by C130S integrase(IC50=2±1 µM);inhibition of 3′-processing catalyzed by C130S integrase(IC50=15 µM);inhibition of strand transfer catalyzed by C130A integrase(IC50=10 µM).##NOTE:soluble mutant,C130S,C130S integrase are mutant IN." No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00062 DRAVPe00062.cif Linear Free Free None L Integrase "Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RT DNA polymerase domain inhibits all three integrase-associated activities (3′-end processing, strand transfer, and disintegration) and inhibit virus replication." 2272.67 C103H174N26O31 CDFHMNPRY IKT 8.5 3 2 1 5 8 -12 -1962 1.3 hour 3 min 2 min 112 5500 289.47 15790559##16879966 J Biol Chem. 2005 Jun 10;280(23):21987-96.##Bioorg Med Chem Lett. 2006 Oct 1;16(19):5199-202. "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.##Zawahir Z, Neamati N." Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.##Inhibition of HIV-1 integrase activity by synthetic peptides derived from the HIV-1 HXB2 Pol region of the viral genome. 10.1074/jbc.M414679200##10.1016/j.bmcl.2006.07.022 Anti-HIV DRAVPe00063 TPKFKLPIQKETWETWWTEY 20 4308(derived from DNA-polymerase domain of HIV-1 RT (20-mers)) Synthetic construct(derived from HIV-1 Reverse Transcriptase) No entry found None HIV Retroviridae Dot-blot assay [Ref.15790559]HIV-1:the level of peptide binding to HIV integrase is high. No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00063 DRAVPe00063.cif Linear Free Free None L Integrase "Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RT DNA polymerase domain inhibits all three integrase-associated activities (3′-end processing, strand transfer, and disintegration) and inhibit virus replication." 2611.98 C127H179N27O33 ACDGHMNRSV T 5.9 3 3 0 5 6 -123 -3323 7.2 hour >20 hour >10 hour 39 17990 946.84 15790559 J Biol Chem. 2005 Jun 10;280(23):21987-96. "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A." Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase. 10.1074/jbc.M414679200 Anti-HIV DRAVPe00064 ETWETWWTEYWQATWIPEWE 20 "4309(derived from DNA-polymerase domain of HIV-1 RT (20-mers)),56(derived from the HIV-1 HXB2 Pol region of the viral genome)" Synthetic construct(derived from HIV-1 Reverse Transcriptase) No entry found None HIV Retroviridae Dot-blot assay "[Ref.16879966]HIV:inhibition of 3′-processing catalyzed by wild-type integrase(IC50=6±1 µM);inhibition of strand transfer catalyzed by wild-type integrase(IC50=2±1 µM);inhibition of 3′-processing catalyzed by soluble mutant integrase(IC50=13±2 µM);inhibition of strand transfer catalyzed by soluble mutant integrase(IC50=9±2 µM);inhibition of 3′-processing catalyzed by C130S integrase(IC50=126±3 µM);inhibition of strand transfer catalyzed by C130S integrase(IC50=27±1 µM);inhibition of 3′-processing catalyzed by C130S integrase(IC50=25 µM);inhibition of strand transfer catalyzed by C130A integrase(IC50=5 µM).##NOTE:soluble mutant,C130S,C130S integrase are mutant IN." No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00064 DRAVPe00064.cif Linear Free Free None L Integrase "Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RT DNA polymerase domain inhibits all three integrase-associated activities (3′-end processing, strand transfer, and disintegration) and inhibit virus replication." 2757.95 C135H165N27O37 CDFGHKLMNRSV W 3.51 0 5 -5 5 8 -129 -2930 1 hour 30 min >10 hour 24.5 34490 1815.26 15790559##16879966 J Biol Chem. 2005 Jun 10;280(23):21987-96.##Bioorg Med Chem Lett. 2006 Oct 1;16(19):5199-202. "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.##Zawahir Z, Neamati N." Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.##Inhibition of HIV-1 integrase activity by synthetic peptides derived from the HIV-1 HXB2 Pol region of the viral genome. 10.1074/jbc.M414679200##10.1016/j.bmcl.2006.07.022 Anti-HIV DRAVPe00065 GYVTNRGRQKVVTLTDTTNQ 20 4315(derived from the RNase H domain of HIV-1 RT (20-mes)) Synthetic construct(derived from HIV-1 Reverse Transcriptase) No entry found None HIV Retroviridae Dot-blot assay [Ref.15790559]HIV-1:the level of peptide binding to HIV integrase is very low No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00065 DRAVPe00065.cif Linear Free Free None L Integrase Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RNase H domain of HIV-1 RT inhibits integrase-associated activities (3′-end processing and strand transfer) and inhibit virus replication. 2251.48 C94H159N31O33 ACEFHIMPSW T 9.99 3 1 2 10 4 -98 -6254 30 hour >20 hour >10 hour 63 1490 78.42 15790559 J Biol Chem. 2005 Jun 10;280(23):21987-96. "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A." Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase. 10.1074/jbc.M414679200 Anti-HIV DRAVPe00066 VVTLTDTTNQKTELQAIYLA 20 4316(derived from the RNase H domain of HIV-1 RT (20-mes)) Synthetic construct(derived from HIV-1 Reverse Transcriptase) No entry found None HIV Retroviridae Dot-blot assay [Ref.15790559]HIV-1:the level of peptide binding to HIV integrase is high. No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00066 DRAVPe00066.cif Linear Free Free None L Integrase Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RNase H domain of HIV-1 RT inhibits integrase-associated activities (3′-end processing and strand transfer) and inhibit virus replication. 2222.52 C98H164N24O34 CFGHMPRSW T 4.37 1 2 -1 7 8 8.5 -2041 100 hour >20 hour >10 hour 117 1490 78.42 15790559 J Biol Chem. 2005 Jun 10;280(23):21987-96. "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A." Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase. 10.1074/jbc.M414679200 Anti-HIV DRAVPe00067 KTELQAIYLALQDSGLEVNI 20 4317(derived from the RNase H domain of HIV-1 RT (20-mes)) Synthetic construct(derived from HIV-1 Reverse Transcriptase) No entry found None HIV Retroviridae Dot-blot assay [Ref.15790559]HIV-1:the level of peptide binding to HIV integrase is low No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00067 DRAVPe00067.cif Linear Free Free None L Integrase Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RNase H domain of HIV-1 RT inhibits integrase-associated activities (3′-end processing and strand transfer) and inhibit virus replication. 2218.53 C99H164N24O33 CFHMPRW L 4.14 1 3 -2 5 9 19.5 -1360 1.3 hour 3 min 2 min 141.5 1490 78.42 15790559 J Biol Chem. 2005 Jun 10;280(23):21987-96. "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A." Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase. 10.1074/jbc.M414679200 Anti-HIV DRAVPe00068 LQDSGLEVNIVTDSQYALGI 20 "4318(derived from the RNase H domain of HIV-1 RT (20-mes)),65(derived from the HIV-1 HXB2 Pol region of the viral genome)" Synthetic construct(derived from HIV-1 Reverse Transcriptase) No entry found None HIV Retroviridae Dot-blot assay "[Ref.16879966]HIV:inhibition of 3′-processing catalyzed by wild-type integrase(IC50=11±1 µM);inhibition of strand transfer catalyzed by wild-type integrase(IC50=2±1 µM);inhibition of 3′-processing catalyzed by soluble mutant integrase(IC50>167 µM);inhibition of strand transfer catalyzed by soluble mutant integrase(IC50=36±14 µM);inhibition of 3′-processing catalyzed by C130S integrase(IC50=18±3 µM);inhibition of strand transfer catalyzed by C130S integrase(IC50=4±1 µM);inhibition of 3′-processing catalyzed by C130S integrase(IC50>167 µM);inhibition of strand transfer catalyzed by C130A integrase(IC50=20 µM).##NOTE:soluble mutant,C130S,C130S integrase are mutant IN." No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00068 DRAVPe00068.cif Linear Free Free None L Integrase Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RNase H domain of HIV-1 RT inhibits integrase-associated activities (3′-end processing and strand transfer) and inhibit virus replication. 2135.36 C93H151N23O34 CFHKMPRW L 3.49 0 3 -3 7 8 26 -1511 5.5 hour 3 min 2 min 131.5 1490 78.42 15790559##16879966 J Biol Chem. 2005 Jun 10;280(23):21987-96.##Bioorg Med Chem Lett. 2006 Oct 1;16(19):5199-202. "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.##Zawahir Z, Neamati N." Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.##Inhibition of HIV-1 integrase activity by synthetic peptides derived from the HIV-1 HXB2 Pol region of the viral genome. 10.1074/jbc.M414679200##10.1016/j.bmcl.2006.07.022 Anti-HIV DRAVPe00069 VTDSQYALGIIQAQPDQSES 20 4319(derived from the RNase H domain of HIV-1 RT (20-mes)) Synthetic construct(derived from HIV-1 Reverse Transcriptase) No entry found None HIV Retroviridae Dot-blot assay [Ref.15790559]HIV-1:the level of peptide binding to HIV integrase is low. No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00069 DRAVPe00069.cif Linear Free Free None L Integrase Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RNase H domain of HIV-1 RT inhibits integrase-associated activities (3′-end processing and strand transfer) and inhibit virus replication. 2150.28 C91H144N24O36 CFHKMNRW Q 3.49 0 3 -3 6 6 -51.5 -3596 100 hour >20 hour >10 hour 83 1490 78.42 15790559 J Biol Chem. 2005 Jun 10;280(23):21987-96. "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A." Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase. 10.1074/jbc.M414679200 Anti-HIV DRAVPe00070 IQAQPDQSESELVNQIIEQL 20 4320(derived from the RNase H domain of HIV-1 RT (20-mes)) Synthetic construct(derived from HIV-1 Reverse Transcriptase) No entry found None HIV Retroviridae Dot-blot assay [Ref.15790559]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>120 µM);inhibition of strand transfer catalyzed by integrase(IC50>120 µM);inhibition of disintegration catalyzed by integrase(IC50>120 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00070 DRAVPe00070.cif Linear Free Free None L Integrase Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RNase H domain of HIV-1 RT inhibits integrase-associated activities (3′-end processing and strand transfer) and inhibit virus replication. 2282.49 C97H160N26O37 CFGHKMRTWY Q 3.5 0 4 -4 3 7 -55.5 -3984 20 hour 30 min >10 hour 117 0 0 15790559 J Biol Chem. 2005 Jun 10;280(23):21987-96. "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A." Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase. 10.1074/jbc.M414679200 Anti-HIV DRAVPe00071 ELVNQIIEQLIKKEKVYLAW 20 "4321(derived from the RNase H domain of HIV-1 RT (20-mes)),64(derived from the HIV-1 HXB2 Pol region of the viral genome)" Synthetic construct(derived from HIV-1 Reverse Transcriptase) No entry found None HIV Retroviridae Dot-blot assay "[Ref.15790559]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50=6.9 µM);inhibition of strand transfer catalyzed by integrase(IC50=5 µM);inhibition of disintegration catalyzed by integrase(IC50>100 µM);##HIV-1:the level of peptide binding to HIV integrase is high.##[Ref.16879966]HIV:inhibition of 3′-processing catalyzed by wild-type integrase(IC50=15±2 µM);inhibition of strand transfer catalyzed by wild-type integrase(IC50=14±4 µM);inhibition of 3′-processing catalyzed by soluble mutant integrase(IC50=113±11 µM);inhibition of strand transfer catalyzed by soluble mutant integrase(IC50=83±5 µM);inhibition of 3′-processing catalyzed by C130S integrase(IC50=136±5 µM);inhibition of strand transfer catalyzed by C130S integrase(IC50=7±1 µM);inhibition of 3′-processing catalyzed by C130S integrase(IC50=45 µM);inhibition of strand transfer catalyzed by C130A integrase(IC50=15 µM).##NOTE:soluble mutant,C130S,C130S integrase are mutant IN." No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00071 DRAVPe00071.cif Linear Free Free None L Integrase Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RNase H domain of HIV-1 RT inhibits integrase-associated activities (3′-end processing and strand transfer) and inhibit virus replication. 2457.94 C116H189N27O31 CDFGHMPRST EIKL 6.32 3 3 0 2 10 1 -1320 1 hour 30 min >10 hour 151 6990 367.89 15790559##16879966 J Biol Chem. 2005 Jun 10;280(23):21987-96.##Bioorg Med Chem Lett. 2006 Oct 1;16(19):5199-202. "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.##Zawahir Z, Neamati N." Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.##Inhibition of HIV-1 integrase activity by synthetic peptides derived from the HIV-1 HXB2 Pol region of the viral genome. 10.1074/jbc.M414679200##10.1016/j.bmcl.2006.07.022 Anti-HIV DRAVPe00072 NQIIEQLIKKEKVY 14 4321’-1( derived from the RNase H domain of HIV-1 RT (15-mer)) Synthetic construct(derived from HIV-1 Reverse Transcriptase) No entry found None HIV Retroviridae Dot-blot assay [Ref.15790559]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>240 µM);inhibition of strand transfer catalyzed by integrase(IC50>240 µM);inhibition of disintegration catalyzed by integrase(IC50>120 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00072 DRAVPe00072.cif Linear Free Free None L Integrase Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RNase H domain of HIV-1 RT inhibits integrase-associated activities (3′-end processing and strand transfer) and inhibit virus replication. 1746.08 C80H136N20O23 ACDFGHMPRSTW IK 8.43 3 2 1 2 5 -64.29 -2441 1.4 hour 3 min >10 hour 132.14 1490 114.62 15790559 J Biol Chem. 2005 Jun 10;280(23):21987-96. "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A." Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase. 10.1074/jbc.M414679200 Anti-HIV DRAVPe00073 IKKEKVYLAWVPAHKGIGN 19 4322(derived from the RNase H domain of HIV-1 RT (20-mes)) Synthetic construct(derived from HIV-1 Reverse Transcriptase) No entry found None HIV Retroviridae Dot-blot assay [Ref.15790559]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>120 µM);inhibition of strand transfer catalyzed by integrase(IC50>120 µM);inhibition of disintegration catalyzed by integrase(IC50>120 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00073 DRAVPe00073.cif Linear Free Free None L Integrase Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RNase H domain of HIV-1 RT inhibits integrase-associated activities (3′-end processing and strand transfer) and inhibit virus replication. 2151.58 C102H163N27O24 CDFMQRST K 9.83 5 1 4 4 8 -29.47 -978 20 hour 30 min >10 hour 102.63 6990 388.33 15790559 J Biol Chem. 2005 Jun 10;280(23):21987-96. "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A." Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase. 10.1074/jbc.M414679200 Anti-HIV DRAVPe00074 EQVDKLVSAGIRKVLFLDGI 20 4324(derived from the RNase H domain of HIV-1 RT (20-mes)) Synthetic construct(derived from HIV-1 Reverse Transcriptase) No entry found None HIV Retroviridae Dot-blot assay [Ref.15790559]HIV-1:the level of peptide binding to HIV integrase is high. No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00074 DRAVPe00074.cif Linear Free Free None L Integrase Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RNase H domain of HIV-1 RT inhibits integrase-associated activities (3′-end processing and strand transfer) and inhibit virus replication. 2200.61 C100H170N26O29 CHMNPTWY LV 6.22 3 3 0 3 10 48.5 -1582 1 hour 30 min >10 hour 146 0 0 15790559 J Biol Chem. 2005 Jun 10;280(23):21987-96. "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A." Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase. 10.1074/jbc.M414679200 Anti-HIV DRAVPe00075 ESELVSQIIEQLIKK 15 5628(derived from RNase H domain of HIV-1 RT (15-mers)) Synthetic construct(derived from HIV-1 Reverse Transcriptase) No entry found None HIV Retroviridae Dot-blot assay [Ref.15790559]HIV-1:Inhibition of 3′-processing catalyzed by integrase(IC50>120 µM);inhibition of strand transfer catalyzed by integrase(IC50=60 µM);inhibition of disintegration catalyzed by integrase(IC50>120 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00075 DRAVPe00075.cif Linear Free Free None L Integrase Two viral encoded enzymes(reverse transcriptase and integrase) play central roles in the early stages of the replication of retroviruses and retrotransposons.The peptide derived from the RNase H domain of HIV-1 RT inhibits integrase-associated activities (3′-end processing and strand transfer) and inhibit virus replication. 1757.06 C78H137N19O26 ACDFGHMNPRTWY EI 4.79 2 3 -1 2 6 -10.67 -2077 1 hour 30 min >10 hour 149.33 0 0 15790559 J Biol Chem. 2005 Jun 10;280(23):21987-96. "Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A." Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase. 10.1074/jbc.M414679200 Anti-HIV DRAVPe00076 LQQLLFIHFRIGCQH 15 Vpr 15 Synthetic construct(HIV-1 gene product) No entry found None HIV Retroviridae Luciferase assay [Ref.20586421]HIV-1:inhibition of strand transfer catalyzed by integrase(IC50=5.5 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00076 DRAVPe00076.cif Linear Free Free None L Integrase "IN is an essential enzyme for the stable infection of host cells because it catalyzes the insertion of viral DNA inside the pre-integration complex (PIC) into the genome of host cells in two successive reactions, designated as strand transfer and 3′-end-processing. The peptide could inhibit the activity of integrase and thus inhibit virus replication." 1853.22 C86H133N25O19S ADEKMNPSTVWY LQ 8.27 3 0 3 2 7 44.67 -808 5.5 hour 3 min 2 min 130 0 0 20586421 J Med Chem. 2010 Jul 22;53(14):5356-60. "Suzuki S, Urano E, Hashimoto C, Tsutsumi H, Nakahara T, Tanaka T, Nakanishi Y, Maddali K, Han Y, Hamatake M, Miyauchi K, Pommier Y, Beutler JA, Sugiura W, Fuji H, Hoshino T, Itotani K, Nomura W, Narumi T, Yamamoto N, Komano JA, Tamamura H. " Peptide HIV-1 integrase inhibitors from HIV-1 gene products. 10.1021/jm1003528 Anti-HIV DRAVPe00077 TNWLWYIKIFIMIV 14 Env4-4 Synthetic construct No entry found None HIV Retroviridae Luciferase assay [Ref.20586421]HIV-1:inhibition of strand transfer catalyzed by integrase(IC50=1.9 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00077 DRAVPe00077.cif Linear Free Free None L Integrase "IN is an essential enzyme for the stable infection of host cells because it catalyzes the insertion of viral DNA inside the pre-integration complex (PIC) into the genome of host cells in two successive reactions, designated as strand transfer and 3′-end-processing. The peptide could inhibit the activity of integrase and thus inhibit virus replication." 1840.3 C94H138N18O18S ACDEGHPQRS I 8.26 1 0 1 3 9 139.29 2373 7.2 hour >20 hour >10 hour 160 12490 960.77 20586421 J Med Chem. 2010 Jul 22;53(14):5356-60. "Suzuki S, Urano E, Hashimoto C, Tsutsumi H, Nakahara T, Tanaka T, Nakanishi Y, Maddali K, Han Y, Hamatake M, Miyauchi K, Pommier Y, Beutler JA, Sugiura W, Fuji H, Hoshino T, Itotani K, Nomura W, Narumi T, Yamamoto N, Komano JA, Tamamura H. " Peptide HIV-1 integrase inhibitors from HIV-1 gene products. 10.1021/jm1003528 Anti-HIV DRAVPe00078 LQQLLF 6 Vpr-1 Synthetic construct(derived from HIV-1 gene products(Vpr)) No entry found None HIV Retroviridae Luciferase assay [Ref.20586421]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50>11 µM);inhibition of strand transfer catalyzed by integrase(IC50=68±1.0 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00078 DRAVPe00078.cif Linear Acetylation Amidation None L Integrase "IN is an essential enzyme for the stable infection of host cells because it catalyzes the insertion of viral DNA inside the pre-integration complex (PIC) into the genome of host cells in two successive reactions, designated as strand transfer and 3′-end-processing. The peptide could inhibit the activity of integrase and thus inhibit virus replication." 760.93 C37H60N8O9 ACDEGHIKMNPRSTVWY L 5.52 0 0 0 0 4 120 666 5.5 hour 3 min 2 min 195 0 0 20586421 J Med Chem. 2010 Jul 22;53(14):5356-60. "Suzuki S, Urano E, Hashimoto C, Tsutsumi H, Nakahara T, Tanaka T, Nakanishi Y, Maddali K, Han Y, Hamatake M, Miyauchi K, Pommier Y, Beutler JA, Sugiura W, Fuji H, Hoshino T, Itotani K, Nomura W, Narumi T, Yamamoto N, Komano JA, Tamamura H. " Peptide HIV-1 integrase inhibitors from HIV-1 gene products. 10.1021/jm1003528 Anti-HIV DRAVPe00079 LQQLLFRRRRRRRR 14 Vpr-1 R8 Synthetic construct(derived from HIV-1 gene products(Vpr)) No entry found None HIV Retroviridae Luciferase assay [Ref.20586421]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=6.1±1.1 µM);inhibition of strand transfer catalyzed by integrase(IC50>11 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00079 DRAVPe00079.cif Linear Acetylation Amidation None L Integrase "IN is an essential enzyme for the stable infection of host cells because it catalyzes the insertion of viral DNA inside the pre-integration complex (PIC) into the genome of host cells in two successive reactions, designated as strand transfer and 3′-end-processing. The peptide could inhibit the activity of integrase and thus inhibit virus replication." 2010.43 C85H156N40O17 ACDEGHIKMNPSTVWY R 12.85 8 0 8 0 4 -205.71 -11270 5.5 hour 3 min 2 min 83.57 0 0 20586421 J Med Chem. 2010 Jul 22;53(14):5356-60. "Suzuki S, Urano E, Hashimoto C, Tsutsumi H, Nakahara T, Tanaka T, Nakanishi Y, Maddali K, Han Y, Hamatake M, Miyauchi K, Pommier Y, Beutler JA, Sugiura W, Fuji H, Hoshino T, Itotani K, Nomura W, Narumi T, Yamamoto N, Komano JA, Tamamura H. " Peptide HIV-1 integrase inhibitors from HIV-1 gene products. 10.1021/jm1003528 Anti-HIV DRAVPe00080 IHFRIGRRRRRRRR 14 Vpr-2 R8 Synthetic construct(derived from HIV-1 gene products(Vpr)) No entry found None HIV Retroviridae Luciferase assay [Ref.20586421]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=0.70±0.06 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.83±0.07 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00080 DRAVPe00080.cif Linear Acetylation Amidation None L Integrase "IN is an essential enzyme for the stable infection of host cells because it catalyzes the insertion of viral DNA inside the pre-integration complex (PIC) into the genome of host cells in two successive reactions, designated as strand transfer and 3′-end-processing. The peptide could inhibit the activity of integrase and thus inhibit virus replication." 1991.39 C83H151N43O15 ACDEKLMNPQSTVWY R 12.9 10 0 10 1 3 -230.71 -12518 20 hour 30 min >10 hour 55.71 0 0 20586421 J Med Chem. 2010 Jul 22;53(14):5356-60. "Suzuki S, Urano E, Hashimoto C, Tsutsumi H, Nakahara T, Tanaka T, Nakanishi Y, Maddali K, Han Y, Hamatake M, Miyauchi K, Pommier Y, Beutler JA, Sugiura W, Fuji H, Hoshino T, Itotani K, Nomura W, Narumi T, Yamamoto N, Komano JA, Tamamura H. " Peptide HIV-1 integrase inhibitors from HIV-1 gene products. 10.1021/jm1003528 Anti-HIV DRAVPe00081 LQQLLFIHFRIGRRRRRRRR 20 Vpr-3 R8 Synthetic construct(derived from HIV-1 gene products(Vpr)) No entry found None HIV Retroviridae Integrase assay [Ref.20586421]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=0.004±0.0001 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.008±0.001 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00081 DRAVPe00081.cif Linear Acetylation Amidation None L Integrase "IN is an essential enzyme for the stable infection of host cells because it catalyzes the insertion of viral DNA inside the pre-integration complex (PIC) into the genome of host cells in two successive reactions, designated as strand transfer and 3′-end-processing. The peptide could inhibit the activity of integrase and thus inhibit virus replication." 2734.31 C120H209N51O23 ACDEKMNPSTVWY R 12.9 10 0 10 1 7 -125.5 -11852 5.5 hour 3 min 2 min 97.5 0 0 20586421 J Med Chem. 2010 Jul 22;53(14):5356-60. "Suzuki S, Urano E, Hashimoto C, Tsutsumi H, Nakahara T, Tanaka T, Nakanishi Y, Maddali K, Han Y, Hamatake M, Miyauchi K, Pommier Y, Beutler JA, Sugiura W, Fuji H, Hoshino T, Itotani K, Nomura W, Narumi T, Yamamoto N, Komano JA, Tamamura H. " Peptide HIV-1 integrase inhibitors from HIV-1 gene products. 10.1021/jm1003528 Anti-HIV DRAVPe00082 EAIIRILQQLLFIHFRIGRRRRRRRR 26 Vpr-4 R8 Synthetic construct(derived from HIV-1 gene products(Vpr)) No entry found None HIV Retroviridae Integrase assay [Ref.20586421]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=0.005±0.002 µM);inhibition of strand transfer catalyzed by integrase(IC50=0.006±0.006 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00082 DRAVPe00082.cif Linear Acetylation Amidation None L Integrase "IN is an essential enzyme for the stable infection of host cells because it catalyzes the insertion of viral DNA inside the pre-integration complex (PIC) into the genome of host cells in two successive reactions, designated as strand transfer and 3′-end-processing. The peptide could inhibit the activity of integrase and thus inhibit virus replication." 3430.17 C152H266N60O31 CDKMNPSTVWY R 12.6 11 1 10 1 11 -68.46 -12368 1 hour 30 min >10 hour 123.85 0 0 20586421 J Med Chem. 2010 Jul 22;53(14):5356-60. "Suzuki S, Urano E, Hashimoto C, Tsutsumi H, Nakahara T, Tanaka T, Nakanishi Y, Maddali K, Han Y, Hamatake M, Miyauchi K, Pommier Y, Beutler JA, Sugiura W, Fuji H, Hoshino T, Itotani K, Nomura W, Narumi T, Yamamoto N, Komano JA, Tamamura H. " Peptide HIV-1 integrase inhibitors from HIV-1 gene products. 10.1021/jm1003528 Anti-HIV DRAVPe00083 TYGDTWAGVEAIIRI 15 Vpr 49-63 Synthetic construct(derived from HIV-1 viral protein R (Vpr)) No entry found None HIV Retroviridae Dot-blot binding assay [Ref.17490682]HIV-1:inhibit the activity of RNA-dependent DNA polymerase(IC50>>150 µM);inhibit the activity of DNA-dependent DNA polymerase(IC50>>150 µM);inhibit the activity of Rnase H(IC50>>200 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00083 DRAVPe00083.cif Linear Free Free None L Reverse Transcriptase The viral enzymes RT and IN have cardinal roles in the early stages of the replication of retroviruses and retrotransposons. The peptide derived from viral protein R (Vpr) could inhibit Reverse Transcriptase(RT) and thus inhibit the replication of HIV-1. 1664.88 C76H117N19O23 CFHKLMNPQS I 4.37 1 2 -1 5 7 36 -910 7.2 hour >20 hour >10 hour 110.67 6990 499.29 17490682 J Mol Biol. 2007 Jun 22;369(5):1230-43. "Gleenberg IO, Herschhorn A, Hizi A." Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr). 10.1016/j.jmb.2007.03.073 Anti-HIV DRAVPe00084 TWAGVEAIIRILQQL 15 Vpr 53-67 Synthetic construct(derived from HIV-1 viral protein R (Vpr)) No entry found None HIV Retroviridae Dot-blot binding assay [Ref.17490682]HIV-1:inhibit the activity of RNA-dependent DNA polymerase(IC50=0.88 µM);inhibit the activity of DNA-dependent DNA polymerase(IC50=0.88 µM);inhibit the activity of Rnase H(IC50=6.9 µM);##Inhibition of 3′-end processing catalyzed by integrase(IC50>200 µM);inhibition of strand transfer catalyzed by integrase(IC50=144 µM);inhibition of disintegration catalyzed by integrase(IC50=27 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00084 DRAVPe00084.cif Linear Free Free None L "Integrase,Reverse Transcriptase" The viral enzymes RT and IN have cardinal roles in the early stages of the replication of retroviruses and retrotransposons. The peptide derived from viral protein R (Vpr) could inhibit integrase(IN) and Reverse Transcriptase(RT) and thus inhibit the replication of HIV-1. 1711.04 C79H131N21O21 CDFHKMNPSY I 5.66 1 1 0 2 9 79.33 15 7.2 hour >20 hour >10 hour 162.67 5500 392.86 17490682 J Mol Biol. 2007 Jun 22;369(5):1230-43. "Gleenberg IO, Herschhorn A, Hizi A." Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr). 10.1016/j.jmb.2007.03.073 Anti-HIV DRAVPe00085 VEAIIRILQQLLFIH 15 Vpr 57-71 Synthetic construct(derived from HIV-1 viral protein R (Vpr)) No entry found None HIV Retroviridae Dot-blot binding assay [Ref.17490682]HIV-1:inhibit the activity of RNA-dependent DNA polymerase(IC50=0.22 µM);inhibit the activity of DNA-dependent DNA polymerase(IC50=0.22 µM);inhibit the activity of Rnase H(IC50=2 µM);##Inhibition of 3′-end processing catalyzed by integrase(IC50=7.8 µM);inhibition of strand transfer catalyzed by integrase(IC50=16 µM);inhibition of disintegration catalyzed by integrase(IC50=3 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00085 DRAVPe00085.cif Linear Free Free None L "Integrase,Reverse Transcriptase" The viral enzymes RT and IN have cardinal roles in the early stages of the replication of retroviruses and retrotransposons. The peptide derived from viral protein R (Vpr) could inhibit integrase(IN) and Reverse Transcriptase(RT) and thus inhibit the replication of HIV-1. 1806.22 C86H144N22O20 CDGKMNPSTWY I 6.72 2 1 1 0 10 133.33 580 100 hour >20 hour >10 hour 208 0 0 17490682 J Mol Biol. 2007 Jun 22;369(5):1230-43. "Gleenberg IO, Herschhorn A, Hizi A." Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr). 10.1016/j.jmb.2007.03.073 Anti-HIV DRAVPe00086 IRILQQLLFIHFRIG 15 Vpr 61-75 Synthetic construct(derived from HIV-1 viral protein R (Vpr)) No entry found None HIV Retroviridae Dot-blot binding assay [Ref.17490682]HIV-1:inhibit the activity of RNA-dependent DNA polymerase(IC50=0.7 µM);inhibit the activity of DNA-dependent DNA polymerase(IC50=1.3 µM);inhibit the activity of Rnase H(IC50=5.25 µM);##Inhibition of 3′-end processing catalyzed by integrase(IC50=1.3 µM);inhibition of strand transfer catalyzed by integrase(IC50=1 µM);inhibition of disintegration catalyzed by integrase(IC50=10 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00086 DRAVPe00086.cif Linear Free Free None L "Integrase,Reverse Transcriptase" The viral enzymes RT and IN have cardinal roles in the early stages of the replication of retroviruses and retrotransposons. The peptide derived from viral protein R (Vpr) could inhibit integrase(IN) and Reverse Transcriptase(RT) and thus inhibit the replication of HIV-1. 1867.31 C90H147N25O18 ACDEKMNPSTVWY I 12 3 0 3 1 9 102.67 -424 20 hour 30 min >10 hour 182 0 0 17490682 J Mol Biol. 2007 Jun 22;369(5):1230-43. "Gleenberg IO, Herschhorn A, Hizi A." Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr). 10.1016/j.jmb.2007.03.073 Anti-HIV DRAVPe00087 QQLLFIHFRIGCQHS 15 Vpr 65-79 Synthetic construct(derived from HIV-1 viral protein R (Vpr)) No entry found None HIV Retroviridae Dot-blot binding assay [Ref.17490682]HIV-1:inhibit the activity of RNA-dependent DNA polymerase(IC50=33 µM);inhibit the activity of DNA-dependent DNA polymerase(IC50=43 µM);inhibit the activity of Rnase H(IC50=16.5 µM);##Inhibition of 3′-end processing catalyzed by integrase(IC50=76 µM);inhibition of strand transfer catalyzed by integrase(IC50=14 µM);inhibition of disintegration catalyzed by integrase(IC50=10 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00087 DRAVPe00087.cif Linear Free Free None L "Integrase,Reverse Transcriptase" The viral enzymes RT and IN have cardinal roles in the early stages of the replication of retroviruses and retrotransposons. The peptide derived from viral protein R (Vpr) could inhibit integrase(IN) and Reverse Transcriptase(RT) and thus inhibit the replication of HIV-1. 1827.14 C83H127N25O20S ADEKMNPTVWY Q 8.27 3 0 3 3 6 14 -1640 0.8 hour 10 min >10 hour 104 0 0 17490682 J Mol Biol. 2007 Jun 22;369(5):1230-43. "Gleenberg IO, Herschhorn A, Hizi A." Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr). 10.1016/j.jmb.2007.03.073 Anti-HIV DRAVPe00088 FIHFRIGCQHSRIGI 15 Vpr 69-83 Synthetic construct(derived from HIV-1 viral protein R (Vpr)) No entry found None HIV Retroviridae Dot-blot binding assay [Ref.17490682]HIV-1:inhibit the activity of RNA-dependent DNA polymerase(IC50>>200 µM);inhibit the activity of DNA-dependent DNA polymerase(IC50>>200 µM);inhibit the activity of Rnase H(IC50>>200 µM);##Inhibition of 3′-end processing catalyzed by integrase(IC50>>200 µM);inhibition of strand transfer catalyzed by integrase(IC50>>200 µM);inhibition of disintegration catalyzed by integrase(IC50>>200 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00088 DRAVPe00088.cif Linear Free Free None L "Integrase,Reverse Transcriptase" The viral enzymes RT and IN have cardinal roles in the early stages of the replication of retroviruses and retrotransposons. The peptide derived from viral protein R (Vpr) could inhibit integrase(IN) and Reverse Transcriptase(RT) and thus inhibit the replication of HIV-1. 1784.11 C81H126N26O18S ADEKLMNPTVWY I 10.35 4 0 4 4 6 37.33 -1930 1.1 hour 3 min 2 min 104 0 0 17490682 J Mol Biol. 2007 Jun 22;369(5):1230-43. "Gleenberg IO, Herschhorn A, Hizi A." Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr). 10.1016/j.jmb.2007.03.073 Anti-HIV DRAVPe00089 HFPRIWLHSLGQHIY 15 Vpr 33-47 Synthetic construct(derived from HIV-1 viral protein R (Vpr)) No entry found None HIV Retroviridae Dot-blot binding assay [Ref.17490682]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=187 µM);inhibition of strand transfer catalyzed by integrase(IC50=41 µM);inhibition of disintegration catalyzed by integrase(IC50=73 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00089 DRAVPe00089.cif Linear Free Free None L Integrase The viral enzymes RT and IN have cardinal roles in the early stages of the replication of retroviruses and retrotransposons. The peptide derived from viral protein R (Vpr) could inhibit integrase(IN) and thus inhibit the replication of HIV-1. 1904.21 C92H130N26O19 ACDEKMNTV H 8.77 4 0 4 3 6 -21.33 -1205 3.5 hour 10 min >10 hour 104 6990 499.29 17490682 J Mol Biol. 2007 Jun 22;369(5):1230-43. "Gleenberg IO, Herschhorn A, Hizi A." Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr). 10.1016/j.jmb.2007.03.073 Anti-HIV DRAVPe00090 QLLIRMIYKNILFYLVPGPGHGAEPERRNIKYL 33 I33 Synthetic construct No entry found None HIV Retroviridae Disintegration assay [Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=9 µM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM. DRAVPe00090 DRAVPe00090.cif Linear Free Free None L Integrase "The peptide bound tightly to the integrase(IN) and inhibited both in vitro IN activities, containing 3′ end processing and strand transfer." 3913.69 C183H291N49O44S CDSTW L 9.82 6 2 4 8 12 -12.73 -3510 0.8 hour 10 min >10 hour 118.18 4470 139.69 12054767 J Mol Biol. 2002 Apr 19;318(1):45-58. "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase. 10.1016/S0022-2836(02)00033-5 Anti-HIV DRAVPe00091 RMIYKNILFYLVPGPGHGAEPERRNIKYL 29 I29 Synthetic construct No entry found None HIV Retroviridae Disintegration assay [Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=85 µM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM. DRAVPe00091 DRAVPe00091.cif Linear Free Free None L Integrase Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus. 3446.08 C160H250N44O39S CDQSTW GILPRY 9.82 6 2 4 8 9 -44.14 -4432 1 hour 2 min 2 min 94.14 4470 159.64 12054767 J Mol Biol. 2002 Apr 19;318(1):45-58. "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase. 10.1016/S0022-2836(02)00033-5 Anti-HIV DRAVPe00092 QLLIRMI 7 LCD278B Synthetic construct No entry found None HIV Retroviridae Disintegration assay [Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50>200 µM);no inhibition of HIV-1 infection up to 100 μM. No hemolysis information or data found in the reference(s) presented in this entry [Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM. DRAVPe00092 DRAVPe00092.cif Linear Free Free None L Integrase Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus. 886.16 C40H75N11O9S ACDEFGHKNPSTVWY IL 9.75 1 0 1 0 4 150 157 0.8 hour 10 min >10 hour 222.86 0 0 12054767 J Mol Biol. 2002 Apr 19;318(1):45-58. "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase. 10.1016/S0022-2836(02)00033-5 Anti-HIV DRAVPe00093 AEPERRNIKYL 11 EBR24 Synthetic construct No entry found None HIV Retroviridae Disintegration assay [Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=50 µM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM. DRAVPe00093 DRAVPe00093.cif Linear Free Free None L Integrase Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus. 1388.59 C61H101N19O18 CDFGHMQSTVW ER 8.63 3 2 1 2 3 -147.27 -4414 4.4 hour >20 hour >10 hour 80 1490 149 12054767 J Mol Biol. 2002 Apr 19;318(1):45-58. "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase. 10.1016/S0022-2836(02)00033-5 Anti-HIV DRAVPe00094 LFYLVPGPGH 10 EBR26 Synthetic construct No entry found None HIV Retroviridae Disintegration assay [Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50>200 µM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM. DRAVPe00094 DRAVPe00094.cif Linear Free Free None L Integrase Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus. 1099.3 C55H78N12O12 ACDEIKMNQRSTW GLP 6.74 1 0 1 3 4 61 1394 5.5 hour 3 min 2 min 107 1490 165.56 12054767 J Mol Biol. 2002 Apr 19;318(1):45-58. "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase. 10.1016/S0022-2836(02)00033-5 Anti-HIV DRAVPe00095 YQLLIRMIYKNI 12 EBR28 Synthetic construct No entry found None HIV Retroviridae Disintegration assay [Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=5 µM);inhibition of HIV-1 infection in HeLa CD4-β-Gal cells(IC50=40 μM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM. DRAVPe00095 DRAVPe00095.cif Linear Free Free None L Integrase Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus. 1567.95 C74H122N18O17S ACDEFGHPSTVW I 9.7 2 0 2 3 5 41.67 -598 2.8 hour 10 min 2 min 162.5 2980 270.91 12054767 J Mol Biol. 2002 Apr 19;318(1):45-58. "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase. 10.1016/S0022-2836(02)00033-5 Anti-HIV DRAVPe00096 YALLIRMIYKNI 12 EBR28[Q2A] Synthetic construct No entry found None HIV Retroviridae Disintegration assay [Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=8 µM);inhibition of HIV-1 infection in HeLa CD4-β-Gal cells(IC50~100 μM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM. DRAVPe00096 DRAVPe00096.cif Linear Free Free None L Integrase Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus. 1510.9 C72H119N17O16S CDEFGHPQSTVW I 9.7 2 0 2 3 6 85.83 137 2.8 hour 10 min 2 min 170.83 2980 270.91 12054767 J Mol Biol. 2002 Apr 19;318(1):45-58. "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase. 10.1016/S0022-2836(02)00033-5 Anti-HIV DRAVPe00097 YQALIRMIYKNI 12 EBR28[L3A] Synthetic construct No entry found None HIV Retroviridae Disintegration assay [Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=165 µM);no inhibition of HIV-1 infection up to 100 μM. No hemolysis information or data found in the reference(s) presented in this entry [Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM. DRAVPe00097 DRAVPe00097.cif Linear Free Free None L Integrase Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus. 1525.87 C71H116N18O17S CDEFGHPSTVW I 9.7 2 0 2 3 5 25 -909 2.8 hour 10 min 2 min 138.33 2980 270.91 12054767 J Mol Biol. 2002 Apr 19;318(1):45-58. "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase. 10.1016/S0022-2836(02)00033-5 Anti-HIV DRAVPe00098 YQLAIRMIYKNI 12 EBR28[L4A] Synthetic construct No entry found None HIV Retroviridae Disintegration assay [Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=14 µM);no inhibition of HIV-1 infection up to 100 μM. No hemolysis information or data found in the reference(s) presented in this entry [Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM. DRAVPe00098 DRAVPe00098.cif Linear Free Free None L Integrase Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus. 1525.87 C71H116N18O17S CDEFGHPSTVW I 9.7 2 0 2 3 5 25 -909 2.8 hour 10 min 2 min 138.33 2980 270.91 12054767 J Mol Biol. 2002 Apr 19;318(1):45-58. "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase. 10.1016/S0022-2836(02)00033-5 Anti-HIV DRAVPe00099 YQLLARMIYKNI 12 EBR28[I5A] Synthetic construct No entry found None HIV Retroviridae Disintegration assay [Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=45 µM);no inhibition of HIV-1 infection up to 100 μM. No hemolysis information or data found in the reference(s) presented in this entry [Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM. DRAVPe00099 DRAVPe00099.cif Linear Free Free None L Integrase Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus. 1525.87 C71H116N18O17S CDEFGHPSTVW ILY 9.7 2 0 2 3 5 19.17 -909 2.8 hour 10 min 2 min 138.33 2980 270.91 12054767 J Mol Biol. 2002 Apr 19;318(1):45-58. "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase. 10.1016/S0022-2836(02)00033-5 Anti-HIV DRAVPe00100 YQLLIAMIYKNI 12 EBR28[R6A] Synthetic construct No entry found None HIV Retroviridae Disintegration assay [Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=34 µM);no inhibition of HIV-1 infection up to 100 μM. No hemolysis information or data found in the reference(s) presented in this entry [Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM. DRAVPe00100 DRAVPe00100.cif Linear Free Free None L Integrase Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus. 1482.84 C71H115N15O17S CDEFGHPRSTVW I 8.5 1 0 1 3 6 94.17 1075 2.8 hour 10 min 2 min 170.83 2980 270.91 12054767 J Mol Biol. 2002 Apr 19;318(1):45-58. "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase. 10.1016/S0022-2836(02)00033-5 Anti-HIV DRAVPe00101 YQLLIRAIYKNI 12 EBR28[M7A] Synthetic construct No entry found None HIV Retroviridae Disintegration assay [Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=70 µM);inhibition of HIV-1 infection in HeLa CD4-β-Gal cells(IC50~100 μM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM. DRAVPe00101 DRAVPe00101.cif Linear Free Free None L Integrase Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus. 1507.84 C72H118N18O17 CDEFGHMPSTVW I 9.7 2 0 2 3 6 40.83 -652 2.8 hour 10 min 2 min 170.83 2980 270.91 12054767 J Mol Biol. 2002 Apr 19;318(1):45-58. "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase. 10.1016/S0022-2836(02)00033-5 Anti-HIV DRAVPe00102 YQLLIRMAYKNI 12 EBR28[I8A] Synthetic construct No entry found None HIV Retroviridae Disintegration assay [Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=35 µM);no inhibition of HIV-1 infection up to 100 μM. No hemolysis information or data found in the reference(s) presented in this entry [Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM. DRAVPe00102 DRAVPe00102.cif Linear Free Free None L Integrase Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus. 1525.87 C71H116N18O17S CDEFGHPSTVW ILY 9.7 2 0 2 3 5 19.17 -909 2.8 hour 10 min 2 min 138.33 2980 270.91 12054767 J Mol Biol. 2002 Apr 19;318(1):45-58. "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase. 10.1016/S0022-2836(02)00033-5 Anti-HIV DRAVPe00103 YQLLIRMIAKNI 12 EBR28[Y9A] Synthetic construct No entry found None HIV Retroviridae Disintegration assay [Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=40 µM);inhibition of HIV-1 infection in HeLa CD4-β-Gal cells(IC50~100 μM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM. DRAVPe00103 DRAVPe00103.cif Linear Free Free None L Integrase Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus. 1475.86 C68H118N18O16S CDEFGHPSTVW I 9.99 2 0 2 2 6 67.5 -403 2.8 hour 10 min 2 min 170.83 1490 135.45 12054767 J Mol Biol. 2002 Apr 19;318(1):45-58. "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase. 10.1016/S0022-2836(02)00033-5 Anti-HIV DRAVPe00104 YQLLIRMIYANI 12 EBR28[K10A] Synthetic construct No entry found None HIV Retroviridae Disintegration assay [Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=11 µM);no inhibition of HIV-1 infection up to 100 μM. No hemolysis information or data found in the reference(s) presented in this entry [Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM. DRAVPe00104 DRAVPe00104.cif Linear Free Free None L Integrase Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus. 1510.86 C71H115N17O17S CDEFGHKPSTVW I 8.59 1 0 1 3 6 89.17 138 2.8 hour 10 min 2 min 170.83 2980 270.91 12054767 J Mol Biol. 2002 Apr 19;318(1):45-58. "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase. 10.1016/S0022-2836(02)00033-5 Anti-HIV DRAVPe00105 YQLLIRMIYKAI 12 EBR28[N11A] Synthetic construct No entry found None HIV Retroviridae Disintegration assay [Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=7 µM);inhibition of HIV-1 infection in HeLa CD4-β-Gal cells(IC50~100 μM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM. DRAVPe00105 DRAVPe00105.cif Linear Free Free None L Integrase Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus. 1524.93 C73H121N17O16S CDEFGHNPSTVW I 9.7 2 0 2 2 6 85.83 247 2.8 hour 10 min 2 min 170.83 2980 270.91 12054767 J Mol Biol. 2002 Apr 19;318(1):45-58. "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase. 10.1016/S0022-2836(02)00033-5 Anti-HIV DRAVPe00106 YQLLIRMIYKNA 12 EBR28[I12A] Synthetic construct No entry found None HIV Retroviridae Disintegration assay [Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=11 µM);inhibition of HIV-1 infection in HeLa CD4-β-Gal cells(IC50~100 μM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM. DRAVPe00106 DRAVPe00106.cif Linear Free Free None L Integrase Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus. 1525.87 C71H116N18O17S CDEFGHPSTVW ILY 9.7 2 0 2 3 5 19.17 -909 2.8 hour 10 min 2 min 138.33 2980 270.91 12054767 J Mol Biol. 2002 Apr 19;318(1):45-58. "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase. 10.1016/S0022-2836(02)00033-5 Anti-HIV DRAVPe00107 YQLLIRMIY 9 LCE41 Synthetic construct No entry found None HIV Retroviridae Disintegration assay [Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=5 µM);inhibition of HIV-1 infection in HeLa CD4-β-Gal cells(IC50=55 μM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM. DRAVPe00107 DRAVPe00107.cif Linear Free Free None L Integrase Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus. 1212.52 C58H93N13O13S ACDEFGHKNPSTVW ILY 8.59 1 0 1 2 4 87.78 129 2.8 hour 10 min 2 min 173.33 2980 372.5 12054767 J Mol Biol. 2002 Apr 19;318(1):45-58. "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase. 10.1016/S0022-2836(02)00033-5 Anti-HIV DRAVPe00108 YQLLIRMI 8 LCE40 Synthetic construct No entry found None HIV Retroviridae Disintegration assay [Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=120 µM);no inhibition of HIV-1 infection up to 100 μM. No hemolysis information or data found in the reference(s) presented in this entry [Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM. DRAVPe00108 DRAVPe00108.cif Linear Free Free None L Integrase Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus. 1049.34 C49H84N12O11S ACDEFGHKNPSTVW IL 8.75 1 0 1 1 4 115 143 2.8 hour 10 min 2 min 195 1490 212.86 12054767 J Mol Biol. 2002 Apr 19;318(1):45-58. "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase. 10.1016/S0022-2836(02)00033-5 Anti-HIV DRAVPe00109 QLLIRMIYKNI 11 LCD278C Synthetic construct No entry found None HIV Retroviridae Disintegration assay [Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=21 µM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM. DRAVPe00109 DRAVPe00109.cif Linear Free Free None L Integrase Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus. 1404.78 C65H113N17O15S ACDEFGHPSTVW I 9.99 2 0 2 2 5 57.27 -584 0.8 hour 10 min >10 hour 177.27 1490 149 12054767 J Mol Biol. 2002 Apr 19;318(1):45-58. "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase. 10.1016/S0022-2836(02)00033-5 Anti-HIV DRAVPe00110 YQLLIRPIYKNI 12 ProEBR28 Synthetic construct No entry found None HIV Retroviridae Disintegration assay [Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50>200 µM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM. DRAVPe00110 DRAVPe00110.cif Linear Free Free None L Integrase Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus. 1533.88 C74H120N18O17 ACDEFGHMSTVW I 9.7 2 0 2 3 5 12.5 -833 2.8 hour 10 min 2 min 162.5 2980 270.91 12054767 J Mol Biol. 2002 Apr 19;318(1):45-58. "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase. 10.1016/S0022-2836(02)00033-5 Anti-HIV DRAVPe00111 LSELDDRADALQAGASQFETSAAKLKRKYWWKN 33 C35 Synthetic construct No entry found None HIV Retroviridae Disintegration assay [Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50>200 µM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM. DRAVPe00111 DRAVPe00111.cif Linear Free Free None L Integrase Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus. 3798.23 C169H262N48O52 CHIMPV A 8.38 6 5 1 7 13 -92.12 -8333 5.5 hour 3 min 2 min 65.45 12490 390.31 12054767 J Mol Biol. 2002 Apr 19;318(1):45-58. "de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. " A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase. 10.1016/S0022-2836(02)00033-5 Anti-HIV DRAVPe00112 TGEKVWDRGNVTLLCDCP 18 P11(derived from E2 envelope protein of GB virus C) Synthetic construct(derived from E2 envelope protein of GB virus C) No entry found None HIV Retroviridae Gp41-Mediated Cell-Cell Fusion Assay [Ref.20718496]HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells(IC50=439.7 μM);inhibition of HIV(HXB2) infection in TZM-bl Cells(IC50=162.1 μM);inhibition of HIV(BAL) infection in TZM-bl Cells(IC50=484.5 μM);inhibition of HIV(69-7) infection in TZM-bl Cells(IC50=208.8 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00112 DRAVPe00112.cif Linear Free Free None L membrane "E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner." 2006.28 C85H136N24O28S2 AFHIMQSY CDGLTV 4.56 2 3 -1 7 5 -33.89 -3181 7.2 hour >20 hour >10 hour 75.56 5625 330.88 20718496 J Med Chem. 2010 Aug 26;53(16):6054-63.  "Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. " Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection. 10.1021/jm100452c Anti-HIV DRAVPe00113 LPAFCQAIGWGDPITHWS 18 P19(derived from E2 envelope protein of GB virus C) Synthetic construct(derived from E2 envelope protein of GB virus C) No entry found None HIV Retroviridae Gp41-Mediated Cell-Cell Fusion Assay [Ref.20718496]HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells(IC50=369.5 μM);inhibition of HIV(HXB2) infection in TZM-bl Cells(IC50=46.0 μM);inhibition of HIV(BAL) infection in TZM-bl Cells(IC50=194.3 μM);inhibition of HIV(69-7) infection in TZM-bl Cells(IC50=71.4 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00113 DRAVPe00113.cif Linear Free Free None L membrane "E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner." 1999.27 C94H131N23O24S EKMNRVY AGIPW 5.08 1 1 0 5 8 23.33 429 5.5 hour 3 min 2 min 76.11 11000 647.06 20718496 J Med Chem. 2010 Aug 26;53(16):6054-63.  "Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. " Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection. 10.1021/jm100452c Anti-HIV DRAVPe00114 FCQAIGWGDPITHWSHGQ 18 P20(derived from E2 envelope protein of GB virus C) Synthetic construct(derived from E2 envelope protein of GB virus C) No entry found None HIV Retroviridae Gp41-Mediated Cell-Cell Fusion Assay [Ref.20718496]HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells(IC50=347.6 μM);inhibition of HIV(HXB2) infection in TZM-bl Cells(IC50=70.1 μM);inhibition of HIV(BAL) infection in TZM-bl Cells(IC50=125.5 μM);inhibition of HIV(69-7) infection in TZM-bl Cells(IC50=111.1 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00114 DRAVPe00114.cif Linear Free Free None L membrane "E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner." 2040.24 C93H126N26O25S EKLMNRVY G 5.97 2 1 1 6 6 -38.33 -1170 1.1 hour 3 min 2 min 48.89 11000 647.06 20718496 J Med Chem. 2010 Aug 26;53(16):6054-63.  "Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. " Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection. 10.1021/jm100452c Anti-HIV DRAVPe00115 AIGWGDPITHWSHGQNRW 18 P21(derived from E2 envelope protein of GB virus C) Synthetic construct(derived from E2 envelope protein of GB virus C) No entry found None HIV Retroviridae Gp41-Mediated Cell-Cell Fusion Assay [Ref.20718496]HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells(IC50=832.9 μM);inhibition of HIV(HXB2) infection in TZM-bl Cells(IC50=44.9 μM);inhibition of HIV(BAL) infection in TZM-bl Cells(IC50=529.1 μM);inhibition of HIV(69-7) infection in TZM-bl Cells(IC50=371.1 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00115 DRAVPe00115.cif Linear Free Free None L membrane "E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner." 2118.3 C97H132N30O25 CEFKLMVY GW 6.96 3 1 2 6 6 -97.78 -2965 4.4 hour >20 hour >10 hour 48.89 16500 970.59 20718496 J Med Chem. 2010 Aug 26;53(16):6054-63.  "Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. " Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection. 10.1021/jm100452c Anti-HIV DRAVPe00116 PITHWSHGQNRWPLSCPQ 18 P23(derived from E2 envelope protein of GB virus C) Synthetic construct(derived from E2 envelope protein of GB virus C) No entry found None HIV Retroviridae Gp41-Mediated Cell-Cell Fusion Assay [Ref.20718496]HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells(IC50=508.8 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00116 DRAVPe00116.cif Linear Free Free None L membrane "E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner." 2144.4 C96H138N30O25S ADEFKMVY P 8.68 3 0 3 6 4 -110.56 -3461 >20 hour >20 hour ? 43.33 11000 647.06 20718496 J Med Chem. 2010 Aug 26;53(16):6054-63.  "Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. " Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection. 10.1021/jm100452c Anti-HIV DRAVPe00117 HGQNRWPLSCPQYVYGSV 18 P25(derived from E2 envelope protein of GB virus C) Synthetic construct(derived from E2 envelope protein of GB virus C) No entry found None HIV Retroviridae Gp41-Mediated Cell-Cell Fusion Assay [Ref.20718496]HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells(IC50=304.4 μM) No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00117 DRAVPe00117.cif Linear Free Free None L membrane "E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner." 2091.33 C94H135N27O26S ADEFIKMT GPQSVY 8.21 2 0 2 8 4 -70 -2589 3.5 hour 10 min >10 hour 53.89 8480 498.82 20718496 J Med Chem. 2010 Aug 26;53(16):6054-63.  "Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. " Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection. 10.1021/jm100452c Anti-HIV DRAVPe00118 SWFASTGGRDSKIDVWSL 18 P34(derived from E2 envelope protein of GB virus C) Synthetic construct(derived from E2 envelope protein of GB virus C) No entry found None HIV Retroviridae Gp41-Mediated Cell-Cell Fusion Assay [Ref.20718496]HIV-1:inhibition of HIV(HXB2) infection in TZM-bl Cells(IC50=237.4 μM);inhibition of HIV(BAL) infection in TZM-bl Cells(IC50=411.2 μM);inhibition of HIV(69-7) infection in TZM-bl Cells(IC50=118.6 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00118 DRAVPe00118.cif Linear Free Free None L membrane "E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner." 2012.21 C91H134N24O28 CEHMNPQY S 5.68 2 2 0 7 7 -26.67 -2887 1.9 hour >20 hour >10 hour 65 11000 647.06 20718496 J Med Chem. 2010 Aug 26;53(16):6054-63.  "Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. " Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection. 10.1021/jm100452c Anti-HIV DRAVPe00119 SDRDTVVELSEWGVPCAT 18 P45(derived from E2 envelope protein of GB virus C) Synthetic construct(derived from E2 envelope protein of GB virus C) No entry found None HIV Retroviridae Gp41-Mediated Cell-Cell Fusion Assay [Ref.20718496]HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells(IC50=141.2 μM);inhibition of HIV(HXB2) infection in TZM-bl Cells(IC50=48.8 μM);inhibition of HIV(BAL) infection in TZM-bl Cells(IC50=505.5 μM);inhibition of HIV(69-7) infection in TZM-bl Cells(IC50=43.7 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00119 DRAVPe00119.cif Linear Free Free None L membrane "E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner." 1964.13 C83H130N22O31S FHIKMNQY V 3.92 1 4 -3 6 6 -20.56 -3452 1.9 hour >20 hour >10 hour 75.56 5500 323.53 20718496 J Med Chem. 2010 Aug 26;53(16):6054-63.  "Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. " Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection. 10.1021/jm100452c Anti-HIV DRAVPe00120 DTVVELSEWGVPCATCIL 18 P46(derived from E2 envelope protein of GB virus C) Synthetic construct(derived from E2 envelope protein of GB virus C) No entry found None HIV Retroviridae Gp41-Mediated Cell-Cell Fusion Assay [Ref.20718496]HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells(IC50=428.8 μM);inhibition of HIV(HXB2) infection in TZM-bl Cells(IC50=39.9 μM);inhibition of HIV(BAL) infection in TZM-bl Cells(IC50=462.8 μM);inhibition of HIV(69-7) infection in TZM-bl Cells(IC50=24.1 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00120 DRAVPe00120.cif Linear Free Free None L membrane "E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner." 1935.24 C85H135N19O28S2 FHKMNQRY V 3.57 0 3 -3 6 8 88.33 364 1.1 hour 3 min >10 hour 118.89 5625 330.88 20718496 J Med Chem. 2010 Aug 26;53(16):6054-63.  "Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. " Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection. 10.1021/jm100452c Anti-HIV DRAVPe00121 VELSEWGVPCATCILDRR 18 P47(derived from E2 envelope protein of GB virus C) Synthetic construct(derived from E2 envelope protein of GB virus C) No entry found None HIV Retroviridae Gp41-Mediated Cell-Cell Fusion Assay [Ref.20718496]HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells(IC50=330.8 μM);inhibition of HIV(HXB2) infection in TZM-bl Cells(IC50=58.6 μM);inhibition of HIV(BAL) infection in TZM-bl Cells(IC50=140.3 μM);inhibition of HIV(69-7) infection in TZM-bl Cells(IC50=20.1 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00121 DRAVPe00121.cif Linear Free Free None L membrane "E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner." 2047.37 C88H143N25O27S2 FHKMNQY CELRV 4.68 2 3 -1 5 7 18.89 -2767 100 hour >20 hour >10 hour 102.78 5625 330.88 20718496 J Med Chem. 2010 Aug 26;53(16):6054-63.  "Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. " Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection. 10.1021/jm100452c Anti-HIV DRAVPe00122 RFPFHRCGAGPKLTKDLE 18 P59(derived from E2 envelope protein of GB virus C) Synthetic construct(derived from E2 envelope protein of GB virus C) No entry found None HIV Retroviridae Gp41-Mediated Cell-Cell Fusion Assay [Ref.20718496]HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells(IC50=529.6 μM) No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00122 DRAVPe00122.cif Linear Free Free None L membrane "E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner." 2072.42 C93H146N28O24S IMNQSVWY FGKLPR 9.31 5 2 3 4 5 -78.89 -4293 1 hour 2 min 2 min 48.89 0 0 20718496 J Med Chem. 2010 Aug 26;53(16):6054-63.  "Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. " Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection. 10.1021/jm100452c Anti-HIV DRAVPe00123 LVRRRSELMGRRNPVCPG 18 P97(derived from E2 envelope protein of GB virus C) Synthetic construct(derived from E2 envelope protein of GB virus C) No entry found None HIV Retroviridae Gp41-Mediated Cell-Cell Fusion Assay [Ref.20718496]HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells(IC50=537.6 μM) No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00123 DRAVPe00123.cif Linear Free Free None L membrane "E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner." 2096.5 C86H154N34O23S2 ADFHIKQTWY R 11.82 5 1 4 5 4 -77.22 -6802 5.5 hour 3 min 2 min 75.56 0 0 20718496 J Med Chem. 2010 Aug 26;53(16):6054-63.  "Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. " Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection. 10.1021/jm100452c Anti-HIV DRAVPe00124 LQEVDAGNFIPPPRWLLL 18 P109(derived from E2 envelope protein of GB virus C) Synthetic construct(derived from E2 envelope protein of GB virus C) No entry found None HIV Retroviridae Gp41-Mediated Cell-Cell Fusion Assay [Ref.20718496]HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells(IC50=687.1 μM);inhibition of HIV(HXB2) infection in TZM-bl Cells(IC50=37.5 μM);inhibition of HIV(BAL) infection in TZM-bl Cells(IC50=294.8 μM);inhibition of HIV(69-7) infection in TZM-bl Cells(IC50=60.8 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00124 DRAVPe00124.cif Linear Free Free None L membrane "E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner." 2078.44 C99H152N24O25 CHKMSTY L 4.37 1 2 -1 2 9 21.67 -593 5.5 hour 3 min 2 min 130 5500 323.53 20718496 J Med Chem. 2010 Aug 26;53(16):6054-63.  "Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. " Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection. 10.1021/jm100452c Anti-HIV DRAVPe00125 WVNQLAVLGLPAVDAAVA 18 P124(derived from E2 envelope protein of GB virus C) Synthetic construct(derived from E2 envelope protein of GB virus C) No entry found None HIV Retroviridae Gp41-Mediated Cell-Cell Fusion Assay [Ref.20718496]HIV-1:inhibition of gp41-induced cell-cell fusion in CEM-174 cells(IC50=332.7 μM);inhibition of HIV(BAL) infection in TZM-bl Cells(IC50=94.7 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00125 DRAVPe00125.cif Linear Free Free None L membrane "E2 GBV-C domain interferes with the HIV-1 fusion peptide-vesicle interaction, produce a notable decrease the cellular membrane fusion, and interfere with the HIV-1 infectivity in a dose-dependent manner." 1807.12 C84H135N21O23 CEFHIKMRSTY A 3.8 0 1 -1 2 13 132.22 2234 2.8 hour 3 min 2 min 157.22 5500 323.53 20718496 J Med Chem. 2010 Aug 26;53(16):6054-63.  "Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I. " Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection. 10.1021/jm100452c Anti-HIV DRAVPe00126 SAnti-VSVGMKPSPRP 12 VMI5 Synthetic construct(phage display) No entry found None HIV Retroviridae Affinity binding assay [Ref.12480936]HIV-1:binding with vif proteins. No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00126 DRAVPe00126.cif Linear Free Free None L Vif proteins "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." 1241.47 C53H92N16O16S ACDEFHILNQTWY PS 11 2 0 2 4 2 -47.5 -1930 1.9 hour >20 hour >10 hour 48.33 0 0 12480936 J Biol Chem. 2003 Feb 21;278(8):6596-602. "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. 10.1074/jbc.M210164200 Anti-HIV DRAVPe00127 SNQGGSPLPRSV 12 VMI7 Synthetic construct(phage display) No entry found None HIV Retroviridae Affinity binding assay [Ref.12480936]HIV-1:inhibition of Vif-Vif bingding(IC50=7.43 μM);##The peptide is able to effectively inhibit HIV-1 replication At the concentration of 50 μM. No hemolysis information or data found in the reference(s) presented in this entry [Ref.12480936]No significant cytotoxicity on H9 cells up to 50 μM. DRAVPe00127 DRAVPe00127.cif Linear Free Free None L Vif proteins "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." 1198.3 C49H83N17O18 ACDEFHIKMTWY S 9.47 1 0 1 6 2 -82.5 -2646 1.9 hour >20 hour >10 hour 56.67 0 0 12480936 J Biol Chem. 2003 Feb 21;278(8):6596-602. "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. 10.1074/jbc.M210164200 Anti-HIV DRAVPe00128 LPLPAPSFHRTT 12 VMI9 Synthetic construct(phage display) No entry found None HIV Retroviridae Affinity binding assay [Ref.12480936]HIV-1:inhibition of Vif-Vif bingding(IC50=4.84 μM);####The peptide is able to effectively inhibit HIV-1 replication At the concentration of 50 μM. No hemolysis information or data found in the reference(s) presented in this entry [Ref.12480936]No significant cytotoxicity on H9 cells up to 50 μM. DRAVPe00128 DRAVPe00128.cif Linear Free Free None L Vif proteins "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." 1336.56 C62H97N17O16 CDEGIKMNQVWY P 9.76 2 0 2 3 4 -20.83 -1349 5.5 hour 3 min 2 min 73.33 0 0 12480936 J Biol Chem. 2003 Feb 21;278(8):6596-602. "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. 10.1074/jbc.M210164200 Anti-HIV DRAVPe00129 SPYPSWSTPAGR 12 VMI16 Synthetic construct(phage display) No entry found None HIV Retroviridae Affinity binding assay [Ref.12480936]HIV-1:binding with vif proteins. No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00129 DRAVPe00129.cif Linear Free Free None L Vif proteins "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." 1305.41 C59H84N16O18 CDEFHIKLMNQV PS 8.46 1 0 1 6 2 -110 -2275 1.9 hour >20 hour >10 hour 8.33 6990 635.45 12480936 J Biol Chem. 2003 Feb 21;278(8):6596-602. "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. 10.1074/jbc.M210164200 Anti-HIV DRAVPe00130 KPKQIKPPLPSV 12 vif 155-166 Synthetic construct(derived from the proline-enriched C terminus of Vif) No entry found None HIV Retroviridae ELISA [Ref.12480936]HIV-1:inhibition of Vif-Vif bingding(IC50=17.39 μM);####The peptide is able to effectively inhibit HIV-1 replication At the concentration of 50 μM. No hemolysis information or data found in the reference(s) presented in this entry [Ref.12480936]No significant cytotoxicity on H9 cells up to 50 μM. DRAVPe00130 DRAVPe00130.cif Linear Free Free None L Vif proteins "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." 1331.66 C63H110N16O15 ACDEFGHMNRTWY P 10.3 3 0 3 1 3 -82.5 -1171 1.3 hour 3 min 2 min 89.17 0 0 12480936 J Biol Chem. 2003 Feb 21;278(8):6596-602. "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. 10.1074/jbc.M210164200 Anti-HIV DRAVPe00131 WQVMIVWQVDRMRIR 15 vif 5-19 Synthetic construct(derived from HIV-1 Vif protein) No entry found None HIV Retroviridae ELISA [Ref.12480936]HIV-1:inhibit vif-vif binding. No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00131 DRAVPe00131.cif Linear Free Free None L Vif proteins "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." 2016.46 C91H146N28O20S2 ACEFGHKLNPSTY RV 11.7 3 1 2 0 7 -2.67 -3324 2.8 hour 3 min 2 min 110 11000 785.71 12480936 J Biol Chem. 2003 Feb 21;278(8):6596-602. "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. 10.1074/jbc.M210164200 Anti-HIV DRAVPe00132 RHHYESTHPRISSEV 15 vif 41-55 Synthetic construct(derived from HIV-1 Vif protein) No entry found None HIV Retroviridae ELISA [Ref.12480936]HIV-1:inhibit vif-vif binding. No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00132 DRAVPe00132.cif Linear Free Free None L Vif proteins "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." 1834.97 C78H119N27O25 ACDFGKLMNQW HS 7.03 5 2 3 5 2 -152.67 -6139 1 hour 2 min 2 min 45.33 1490 106.43 12480936 J Biol Chem. 2003 Feb 21;278(8):6596-602. "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. 10.1074/jbc.M210164200 Anti-HIV DRAVPe00133 ESTHPRISSEVHIPL 15 vif 45-59 Synthetic construct(derived from HIV-1 Vif protein) No entry found None HIV Retroviridae ELISA [Ref.12480936]HIV-1:inhibit vif-vif binding. No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00133 DRAVPe00133.cif Linear Free Free None L Vif proteins "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." 1701.9 C74H120N22O24 ACDFGKMNQWY S 6.01 3 2 1 4 4 -48 -3183 1 hour 30 min >10 hour 97.33 0 0 12480936 J Biol Chem. 2003 Feb 21;278(8):6596-602. "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. 10.1074/jbc.M210164200 Anti-HIV DRAVPe00134 HTGERDWHLGQGVSI 15 vif 73-87 Synthetic construct(derived from HIV-1 Vif protein) No entry found None HIV Retroviridae ELISA [Ref.12480936]HIV-1:inhibit vif-vif binding. No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00134 DRAVPe00134.cif Linear Free Free None L Vif proteins "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." 1691.82 C73H110N24O23 ACFKMNPY G 5.99 3 2 1 5 4 -83.33 -3225 3.5 hour 10 min >10 hour 71.33 5500 392.86 12480936 J Biol Chem. 2003 Feb 21;278(8):6596-602. "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. 10.1074/jbc.M210164200 Anti-HIV DRAVPe00135 RDWHLGQGVSIEWRK 15 vif 77-91 Synthetic construct(derived from HIV-1 Vif protein) No entry found None HIV Retroviridae ELISA [Ref.12480936]HIV-1:inhibit vif-vif binding. No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00135 DRAVPe00135.cif Linear Free Free None L Vif proteins "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." 1867.1 C84H127N27O22 ACFMNPTY GRW 8.75 4 2 2 3 5 -116.67 -4410 1 hour 2 min 2 min 71.33 11000 785.71 12480936 J Biol Chem. 2003 Feb 21;278(8):6596-602. "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. 10.1074/jbc.M210164200 Anti-HIV DRAVPe00136 LGQGVSIEWRKKRYS 15 vif 81-95 Synthetic construct(derived from HIV-1 Vif protein) No entry found None HIV Retroviridae ELISA [Ref.12480936]HIV-1:inhibit vif-vif binding. No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00136 DRAVPe00136.cif Linear Free Free None L Vif proteins "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." 1807.09 C81H131N25O22 ACDFHMNPT GKRS 10.28 4 1 3 5 4 -106 -4214 5.5 hour 3 min 2 min 71.33 6990 499.29 12480936 J Biol Chem. 2003 Feb 21;278(8):6596-602. "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. 10.1074/jbc.M210164200 Anti-HIV DRAVPe00137 RYSTQVDPDLADQLI 15 vif 93-107 Synthetic construct(derived from HIV-1 Vif protein) No entry found None HIV Retroviridae ELISA [Ref.12480936]HIV-1:inhibit vif-vif binding. No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00137 DRAVPe00137.cif Linear Free Free None L Vif proteins "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." 1733.9 C75H120N20O27 CEFGHKMNW D 3.93 1 3 -2 3 5 -55.33 -3766 1 hour 2 min 2 min 104 1490 106.43 12480936 J Biol Chem. 2003 Feb 21;278(8):6596-602. "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. 10.1074/jbc.M210164200 Anti-HIV DRAVPe00138 QVDPDLADQLIHLYY 15 vif 97-111 Synthetic construct(derived from HIV-1 Vif protein) No entry found None HIV Retroviridae ELISA [Ref.12480936]HIV-1:inhibit vif-vif binding. No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00138 DRAVPe00138.cif Linear Free Free None L Vif proteins "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." 1803 C83H123N19O26 CEFGKMNRSTW DL 3.93 1 3 -2 2 6 -20 -1665 0.8 hour 10 min >10 hour 130 2980 212.86 12480936 J Biol Chem. 2003 Feb 21;278(8):6596-602. "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. 10.1074/jbc.M210164200 Anti-HIV DRAVPe00139 DLADQLIHLYYFDCF 15 vif 101-115 Synthetic construct(derived from HIV-1 Vif protein) No entry found None HIV Retroviridae ELISA [Ref.12480936]HIV-1:inhibit vif-vif binding. No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00139 DRAVPe00139.cif Linear Free Free None L Vif proteins "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." 1876.11 C89H122N18O25S EGKMNPRSTVW DL 3.93 1 3 -2 3 7 40 -791 1.1 hour 3 min >10 hour 110.67 2980 212.86 12480936 J Biol Chem. 2003 Feb 21;278(8):6596-602. "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. 10.1074/jbc.M210164200 Anti-HIV DRAVPe00140 QLIHLYYFDCFSESA 15 vif 105-119 Synthetic construct(derived from HIV-1 Vif protein) No entry found None HIV Retroviridae ELISA [Ref.12480936]HIV-1:inhibit vif-vif binding. No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00140 DRAVPe00140.cif Linear Free Free None L Vif proteins "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." 1836.05 C86H118N18O25S GKMNPRTVW FLSY 4.35 1 2 -1 5 6 27.33 -900 0.8 hour 10 min >10 hour 84.67 2980 212.86 12480936 J Biol Chem. 2003 Feb 21;278(8):6596-602. "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. 10.1074/jbc.M210164200 Anti-HIV DRAVPe00141 LYYFDCFSESAIRKA 15 vif 109-123 Synthetic construct(derived from HIV-1 Vif protein) No entry found None HIV Retroviridae ELISA [Ref.12480936]HIV-1:inhibit vif-vif binding. No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00141 DRAVPe00141.cif Linear Free Free None L Vif proteins "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." 1813.06 C84H121N19O24S GHMNPQTVW AFSY 6.06 2 2 0 5 6 2.67 -2238 5.5 hour 3 min 2 min 65.33 2980 212.86 12480936 J Biol Chem. 2003 Feb 21;278(8):6596-602. "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. 10.1074/jbc.M210164200 Anti-HIV DRAVPe00142 ESAIRKAILGHIVSP 15 vif 117-131 Synthetic construct(derived from HIV-1 Vif protein) No entry found None HIV Retroviridae ELISA [Ref.12480936]HIV-1:inhibit vif-vif binding. No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00142 DRAVPe00142.cif Linear Free Free None L Vif proteins "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." 1590.89 C71H123N21O20 CDFMNQTWY I 8.85 3 1 2 3 7 42.67 -1046 1 hour 30 min >10 hour 136.67 0 0 12480936 J Biol Chem. 2003 Feb 21;278(8):6596-602. "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. 10.1074/jbc.M210164200 Anti-HIV DRAVPe00143 RKAILGHIVSPRCEY 15 vif 121-135 Synthetic construct(derived from HIV-1 Vif protein) No entry found None HIV Retroviridae ELISA [Ref.12480936]HIV-1:inhibit vif-vif binding. No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00143 DRAVPe00143.cif Linear Free Free None L Vif proteins "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." 1742.07 C77H128N24O20S DFMNQTW IR 9.31 4 1 3 4 5 -16 -2757 1 hour 2 min 2 min 104 1490 106.43 12480936 J Biol Chem. 2003 Feb 21;278(8):6596-602. "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. 10.1074/jbc.M210164200 Anti-HIV DRAVPe00144 VSPRCEYQAGHNKVG 15 vif 129-143 Synthetic construct(derived from HIV-1 Vif protein) No entry found None HIV Retroviridae ELISA [Ref.12480936]HIV-1:inhibit vif-vif binding. No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00144 DRAVPe00144.cif Linear Free Free None L Vif proteins "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." 1644.83 C69H109N23O22S DFILMTW GV 8.18 3 1 2 6 3 -92.67 -3461 100 hour >20 hour >10 hour 45.33 1490 106.43 12480936 J Biol Chem. 2003 Feb 21;278(8):6596-602. "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. 10.1074/jbc.M210164200 Anti-HIV DRAVPe00145 CEYQAGHNKVGSLQY 15 vif 133-147 Synthetic construct(derived from HIV-1 Vif protein) No entry found None HIV Retroviridae ELISA [Ref.12480936]HIV-1:inhibit vif-vif binding. No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00145 DRAVPe00145.cif Linear Free Free None L Vif proteins "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." 1696.85 C73H109N21O24S DFIMPRTW GQY 6.74 2 1 1 7 3 -86.67 -2449 1.2 hour >20 hour >10 hour 52 2980 212.86 12480936 J Biol Chem. 2003 Feb 21;278(8):6596-602. "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. 10.1074/jbc.M210164200 Anti-HIV DRAVPe00146 AGHNKVGSLQYLALA 15 vif 137-151 Synthetic construct(derived from HIV-1 Vif protein) No entry found None HIV Retroviridae ELISA [Ref.12480936]HIV-1:inhibit vif-vif binding. No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00146 DRAVPe00146.cif Linear Free Free None L Vif proteins "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." 1541.77 C69H112N20O20 CDEFIMPRTW AL 8.64 2 0 2 5 7 26.67 18 4.4 hour >20 hour >10 hour 117.33 1490 106.43 12480936 J Biol Chem. 2003 Feb 21;278(8):6596-602. "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. 10.1074/jbc.M210164200 Anti-HIV DRAVPe00147 KVGSLQYLALAALIT 15 vif 141-155 Synthetic construct(derived from HIV-1 Vif protein) No entry found None HIV Retroviridae ELISA [Ref.12480936]HIV-1:inhibit vif-vif binding. No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00147 DRAVPe00147.cif Linear Free Free None L Vif proteins "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." 1560.9 C73H125N17O20 CDEFHMNPRW L 8.59 1 0 1 4 9 124.67 1781 1.3 hour 3 min 2 min 169.33 1490 106.43 12480936 J Biol Chem. 2003 Feb 21;278(8):6596-602. "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. 10.1074/jbc.M210164200 Anti-HIV DRAVPe00148 LQYLALAALITPKKI 15 vif 145-159 Synthetic construct(derived from HIV-1 Vif protein) No entry found None HIV Retroviridae ELISA [Ref.12480936]HIV-1:inhibit vif-vif binding. No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00148 DRAVPe00148.cif Linear Free Free None L Vif proteins "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." 1656.08 C80H138N18O19 CDEFGHMNRSVW L 9.7 2 0 2 2 9 98 1560 5.5 hour 3 min 2 min 176 1490 106.43 12480936 J Biol Chem. 2003 Feb 21;278(8):6596-602. "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. 10.1074/jbc.M210164200 Anti-HIV DRAVPe00149 ALAALITPKKIKPPL 15 vif 149-163 Synthetic construct(derived from HIV-1 Vif protein) No entry found None HIV Retroviridae ELISA [Ref.12480936]HIV-1:inhibit vif-vif binding. No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00149 DRAVPe00149.cif Linear Free Free None L Vif proteins "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." 1574.03 C76H136N18O17 CDEFGHMNQRSVWY AKLP 10.3 3 0 3 1 8 57.33 1081 4.4 hour >20 hour >10 hour 150 0 0 12480936 J Biol Chem. 2003 Feb 21;278(8):6596-602. "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. 10.1074/jbc.M210164200 Anti-HIV DRAVPe00150 LITPKKIKPPLPSVT 15 vif 153-167 Synthetic construct(derived from HIV-1 Vif protein) No entry found None HIV Retroviridae ELISA [Ref.12480936]HIV-1:inhibit vif-vif binding. No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00150 DRAVPe00150.cif Linear Free Free None L Vif proteins "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." 1632.06 C78H138N18O19 ACDEFGHMNQRWY P 10.3 3 0 3 3 5 3.33 -147 5.5 hour 3 min 2 min 123.33 0 0 12480936 J Biol Chem. 2003 Feb 21;278(8):6596-602. "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. 10.1074/jbc.M210164200 Anti-HIV DRAVPe00151 KKIKPPLPSVTKLTE 15 vif 157-171 Synthetic construct(derived from HIV-1 Vif protein) No entry found None HIV Retroviridae ELISA [Ref.12480936]HIV-1:inhibit vif-vif binding. No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00151 DRAVPe00151.cif Linear Free Free None L Vif proteins "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." 1679.08 C78H139N19O21 ACDFGHMNQRWY K 10 4 1 3 3 4 -65.33 -1875 1.3 hour 3 min 2 min 97.33 0 0 12480936 J Biol Chem. 2003 Feb 21;278(8):6596-602. "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. 10.1074/jbc.M210164200 Anti-HIV DRAVPe00152 PPLPSVTKLTEDRWN 15 vif 161-175 Synthetic construct(derived from HIV-1 Vif protein) No entry found None HIV Retroviridae ELISA [Ref.12480936]HIV-1:inhibit vif-vif binding. No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00152 DRAVPe00152.cif Linear Free Free None L Vif proteins "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." 1752.99 C79H125N21O24 ACFGHIMQY P 6.49 2 2 0 4 4 -100 -3497 >20 hour >20 hour ? 71.33 5500 392.86 12480936 J Biol Chem. 2003 Feb 21;278(8):6596-602. "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. 10.1074/jbc.M210164200 Anti-HIV DRAVPe00153 SVTKLTEDRWNKPQK 15 vif 165-179 Synthetic construct(derived from HIV-1 Vif protein) No entry found None HIV Retroviridae ELISA [Ref.12480936]HIV-1:inhibit vif-vif binding. No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00153 DRAVPe00153.cif Linear Free Free None L Vif proteins "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." 1830.07 C80H132N24O25 ACFGHIMY K 9.7 4 2 2 4 3 -179.33 -5653 1.9 hour >20 hour >10 hour 45.33 5500 392.86 12480936 J Biol Chem. 2003 Feb 21;278(8):6596-602. "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. 10.1074/jbc.M210164200 Anti-HIV DRAVPe00154 LTEDRWNKPQKTKGH 15 vif 169-183 Synthetic construct(derived from HIV-1 Vif protein) No entry found None HIV Retroviridae ELISA [Ref.12480936]HIV-1:inhibit vif-vif binding. No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00154 DRAVPe00154.cif Linear Free Free None L Vif proteins "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." 1838.06 C80H128N26O24 ACFIMSVY K 9.7 5 2 3 4 2 -226 -6089 5.5 hour 3 min 2 min 26 5500 392.86 12480936 J Biol Chem. 2003 Feb 21;278(8):6596-602. "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. 10.1074/jbc.M210164200 Anti-HIV DRAVPe00155 RWNKPQKTKGHRGSH 15 vif 173-187 Synthetic construct(derived from HIV-1 Vif protein) No entry found None HIV Retroviridae ELISA [Ref.12480936]HIV-1:inhibit vif-vif binding. No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00155 DRAVPe00155.cif Linear Free Free None L Vif proteins "Vif proteins are essential for HIV-1 replication and able to form multimer, which is critical to the biological activity of many prokaryotic and eukaryotic proteins and is a common mechanism for the functional activation/inactivation of proteins.The peptide could bind with vif proteins and block the multimerization of them,which should inhibit HIV-1 replication." 1817.05 C78H125N31O20 ACDEFILMVY K 12.02 7 0 7 5 1 -259.33 -6975 1 hour 2 min 2 min 0 5500 392.86 12480936 J Biol Chem. 2003 Feb 21;278(8):6596-602. "Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H." Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. 10.1074/jbc.M210164200 Anti-HIV DRAVPe00156 PTGERVWDRGNVTLLCDCPN 20 P4 Synthetic construct(derived from region of GB virus C glycoprotein E2) No entry found None HIV Retroviridae Luciferase assay [Ref.21543477]HIV-1(92UG024):inhibition of HIV replication in TZM-bl cells(IC50=15.07 μM);##HIV-1(RU570):inhibition of HIV replication in TZM-bl cells(IC50=18.28 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00156 DRAVPe00156.cif Linear Free Free None L membrane The possible mechanism of action is that the peptide could inhibit membrane fusion and inhibit HIV-1 replication in cells. 2245.51 C94H149N29O31S2 AFHIKMQSY CDGLNPRTV 4.56 2 3 -1 8 5 -59 -4782 >20 hour >20 hour ? 68 5625 296.05 21543477 J Virol. 2011 Jul;85(14):7037-47. "Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H. " Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition. 10.1128/JVI.02366-10 Anti-HIV DRAVPe00157 WDRGNVTLLCDCPNGPWVWV 20 P4-7 Synthetic construct(derived from region of GB virus C glycoprotein E2) No entry found None HIV Retroviridae Luciferase assay [Ref.21543477]HIV-1(92UG024):inhibition of HIV replication in TZM-bl cells(IC50=2.59 μM);##HIV-1(RU570):inhibition of HIV replication in TZM-bl cells(IC50=2.66 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00157 DRAVPe00157.cif Linear Free Free None L membrane The possible mechanism of action is that the peptide could inhibit membrane fusion and inhibit HIV-1 replication in cells. 2330.66 C106H152N28O28S2 AEFHIKMQSY VW 4.21 1 2 -1 7 8 -3.5 -1482 2.8 hour 3 min 2 min 82.5 16625 875 21543477 J Virol. 2011 Jul;85(14):7037-47. "Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H. " Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition. 10.1128/JVI.02366-10 Anti-HIV DRAVPe00158 WDRGNVTLLCDCPNGPWVWV 20 P4-7 Synthetic construct(derived from region of GB virus C glycoprotein E2) No entry found None HIV Retroviridae Luciferase assay [Ref.21543477]HIV-1(NL4-3):inhibition of HIV replication(IC50=3.0 μM);##HIV-1(YU-2):inhibition of HIV replication(IC50=5.2 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00158 DRAVPe00158.cif Linear Acetylation Free None L membrane The possible mechanism of action is that the peptide could inhibit membrane fusion and inhibit HIV-1 replication in cells. 2330.66 C106H152N28O28S2 AEFHIKMQSY VW 4.21 1 2 -1 7 8 -3.5 -1482 2.8 hour 3 min 2 min 82.5 16625 875 21543477 J Virol. 2011 Jul;85(14):7037-47. "Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H. " Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition. 10.1128/JVI.02366-10 Anti-HIV DRAVPe00159 GPWVWVPAFCQAVGWGDPIT 20 P6 Synthetic construct(derived from region of GB virus C glycoprotein E2) No entry found None HIV Retroviridae Luciferase assay [Ref.21543477]HIV-1(92UG024):inhibition of HIV replication in TZM-bl cells(IC50=16.80 μM);##HIV-1(RU570):inhibition of HIV replication in TZM-bl cells(IC50=3.57 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00159 DRAVPe00159.cif Linear Free Free None L membrane The possible mechanism of action is that the peptide could inhibit membrane fusion and inhibit HIV-1 replication in cells. 2186.52 C106H144N24O25S EHKLMNRSY GPVW 3.8 0 1 -1 5 10 48 1790 30 hour >20 hour >10 hour 73 16500 868.42 21543477 J Virol. 2011 Jul;85(14):7037-47. "Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H. " Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition. 10.1128/JVI.02366-10 Anti-HIV DRAVPe00160 TLLCDCPNGPWVWVPAFCQA 20 P6-1 Synthetic construct(derived from region of GB virus C glycoprotein E2) No entry found None HIV Retroviridae Luciferase assay [Ref.21543477]HIV-1(92UG024):inhibition of HIV replication in TZM-bl cells(IC50=2.36 μM);##HIV-1(RU570):inhibition of HIV replication in TZM-bl cells(IC50=1.29 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00160 DRAVPe00160.cif Linear Free Free None L membrane The possible mechanism of action is that the peptide could inhibit membrane fusion and inhibit HIV-1 replication in cells. 2220.61 C102H146N24O26S3 EHIKMRSY CP 3.8 0 1 -1 6 9 58.5 1049 7.2 hour >20 hour >10 hour 78 11125 585.53 21543477 J Virol. 2011 Jul;85(14):7037-47. "Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H. " Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition. 10.1128/JVI.02366-10 Anti-HIV DRAVPe00161 LCDCPNGPWVWVPAFCQAVG 20 P6-2 Synthetic construct(derived from region of GB virus C glycoprotein E2) No entry found None HIV Retroviridae Luciferase assay [Ref.21543477]HIV-1(92UG024):inhibition of HIV replication in TZM-bl cells(IC50=3.33 μM);##HIV-1(RU570):inhibition of HIV replication in TZM-bl cells(IC50=1.32 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00161 DRAVPe00161.cif Linear Free Free None L membrane The possible mechanism of action is that the peptide could inhibit membrane fusion and inhibit HIV-1 replication in cells. 2162.53 C99H140N24O25S3 EHIKMRSTY CPV 3.8 0 1 -1 6 9 62 1312 5.5 hour 3 min 2 min 73 11125 585.53 21543477 J Virol. 2011 Jul;85(14):7037-47. "Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H. " Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition. 10.1128/JVI.02366-10 Anti-HIV DRAVPe00162 LCDCPNGPWVWVPAFCQAVG 20 P6-2 Synthetic construct(derived from region of GB virus C glycoprotein E2) No entry found None HIV Retroviridae Luciferase assay [Ref.21543477]HIV-1(NL4-3):inhibition of HIV replication(IC50=2.3 μM);##HIV-1(YU-2):inhibition of HIV replication(IC50=2.4 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00162 DRAVPe00162.cif Linear Acetylation Free None L membrane The possible mechanism of action is that the peptide could inhibit membrane fusion and inhibit HIV-1 replication in cells. 2162.53 C99H140N24O25S3 EHIKMRSTY CPV 3.8 0 1 -1 6 9 62 1312 5.5 hour 3 min 2 min 73 11125 585.53 21543477 J Virol. 2011 Jul;85(14):7037-47. "Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H. " Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition. 10.1128/JVI.02366-10 Anti-HIV DRAVPe00163 DCPNGPWVWVPAFCQAVGWG 20 P6-3 Synthetic construct(derived from region of GB virus C glycoprotein E2) No entry found None HIV Retroviridae Luciferase assay [Ref.21543477]HIV-1(92UG024):inhibition of HIV replication in TZM-bl cells(IC50=4.00 μM);##HIV-1(RU570):inhibition of HIV replication in TZM-bl cells(IC50=2.00 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00163 DRAVPe00163.cif Linear Free Free None L membrane The possible mechanism of action is that the peptide could inhibit membrane fusion and inhibit HIV-1 replication in cells. 2189.49 C103H137N25O25S2 EHIKLMRSTY GPVW 3.8 0 1 -1 6 9 24 1019 1.1 hour 3 min >10 hour 53.5 16625 875 21543477 J Virol. 2011 Jul;85(14):7037-47. "Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H. " Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition. 10.1128/JVI.02366-10 Anti-HIV DRAVPe00164 PNGPWVWVPAFCQAVGWGDP 20 P6-4 Synthetic construct(derived from region of GB virus C glycoprotein E2) No entry found None HIV Retroviridae Luciferase assay [Ref.21543477]HIV-1(92UG024):inhibition of HIV replication in TZM-bl cells(IC50=11.88 μM);##HIV-1(RU570):inhibition of HIV replication in TZM-bl cells(IC50=8.04 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00164 DRAVPe00164.cif Linear Free Free None L membrane The possible mechanism of action is that the peptide could inhibit membrane fusion and inhibit HIV-1 replication in cells. 2183.47 C105H139N25O25S EHIKLMRSTY P 3.8 0 1 -1 5 9 3.5 891 >20 hour >20 hour ? 53.5 16500 868.42 21543477 J Virol. 2011 Jul;85(14):7037-47. "Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H. " Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition. 10.1128/JVI.02366-10 Anti-HIV DRAVPe00165 RGTKALTEVIPLTEEAEC 18 PepA Synthetic construct No entry found None HIV Retroviridae RT-Polymerase Assay [Ref.18952602]HIV-1: inhibition of polymerase activity of HIV-1 RT(Ki =35 ± 5 μM).##NOTE:Ki: inhibition constants No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00165 DRAVPe00165.cif Linear Free Free None L Reverse Transcriptase "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." 1960.23 C83H142N22O30S DFHMNQSWY E 4.49 2 4 -2 5 6 -22.78 -3078 1 hour 2 min 2 min 92.22 0 0 18952602 J Biol Chem. 2009 Jan 2;284(1):254-264. "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility. 10.1074/jbc.M802199200 Anti-HIV DRAVPe00166 GTKALTEVIPLTEEAEC 17 P1 Synthetic construct(derived from Pep-A) No entry found None HIV Retroviridae RT-Polymerase Assay "[Ref.18952602]HIV-1: inhibition of polymerase activity of HIV-1 RT(Ki =7.5±2.3 μM);inhibition of PHA-P-activated PBMCs infected with HIV-1-LAI(EC50=78.2 nM,associated with Pep-1).##NOTE:Ki: inhibition constants " No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00166 DRAVPe00166.cif Linear Free Free None L Reverse Transcriptase "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." 1804.04 C77H130N18O29S DFHMNQRSWY E 4.09 1 4 -3 5 6 2.35 -1586 30 hour >20 hour >10 hour 97.65 0 0 18952602 J Biol Chem. 2009 Jan 2;284(1):254-264. "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility. 10.1074/jbc.M802199200 Anti-HIV DRAVPe00167 ATKALTEVIPLTEEAEC 17 P2 Synthetic construct(derived from Pep-A) No entry found None HIV Retroviridae RT-Polymerase Assay [Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =28 ±11 μM).##NOTE:Ki: inhibition constants No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00167 DRAVPe00167.cif Linear Free Free None L Reverse Transcriptase "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." 1818.07 C78H132N18O29S DFGHMNQRSWY E 4.09 1 4 -3 4 7 15.29 -1499 4.4 hour >20 hour >10 hour 103.53 0 0 18952602 J Biol Chem. 2009 Jan 2;284(1):254-264. "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility. 10.1074/jbc.M802199200 Anti-HIV DRAVPe00168 GAKALTEVIPLTEEAEC 17 P3 Synthetic construct(derived from Pep-A) No entry found None HIV Retroviridae RT-Polymerase Assay [Ref.18952602]HIV-1: inhibition of polymerase activity of HIV-1 RT(Ki =10.3 ± 2.1 μM).##NOTE:Ki: inhibition constants No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00168 DRAVPe00168.cif Linear Free Free None L Reverse Transcriptase "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." 1774.02 C76H128N18O28S DFHMNQRSWY E 4.09 1 4 -3 4 7 17.06 -1148 30 hour >20 hour >10 hour 103.53 0 0 18952602 J Biol Chem. 2009 Jan 2;284(1):254-264. "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility. 10.1074/jbc.M802199200 Anti-HIV DRAVPe00169 GTAALTEVIPLTEEAEC 17 P4 Synthetic construct(derived from Pep-A) No entry found None HIV Retroviridae RT-Polymerase Assay [Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =15 ± 2.9 μM).##NOTE:Ki: inhibition constants No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00169 DRAVPe00169.cif Linear Free Free None L Reverse Transcriptase "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." 1746.95 C74H123N17O29S DFHKMNQRSWY E 3.58 0 4 -4 5 7 35.88 -850 30 hour >20 hour >10 hour 103.53 0 0 18952602 J Biol Chem. 2009 Jan 2;284(1):254-264. "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility. 10.1074/jbc.M802199200 Anti-HIV DRAVPe00170 GTKGLTEVIPLTEEAEC 17 P5 Synthetic construct(derived from Pep-A) No entry found None HIV Retroviridae RT-Polymerase Assay [Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =20 ± 3.7 μM).##NOTE:Ki: inhibition constants No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00170 DRAVPe00170.cif Linear Free Free None L Reverse Transcriptase "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." 1790.02 C76H128N18O29S DFHMNQRSWY E 4.09 1 4 -3 6 5 -10.59 -1673 30 hour >20 hour >10 hour 91.76 0 0 18952602 J Biol Chem. 2009 Jan 2;284(1):254-264. "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility. 10.1074/jbc.M802199200 Anti-HIV DRAVPe00171 GTKAATEVIPLTEEAEC 17 P6 Synthetic construct(derived from Pep-A) No entry found None HIV Retroviridae RT-Polymerase Assay "[Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =5.7 ± 2.3 μM);inhibition of PHA-P-activated PBMCs infected with HIV-1-LAI(EC50=170 nM,associated with Pep-1).##NOTE:Ki: inhibition constants " No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00171 DRAVPe00171.cif Linear Free Free None L Reverse Transcriptase "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." 1761.96 C74H124N18O29S DFHMNQRSWY E 4.09 1 4 -3 5 6 -9.41 -1897 30 hour >20 hour >10 hour 80.59 0 0 18952602 J Biol Chem. 2009 Jan 2;284(1):254-264. "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility. 10.1074/jbc.M802199200 Anti-HIV DRAVPe00172 GTKALAEVIPLTEEAEC 17 P7 Synthetic construct(derived from Pep-A) No entry found None HIV Retroviridae RT-Polymerase Assay [Ref.18952602]HIV-1: inhibition of polymerase activity of HIV-1 RT(Ki =13.5 ± 2.1 μM).##NOTE:Ki: inhibition constants No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00172 DRAVPe00172.cif Linear Free Free None L Reverse Transcriptase "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." 1774.02 C76H128N18O28S DFHMNQRSWY E 4.09 1 4 -3 4 7 17.06 -1148 30 hour >20 hour >10 hour 103.53 0 0 18952602 J Biol Chem. 2009 Jan 2;284(1):254-264. "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility. 10.1074/jbc.M802199200 Anti-HIV DRAVPe00173 GTKALTAVIPLTEEAEC 17 P8 Synthetic construct(derived from Pep-A) No entry found None HIV Retroviridae RT-Polymerase Assay "[Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =57 ± 19 μM);inhibition of PHA-P-activated PBMCs infected with HIV-1-LAI(EC50=290 nM,associated with Pep-1).##NOTE:Ki: inhibition constants " No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00173 DRAVPe00173.cif Linear Free Free None L Reverse Transcriptase "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." 1746.01 C75H128N18O27S DFHMNQRSWY AET 4.25 1 3 -2 5 7 33.53 -724 30 hour >20 hour >10 hour 103.53 0 0 18952602 J Biol Chem. 2009 Jan 2;284(1):254-264. "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility. 10.1074/jbc.M802199200 Anti-HIV DRAVPe00174 GTKALTEAIPLTEEAEC 17 P9 Synthetic construct(derived from Pep-A) No entry found None HIV Retroviridae RT-Polymerase Assay [Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =15 ±7.3 μM).##NOTE:Ki: inhibition constants No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00174 DRAVPe00174.cif Linear Free Free None L Reverse Transcriptase "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." 1775.99 C75H126N18O29S DFHMNQRSVWY E 4.09 1 4 -3 5 6 -11.76 -1809 30 hour >20 hour >10 hour 86.47 0 0 18952602 J Biol Chem. 2009 Jan 2;284(1):254-264. "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility. 10.1074/jbc.M802199200 Anti-HIV DRAVPe00175 GTKALTEVAPLTEEAEC 17 P10 Synthetic construct(derived from Pep-A) No entry found None HIV Retroviridae RT-Polymerase Assay "[Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =7.3 ± 2.9 μM);inhibition of PHA-P-activated PBMCs infected with HIV-1-LAI(EC50=140 nM,associated with Pep-1).##NOTE:Ki: inhibition constants " No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00175 DRAVPe00175.cif Linear Free Free None L Reverse Transcriptase "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." 1761.96 C74H124N18O29S DFHIMNQRSWY E 4.09 1 4 -3 5 6 -13.53 -1897 30 hour >20 hour >10 hour 80.59 0 0 18952602 J Biol Chem. 2009 Jan 2;284(1):254-264. "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility. 10.1074/jbc.M802199200 Anti-HIV DRAVPe00176 GTKALTEVIALTEEAEC 17 P11 Synthetic construct(derived from Pep-A) No entry found None HIV Retroviridae RT-Polymerase Assay [Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =7 ± 1.4 μM).##NOTE:Ki: inhibition constants No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00176 DRAVPe00176.cif Linear Free Free None L Reverse Transcriptase "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." 1778 C75H128N18O29S DFHMNPQRSWY E 4.09 1 4 -3 5 7 22.35 -1405 30 hour >20 hour >10 hour 103.53 0 0 18952602 J Biol Chem. 2009 Jan 2;284(1):254-264. "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility. 10.1074/jbc.M802199200 Anti-HIV DRAVPe00177 GTKALTEVIPATEEAEC 17 P12 Synthetic construct(derived from Pep-A) No entry found None HIV Retroviridae RT-Polymerase Assay [Ref.18952602]HIV-1: inhibition of polymerase activity of HIV-1 RT(Ki =22 ± 3 μM).##NOTE:Ki: inhibition constants No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00177 DRAVPe00177.cif Linear Free Free None L Reverse Transcriptase "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." 1761.96 C74H124N18O29S DFHMNQRSWY E 4.09 1 4 -3 5 6 -9.41 -1897 30 hour >20 hour >10 hour 80.59 0 0 18952602 J Biol Chem. 2009 Jan 2;284(1):254-264. "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility. 10.1074/jbc.M802199200 Anti-HIV DRAVPe00178 GTKALTEVIPLAEEAEC 17 P13 Synthetic construct(derived from Pep-A) No entry found None HIV Retroviridae RT-Polymerase Assay [Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =10.2 ± 2.5 μM).##NOTE:Ki: inhibition constants No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00178 DRAVPe00178.cif Linear Free Free None L Reverse Transcriptase "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." 1774.02 C76H128N18O28S DFHMNQRSWY E 4.09 1 4 -3 4 7 17.06 -1148 30 hour >20 hour >10 hour 103.53 0 0 18952602 J Biol Chem. 2009 Jan 2;284(1):254-264. "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility. 10.1074/jbc.M802199200 Anti-HIV DRAVPe00179 GTKALTEVIPLTAEAEC 17 P14 Synthetic construct(derived from Pep-A) No entry found None HIV Retroviridae RT-Polymerase Assay [Ref.18952602]HIV-1: inhibition of polymerase activity of HIV-1 RT(Ki =14 ± 3 μM).##NOTE:Ki: inhibition constants No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00179 DRAVPe00179.cif Linear Free Free None L Reverse Transcriptase "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." 1746.01 C75H128N18O27S DFHMNQRSWY AET 4.25 1 3 -2 5 7 33.53 -724 30 hour >20 hour >10 hour 103.53 0 0 18952602 J Biol Chem. 2009 Jan 2;284(1):254-264. "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility. 10.1074/jbc.M802199200 Anti-HIV DRAVPe00180 GTKALTEVIPLTEAAEC 17 P15 Synthetic construct(derived from Pep-A) No entry found None HIV Retroviridae RT-Polymerase Assay [Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =14 ± 2.2 μM).##NOTE:Ki: inhibition constants No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00180 DRAVPe00180.cif Linear Free Free None L Reverse Transcriptase "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." 1746.01 C75H128N18O27S DFHMNQRSWY AET 4.25 1 3 -2 5 7 33.53 -724 30 hour >20 hour >10 hour 103.53 0 0 18952602 J Biol Chem. 2009 Jan 2;284(1):254-264. "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility. 10.1074/jbc.M802199200 Anti-HIV DRAVPe00181 GTKWLTEVWPLC 12 P16 Synthetic construct(derived from Pep-A) No entry found None HIV Retroviridae RT-Polymerase Assay [Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =14 ± 4 μM).##NOTE:Ki: inhibition constants No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00181 DRAVPe00181.cif Linear Free Free None L Reverse Transcriptase "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." 1432.7 C68H101N15O17S ADFHIMNQRSY LTW 5.99 1 1 0 4 5 14.17 326 30 hour >20 hour >10 hour 89.17 11000 1000 18952602 J Biol Chem. 2009 Jan 2;284(1):254-264. "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility. 10.1074/jbc.M802199200 Anti-HIV DRAVPe00182 GTKAWTEVWPLC 12 P17 Synthetic construct(derived from Pep-A) No entry found None HIV Retroviridae RT-Polymerase Assay [Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =35 ± 11 μM).##NOTE:Ki: inhibition constants No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00182 DRAVPe00182.cif Linear Free Free None L Reverse Transcriptase "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." 1390.62 C65H95N15O17S DFHIMNQRSY TW 5.99 1 1 0 4 5 -2.5 15 30 hour >20 hour >10 hour 65 11000 1000 18952602 J Biol Chem. 2009 Jan 2;284(1):254-264. "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility. 10.1074/jbc.M802199200 Anti-HIV DRAVPe00183 GTKALTEVIPLTC 13 P18 Synthetic construct(derived from Pep-A) No entry found None HIV Retroviridae RT-Polymerase Assay "[Ref.18952602]HIV-1:inhibition of PHA-P-activated PBMCs infected with HIV-1-LAI(EC50>1000 nM,associated with Pep-1);inhibition of polymerase activity of HIV-1 RT(Ki =53± 12 μM).##NOTE:Ki: inhibition constants " No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00183 DRAVPe00183.cif Linear Free Free None L Reverse Transcriptase "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." 1345.62 C59H104N14O19S DFHMNQRSWY T 5.99 1 1 0 5 5 70 276 30 hour >20 hour >10 hour 120 0 0 18952602 J Biol Chem. 2009 Jan 2;284(1):254-264. "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility. 10.1074/jbc.M802199200 Anti-HIV DRAVPe00184 GTKAATEVIPLTC 13 P19 Synthetic construct(derived from Pep-A) No entry found None HIV Retroviridae RT-Polymerase Assay [Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =49 ± 9 μM).##NOTE:Ki: inhibition constants No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00184 DRAVPe00184.cif Linear Free Free None L Reverse Transcriptase "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." 1303.54 C56H98N14O19S DFHMNQRSWY T 5.99 1 1 0 5 5 54.62 -35 30 hour >20 hour >10 hour 97.69 0 0 18952602 J Biol Chem. 2009 Jan 2;284(1):254-264. "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility. 10.1074/jbc.M802199200 Anti-HIV DRAVPe00185 GTKWLTEWIPLC 12 P24 Synthetic construct(derived from Pep-A) No entry found None HIV Retroviridae RT-Polymerase Assay "[Ref.18952602]HIV-1:inhibition of PHA-P-activated PBMCs infected with HIV-1-LAI(EC50=2.3 nM,associated with Pep-1); inhibition of polymerase activity of HIV-1 RT(Ki =0.7 ± 0.05 μM).##NOTE:Ki: inhibition constants " No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00185 DRAVPe00185.cif Linear Free Free None L Reverse Transcriptase "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." 1446.73 C69H103N15O17S ADFHMNQRSVY LTW 5.99 1 1 0 4 5 16.67 414 30 hour >20 hour >10 hour 97.5 11000 1000 18952602 J Biol Chem. 2009 Jan 2;284(1):254-264. "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility. 10.1074/jbc.M802199200 Anti-HIV DRAVPe00186 KWLTEWIPLTAEAEC 15 P26 Synthetic construct(derived from Pep-A) No entry found None HIV Retroviridae RT-Polymerase Assay "[Ref.18952602]HIV-1:inhibition of PHA-P-activated PBMCs infected with HIV-1-LAI(EC50>1000 nM,associated with Pep-1); inhibition of polymerase activity of HIV-1 RT(Ki =1.8± 0.7 μM).##NOTE:Ki: inhibition constants " No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00186 DRAVPe00186.cif Linear Free Free None L Reverse Transcriptase "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." 1790.06 C83H124N18O24S DFGHMNQRSVY E 4.25 1 3 -2 3 7 -6.67 -680 1.3 hour 3 min 2 min 91.33 11000 785.71 18952602 J Biol Chem. 2009 Jan 2;284(1):254-264. "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility. 10.1074/jbc.M802199200 Anti-HIV DRAVPe00187 GTKWLTEWIPLTAEC 15 P27 Synthetic construct(derived from Pep-A) No entry found None HIV Retroviridae RT-Polymerase Assay "[Ref.18952602]HIV-1:inhibition of PHA-P-activated PBMCs infected with HIV-1-LAI(EC50<0.32 nM,associated with Pep-1); inhibition of polymerase activity of HIV-1 RT(Ki =0.05 ± 0.01 μM).##NOTE:Ki: inhibition constants " No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00187 DRAVPe00187.cif Linear Free Free None L Reverse Transcriptase "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." 1748.03 C81H122N18O23S DFHMNQRSVY T 4.53 1 2 -1 5 6 -2.67 -343 30 hour >20 hour >10 hour 84.67 11000 785.71 18952602 J Biol Chem. 2009 Jan 2;284(1):254-264. "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility. 10.1074/jbc.M802199200 Anti-HIV DRAVPe00188 GTKWATEWAPLTAEAEC 17 P28 Synthetic construct(derived from Pep-A) No entry found None HIV Retroviridae RT-Polymerase Assay [Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =2 ± 0.6 μM).##NOTE:Ki: inhibition constants No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00188 DRAVPe00188.cif Linear Free Free None L Reverse Transcriptase "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." 1864.06 C83H122N20O27S DFHIMNQRSVY A 4.25 1 3 -2 5 7 -40 -1465 30 hour >20 hour >10 hour 46.47 11000 687.5 18952602 J Biol Chem. 2009 Jan 2;284(1):254-264. "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility. 10.1074/jbc.M802199200 Anti-HIV DRAVPe00189 KWLTEWIPLTAEC 13 P29 Synthetic construct(derived from Pep-A) No entry found None HIV Retroviridae RT-Polymerase Assay [Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =1 ± 0.4 μM).##NOTE:Ki: inhibition constants No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00189 DRAVPe00189.cif Linear Free Free None L Reverse Transcriptase "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." 1589.87 C75H112N16O20S DFGHMNQRSVY ELTW 4.53 1 2 -1 3 6 5.38 -180 1.3 hour 3 min 2 min 97.69 11000 916.67 18952602 J Biol Chem. 2009 Jan 2;284(1):254-264. "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility. 10.1074/jbc.M802199200 Anti-HIV DRAVPe00190 GTKWLTEWIPLTAEAEC 17 PAW Synthetic construct(derived from Pep-A) No entry found None HIV Retroviridae RT-Polymerase Assay "[Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =0.7 ± 0.2 μM);inhibition of PHA-P-activated PBMCs infected with HIV-1-LAI(EC50=1.8 nM,associated with Pep-1)." No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00190 DRAVPe00190.cif Linear Free Free None L Reverse Transcriptase "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." 1948.22 C89H134N20O27S DFHMNQRSVY ET 4.25 1 3 -2 5 7 -12.35 -843 30 hour >20 hour >10 hour 80.59 11000 687.5 18952602 J Biol Chem. 2009 Jan 2;284(1):254-264. "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility. 10.1074/jbc.M802199200 Anti-HIV DRAVPe00191 GAKTETLVIPETELEAC 17 Pscr Synthetic construct(derived from Pep-A) No entry found None HIV Retroviridae RT-Polymerase Assay [Ref.18952602]HIV-1:inhibition of polymerase activity of HIV-1 RT(Ki =61 ± 12 μM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00191 DRAVPe00191.cif Linear Free Free None L Reverse Transcriptase "HIV-1 reverse transcriptase (RT) plays an essential multifunctional role in the replication of the virus, by catalyzing the synthesis of double-stranded DNA from the single strand retroviral RNA genome.The peptide could inhibit the activity of reverse transcriptase." 1804.04 C77H130N18O29S DFHMNQRSWY E 4.09 1 4 -3 5 6 2.35 -1586 30 hour >20 hour >10 hour 97.65 0 0 18952602 J Biol Chem. 2009 Jan 2;284(1):254-264. "Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G." A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility. 10.1074/jbc.M802199200 Anti-HIV DRAVPe00192 LEAIPMSIPPEVKFNKPFVF 20 VIRIP Synthetic construct(derived from α1-antitrypsin) No entry found None HIV Retroviridae ELISA [Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=14.79±2.56 µM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.17448989]No cytotoxicity against P4-CCR5 cells up tp 1000 µM. DRAVPe00192 DRAVPe00192.cif Linear Free Free None L membrane The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane. 2303.79 C112H171N23O27S CDGHQRTWY P 6.14 2 2 0 2 9 39 118 5.5 hour 3 min 2 min 92.5 0 0 17448989 Cell. 2007 Apr 20;129(2):263-75. "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. 10.1016/j.cell.2007.02.042 Anti-HIV DRAVPe00193 AEAIPMSIPPEVKFNKPFVF 20 VIRIP[A1] Synthetic construct(derived from α1-antitrypsin) No entry found None HIV Retroviridae ELISA [Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50>100 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00193 DRAVPe00193.cif Linear Free Free None L membrane The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane. 2261.71 C109H165N23O27S CDGHLQRTWY P 6.19 2 2 0 2 9 29 -193 4.4 hour >20 hour >10 hour 78 0 0 17448989 Cell. 2007 Apr 20;129(2):263-75. "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. 10.1016/j.cell.2007.02.042 Anti-HIV DRAVPe00194 LAAIPMSIPPEVKFNKPFVF 20 VIRIP[A2] Synthetic construct(derived from α1-antitrypsin) No entry found None HIV Retroviridae ELISA [Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50>100 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00194 DRAVPe00194.cif Linear Free Free None L membrane The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane. 2245.75 C110H169N23O25S CDGHQRTWY P 8.59 2 1 1 2 10 65.5 980 5.5 hour 3 min 2 min 97.5 0 0 17448989 Cell. 2007 Apr 20;129(2):263-75. "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. 10.1016/j.cell.2007.02.042 Anti-HIV DRAVPe00195 LEAAPMSIPPEVKFNKPFVF 20 VIRIP[A4] Synthetic construct(derived from α1-antitrypsin) No entry found None HIV Retroviridae ELISA [Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50>100 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00195 DRAVPe00195.cif Linear Free Free None L membrane The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane. 2261.71 C109H165N23O27S CDGHQRTWY P 6.14 2 2 0 2 9 25.5 -193 5.5 hour 3 min 2 min 78 0 0 17448989 Cell. 2007 Apr 20;129(2):263-75. "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. 10.1016/j.cell.2007.02.042 Anti-HIV DRAVPe00196 LEAIAMSIPPEVKFNKPFVF 20 VIRIP[A5] Synthetic construct(derived from α1-antitrypsin) No entry found None HIV Retroviridae ELISA [Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=23.50±5.19 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00196 DRAVPe00196.cif Linear Free Free None L membrane The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane. 2277.75 C110H169N23O27S CDGHQRTWY FP 6.14 2 2 0 2 10 56 299 5.5 hour 3 min 2 min 97.5 0 0 17448989 Cell. 2007 Apr 20;129(2):263-75. "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. 10.1016/j.cell.2007.02.042 Anti-HIV DRAVPe00197 LEAIPASIPPEVKFNKPFVF 20 VIRIP[A6] Synthetic construct(derived from α1-antitrypsin) No entry found None HIV Retroviridae ELISA [Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=13.00±1.04 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00197 DRAVPe00197.cif Linear Free Free None L membrane The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane. 2243.67 C110H167N23O27 CDGHMQRTWY P 6.14 2 2 0 2 10 38.5 64 5.5 hour 3 min 2 min 97.5 0 0 17448989 Cell. 2007 Apr 20;129(2):263-75. "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. 10.1016/j.cell.2007.02.042 Anti-HIV DRAVPe00198 LEAIPMSAPPEVKFNKPFVF 20 VIRIP[A8] Synthetic construct(derived from α1-antitrypsin) No entry found None HIV Retroviridae ELISA [Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=23.46±0.28 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00198 DRAVPe00198.cif Linear Free Free None L membrane The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane. 2261.71 C109H165N23O27S CDGHQRTWY P 6.14 2 2 0 2 9 25.5 -193 5.5 hour 3 min 2 min 78 0 0 17448989 Cell. 2007 Apr 20;129(2):263-75. "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. 10.1016/j.cell.2007.02.042 Anti-HIV DRAVPe00199 LEAIPMSIAPEVKFNKPFVF 20 VIRIP[A9] Synthetic construct(derived from α1-antitrypsin) No entry found None HIV Retroviridae ELISA [Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=16.33±4.34 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00199 DRAVPe00199.cif Linear Free Free None L membrane The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane. 2277.75 C110H169N23O27S CDGHQRTWY FP 6.14 2 2 0 2 10 56 299 5.5 hour 3 min 2 min 97.5 0 0 17448989 Cell. 2007 Apr 20;129(2):263-75. "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. 10.1016/j.cell.2007.02.042 Anti-HIV DRAVPe00200 LEAIPMSIPAEVKFNKPFVF 20 VIRIP[A10] Synthetic construct(derived from α1-antitrypsin) No entry found None HIV Retroviridae ELISA [Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=9.72±1.66 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00200 DRAVPe00200.cif Linear Free Free None L membrane The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane. 2277.75 C110H169N23O27S CDGHQRTWY FP 6.14 2 2 0 2 10 56 299 5.5 hour 3 min 2 min 97.5 0 0 17448989 Cell. 2007 Apr 20;129(2):263-75. "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. 10.1016/j.cell.2007.02.042 Anti-HIV DRAVPe00201 LEAIPMSIPPAVKFNKPFVF 20 VIRIP[A11] Synthetic construct(derived from α1-antitrypsin) No entry found None HIV Retroviridae ELISA [Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=11.00±4.75 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00201 DRAVPe00201.cif Linear Free Free None L membrane The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane. 2245.75 C110H169N23O25S CDGHQRTWY P 8.59 2 1 1 2 10 65.5 980 5.5 hour 3 min 2 min 97.5 0 0 17448989 Cell. 2007 Apr 20;129(2):263-75. "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. 10.1016/j.cell.2007.02.042 Anti-HIV DRAVPe00202 LEAIPMSIPPEAKFNKPFVF 20 VIRIP[A12] Synthetic construct(derived from α1-antitrypsin) No entry found None HIV Retroviridae ELISA [Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=10.64±2.23 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00202 DRAVPe00202.cif Linear Free Free None L membrane The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane. 2275.73 C110H167N23O27S CDGHQRTWY P 6.14 2 2 0 2 9 27 -105 5.5 hour 3 min 2 min 83 0 0 17448989 Cell. 2007 Apr 20;129(2):263-75. "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. 10.1016/j.cell.2007.02.042 Anti-HIV DRAVPe00203 LEAIPMSIPPEVAFNKPFVF 20 VIRIP[A13] Synthetic construct(derived from α1-antitrypsin) No entry found None HIV Retroviridae ELISA [Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=4.73±0.61 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00203 DRAVPe00203.cif Linear Free Free None L membrane The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane. 2246.69 C109H164N22O27S CDGHQRTWY P 4.53 1 2 -1 2 10 67.5 854 5.5 hour 3 min 2 min 97.5 0 0 17448989 Cell. 2007 Apr 20;129(2):263-75. "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. 10.1016/j.cell.2007.02.042 Anti-HIV DRAVPe00204 LEAIPMSIPPEVKANKPFVF 20 VIRIP[A14] Synthetic construct(derived from α1-antitrypsin) No entry found None HIV Retroviridae ELISA [Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=4.62±1.32 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00204 DRAVPe00204.cif Linear Free Free None L membrane The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane. 2227.69 C106H167N23O27S CDGHQRTWY P 6.14 2 2 0 2 9 34 1 5.5 hour 3 min 2 min 97.5 0 0 17448989 Cell. 2007 Apr 20;129(2):263-75. "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. 10.1016/j.cell.2007.02.042 Anti-HIV DRAVPe00205 LEAIPMSIPPEVKFAKPFVF 20 VIRIP[A15] Synthetic construct(derived from α1-antitrypsin) No entry found None HIV Retroviridae ELISA [Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=17.41±3.66 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00205 DRAVPe00205.cif Linear Free Free None L membrane The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane. 2260.76 C111H170N22O26S CDGHNQRTWY P 6.14 2 2 0 1 10 65.5 963 5.5 hour 3 min 2 min 97.5 0 0 17448989 Cell. 2007 Apr 20;129(2):263-75. "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. 10.1016/j.cell.2007.02.042 Anti-HIV DRAVPe00206 LEAIPMSIPPEVKFNAPFVF 20 VIRIP[A16] Synthetic construct(derived from α1-antitrypsin) No entry found None HIV Retroviridae ELISA [Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=10.81±0.68 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00206 DRAVPe00206.cif Linear Free Free None L membrane The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane. 2246.69 C109H164N22O27S CDGHQRTWY P 4.53 1 2 -1 2 10 67.5 854 5.5 hour 3 min 2 min 97.5 0 0 17448989 Cell. 2007 Apr 20;129(2):263-75. "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. 10.1016/j.cell.2007.02.042 Anti-HIV DRAVPe00207 LEAIPMSIPPEVKFNKAFVF 20 VIRIP[A17] Synthetic construct(derived from α1-antitrypsin) No entry found None HIV Retroviridae ELISA [Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=12.72±10.17 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00207 DRAVPe00207.cif Linear Free Free None L membrane The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane. 2277.75 C110H169N23O27S CDGHQRTWY FP 6.14 2 2 0 2 10 56 299 5.5 hour 3 min 2 min 97.5 0 0 17448989 Cell. 2007 Apr 20;129(2):263-75. "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. 10.1016/j.cell.2007.02.042 Anti-HIV DRAVPe00208 LEAIPMSIPPEVKFNKPAVF 20 VIRIP[A18] Synthetic construct(derived from α1-antitrypsin) No entry found None HIV Retroviridae ELISA [Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50>100 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00208 DRAVPe00208.cif Linear Free Free None L membrane The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane. 2227.69 C106H167N23O27S CDGHQRTWY P 6.14 2 2 0 2 9 34 1 5.5 hour 3 min 2 min 97.5 0 0 17448989 Cell. 2007 Apr 20;129(2):263-75. "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. 10.1016/j.cell.2007.02.042 Anti-HIV DRAVPe00209 LEAIPMSIPPEVKFNKPFAF 20 VIRIP[A19] Synthetic construct(derived from α1-antitrypsin) No entry found None HIV Retroviridae ELISA [Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50>100 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00209 DRAVPe00209.cif Linear Free Free None L membrane The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane. 2275.73 C110H167N23O27S CDGHQRTWY P 6.14 2 2 0 2 9 27 -105 5.5 hour 3 min 2 min 83 0 0 17448989 Cell. 2007 Apr 20;129(2):263-75. "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. 10.1016/j.cell.2007.02.042 Anti-HIV DRAVPe00210 LEAIPMSIPPEVKFNKPFVA 20 VIRIP[A20] Synthetic construct(derived from α1-antitrypsin) No entry found None HIV Retroviridae ELISA [Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50>100 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00210 DRAVPe00210.cif Linear Free Free None L membrane The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane. 2227.69 C106H167N23O27S CDGHQRTWY P 6.14 2 2 0 2 9 34 1 5.5 hour 3 min 2 min 97.5 0 0 17448989 Cell. 2007 Apr 20;129(2):263-75. "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. 10.1016/j.cell.2007.02.042 Anti-HIV DRAVPe00211 LEAIPMSIPPEVKFNKPFVF 20 N-Ac-VIRIP Synthetic construct(derived from α1-antitrypsin) No entry found None HIV Retroviridae ELISA [Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50>100 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00211 DRAVPe00211.cif Linear Acetylation Free None L membrane The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane. 2303.79 C112H171N23O27S CDGHQRTWY P 6.14 2 2 0 2 9 39 118 5.5 hour 3 min 2 min 92.5 0 0 17448989 Cell. 2007 Apr 20;129(2):263-75. "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. 10.1016/j.cell.2007.02.042 Anti-HIV DRAVPe00212 LEAIPMSIPPEVKFNKPFVF 20 VIRIP-amide Synthetic construct(derived from α1-antitrypsin) No entry found None HIV Retroviridae ELISA [Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50>100 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00212 DRAVPe00212.cif Linear Free Amidation None L membrane The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane. 2303.79 C112H171N23O27S CDGHQRTWY P 6.14 2 2 0 2 9 39 118 5.5 hour 3 min 2 min 92.5 0 0 17448989 Cell. 2007 Apr 20;129(2):263-75. "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. 10.1016/j.cell.2007.02.042 Anti-HIV DRAVPe00213 LEAIPMSIPPEVKFNKPFVF 20 N-Ac-VIRIP-amide Synthetic construct(derived from α1-antitrypsin) No entry found None HIV Retroviridae ELISA [Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50>100 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00213 DRAVPe00213.cif Linear Acetylation Amidation None L membrane The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane. 2303.79 C112H171N23O27S CDGHQRTWY P 6.14 2 2 0 2 9 39 118 5.5 hour 3 min 2 min 92.5 0 0 17448989 Cell. 2007 Apr 20;129(2):263-75. "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. 10.1016/j.cell.2007.02.042 Anti-HIV DRAVPe00214 LEAIPMSIPPEVAFAKPFVF 20 "VIRIP[A13,A15]" Synthetic construct(derived from α1-antitrypsin) No entry found None HIV Retroviridae ELISA [Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=3.45±0.44 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00214 DRAVPe00214.cif Linear Free Free None L membrane The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane. 2203.67 C108H163N21O26S CDGHNQRTWY P 4.53 1 2 -1 1 11 94 1699 5.5 hour 3 min 2 min 102.5 0 0 17448989 Cell. 2007 Apr 20;129(2):263-75. "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. 10.1016/j.cell.2007.02.042 Anti-HIV DRAVPe00215 LEAIPMSIPPEVFFNKPFVF 20 VIRIP[F13] Synthetic construct(derived from α1-antitrypsin) No entry found None HIV Retroviridae ELISA [Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=0.66±0.06 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00215 DRAVPe00215.cif Linear Free Free None L membrane The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane. 2322.79 C115H168N22O27S CDGHQRTWY FP 4.53 1 2 -1 2 10 72.5 971 5.5 hour 3 min 2 min 92.5 0 0 17448989 Cell. 2007 Apr 20;129(2):263-75. "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. 10.1016/j.cell.2007.02.042 Anti-HIV DRAVPe00216 LEAIPMCIPPECAFNKPFVF 20 "VIRIP[A13,C7,C12]" Synthetic construct(derived from α1-antitrypsin) No entry found None HIV Retroviridae ELISA [Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=1.00±0.21 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00216 DRAVPe00216.cif Cyclic Free Free Disulfide bond between Cys7 and Cys12 L membrane The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane. 2266.76 C107H160N22O26S3 DGHQRSTWY P 4.53 1 2 -1 3 9 75.5 1046 5.5 hour 3 min 2 min 83 125 6.58 17448989 Cell. 2007 Apr 20;129(2):263-75. "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. 10.1016/j.cell.2007.02.042 Anti-HIV DRAVPe00217 LEAIPCSIPPCVAFNKPFVF 20 "VIRIP[A13,C6,C11]" Synthetic construct(derived from α1-antitrypsin) No entry found None HIV Retroviridae ELISA [Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=0.18±0.08 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00217 DRAVPe00217.cif Cyclic Free Free Disulfide bond between Cys6 and Cys11 L membrane The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane. 2192.66 C105H158N22O25S2 DGHMQRTWY P 5.99 1 1 0 4 10 100.5 1556 5.5 hour 3 min 2 min 97.5 125 6.58 17448989 Cell. 2007 Apr 20;129(2):263-75. "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. 10.1016/j.cell.2007.02.042 Anti-HIV DRAVPe00218 LEAIPCSIPpCVAFNKPFVF 20 "VIRIP[A13,C6,C11,p10]" Synthetic construct(derived from α1-antitrypsin) No entry found None HIV Retroviridae ELISA [Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=0.94±0.54 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00218 DRAVPe00218.cif Cyclic Free Free Disulfide bond between Cys6 and Cys11 Mixed(D-Pro10) membrane The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane. 2192.66 C100H149N21O23S2 DGHMQRTWY FP 5.99 1 1 0 4 10 108.5 1556 5.5 hour 3 min 2 min 97.5 125 6.58 17448989 Cell. 2007 Apr 20;129(2):263-75. "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. 10.1016/j.cell.2007.02.042 Anti-HIV DRAVPe00219 LEAIPCSIPPCVGFGKPFVF 20 "VIRIP[C6,C11,G13,G15]" Synthetic construct(derived from α1-antitrypsin) No entry found None HIV Retroviridae ELISA [Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=0.73±0.13 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00219 DRAVPe00219.cif Cyclic Free Free Disulfide bond between Cys6 and Cys11 L membrane The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane. 2121.58 C102H153N21O24S2 DHMNQRTWY P 5.99 1 1 0 5 9 105 2227 5.5 hour 3 min 2 min 92.5 125 6.58 17448989 Cell. 2007 Apr 20;129(2):263-75. "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. 10.1016/j.cell.2007.02.042 Anti-HIV DRAVPe00220 LEAIPCSIPPCVLFNKPFVF 20 "VIRIP[C6,C11,L13]" Synthetic construct(derived from α1-antitrypsin) No entry found None HIV Retroviridae ELISA [Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=0.84±0.08 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00220 DRAVPe00220.cif Cyclic Free Free Disulfide bond between Cys6 and Cys11 L membrane The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane. 2234.74 C108H164N22O25S2 DGHMQRTWY P 5.99 1 1 0 4 10 110.5 1867 5.5 hour 3 min 2 min 112 125 6.58 17448989 Cell. 2007 Apr 20;129(2):263-75. "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. 10.1016/j.cell.2007.02.042 Anti-HIV DRAVPe00221 LEAIPCSIPPCVFFNKPFVF 20 "VIRIP[C6,C11,F13]" Synthetic construct(derived from α1-antitrypsin) No entry found None HIV Retroviridae ELISA [Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=0.93±0.05 µM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.17448989]No cytotoxicity against P4-CCR5 cells up tp 1000 µM. DRAVPe00221 DRAVPe00221.cif Cyclic Free Free Disulfide bond between Cys6 and Cys11 L membrane The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane. 2268.76 C111H162N22O25S2 DGHMQRTWY FP 5.99 1 1 0 4 10 105.5 1673 5.5 hour 3 min 2 min 92.5 125 6.58 17448989 Cell. 2007 Apr 20;129(2):263-75. "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. 10.1016/j.cell.2007.02.042 Anti-HIV DRAVPe00222 LEAIPCSIPPCFAFNKPFVF 20 "VIRIP[A13,C6,C11,F12]" Synthetic construct(derived from α1-antitrypsin) No entry found None HIV Retroviridae ELISA [Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=0.27±0.04 µM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.17448989]No cytotoxicity against P4-CCR5 cells up tp 1000 µM. DRAVPe00222 DRAVPe00222.cif Cyclic Free Free Disulfide bond between Cys6 and Cys11 L membrane The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane. 2240.71 C109H158N22O25S2 DGHMQRTWY FP 5.99 1 1 0 4 10 93.5 1450 5.5 hour 3 min 2 min 83 125 6.58 17448989 Cell. 2007 Apr 20;129(2):263-75. "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. 10.1016/j.cell.2007.02.042 Anti-HIV DRAVPe00223 LEAIPMSIPPEFLFGKPFVF 20 "VIRIP[F12,L13,G15]" Synthetic construct(derived from α1-antitrypsin) No entry found None HIV Retroviridae ELISA [Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=1.34±0.42 µM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.17448989]No cytotoxicity against P4-CCR5 cells up tp 1000 µM. DRAVPe00223 DRAVPe00223.cif Linear Free Free None L membrane The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane. 2279.77 C114H167N21O26S CDHNQRTWY FP 4.53 1 2 -1 2 10 86 1817 5.5 hour 3 min 2 min 97.5 0 0 17448989 Cell. 2007 Apr 20;129(2):263-75. "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. 10.1016/j.cell.2007.02.042 Anti-HIV DRAVPe00224 LEAIPCSIPPCVFFGKPFVF 20 "VIRIP[C6,C11,F13,G15]" Synthetic construct(derived from α1-antitrypsin) No entry found None HIV Retroviridae ELISA [Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=0.28±0.02 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00224 DRAVPe00224.cif Cyclic Free Free Disulfide bond between Cys6 and Cys11 L membrane The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane. 2211.71 C109H159N21O24S2 DHMNQRTWY FP 5.99 1 1 0 4 10 121 2431 5.5 hour 3 min 2 min 92.5 125 6.58 17448989 Cell. 2007 Apr 20;129(2):263-75. "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. 10.1016/j.cell.2007.02.042 Anti-HIV DRAVPe00225 LEAIPCSIPPCFLFGKPFVF 20 "VIRIP[C6,C11,F12,L13,G15]" Synthetic construct(derived from α1-antitrypsin) No entry found None HIV Retroviridae ELISA [Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=0.39±0.13 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00225 DRAVPe00225.cif Cyclic Free Free Disulfide bond between Cys6 and Cys11 L membrane The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane. 2225.73 C110H161N21O24S2 DHMNQRTWY FP 5.99 1 1 0 4 10 119 2519 5.5 hour 3 min 2 min 97.5 125 6.58 17448989 Cell. 2007 Apr 20;129(2):263-75. "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. 10.1016/j.cell.2007.02.042 Anti-HIV DRAVPe00226 LEAIPCSIPpCVFFNKPFVF 20 "VIRIP[C6,C11,p10,F13]" Synthetic construct(derived from α1-antitrypsin) No entry found None HIV Retroviridae ELISA [Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=0.33±0.07 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00226 DRAVPe00226.cif Cyclic Free Free Disulfide bond between Cys6 and Cys11 Mixed(D-Pro10) membrane The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane. 2268.76 C106H153N21O23S2 DGHMQRTWY F 5.99 1 1 0 4 10 113.5 1673 5.5 hour 3 min 2 min 92.5 125 6.58 17448989 Cell. 2007 Apr 20;129(2):263-75. "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. 10.1016/j.cell.2007.02.042 Anti-HIV DRAVPe00227 LEAIPCSIPpCFLFNKPFVF 20 "VIRIP[C6,C11,p10,F12,L13]" Synthetic construct(derived from α1-antitrypsin) No entry found None HIV Retroviridae ELISA [Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=0.20±0.04 µM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.17448989]No cytotoxicity against P4-CCR5 cells up tp 1000 µM. DRAVPe00227 DRAVPe00227.cif Cyclic Free Free Disulfide bond between Cys6 and Cys11 Mixed(D-Pro10) membrane The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane. 2282.79 C107H155N21O23S2 DGHMQRTWY F 5.99 1 1 0 4 10 111.5 1761 5.5 hour 3 min 2 min 97.5 125 6.58 17448989 Cell. 2007 Apr 20;129(2):263-75. "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. 10.1016/j.cell.2007.02.042 Anti-HIV DRAVPe00228 LEAIPMGIPpEVXFNKPFVF 20 "VIRIP[G7,p10,L-Tic13]" Synthetic construct(derived from α1-antitrypsin) No entry found None HIV Retroviridae ELISA [Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=0.28±0.08 µM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.17448989]No cytotoxicity against P4-CCR5 cells up tp 1000 µM. DRAVPe00228 DRAVPe00228.cif Linear Free Free The 'X' at position 13 is L-tetrahydro-isoquinoline-3-carboxylic acid(Tic). Mixed(D-Pro10) membrane The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane. 2256.92 C100H146N20O22S CDHQRSTWY FP 4.53 1 2 -1 2 9 68.5 1107 5.5 hour 3 min 2 min 92.5 0 0 17448989 Cell. 2007 Apr 20;129(2):263-75. "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. 10.1016/j.cell.2007.02.042 Anti-HIV DRAVPe00229 LEKIPMSIPpEVXFNKPFVF 20 "VIRIP[K3,p10,L-Tic13]" Synthetic construct(derived from α1-antitrypsin) No entry found None HIV Retroviridae ELISA [Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50=0.41±0.13 µM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00229 DRAVPe00229.cif Linear Free Free The 'X' at position 13 is L-tetrahydro-isoquinoline-3-carboxylic acid(Tic). Mixed(D-Pro10) membrane The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane. 2344.04 C104H155N21O23S ACDGHQRTWY FP 6.14 2 2 0 2 8 38 -63 5.5 hour 3 min 2 min 87.5 0 0 17448989 Cell. 2007 Apr 20;129(2):263-75. "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. 10.1016/j.cell.2007.02.042 Anti-HIV DRAVPe00230 KVINPEPIVEPFMSKPFALF 20 scrambled VIRIP Synthetic construct(derived from α1-antitrypsin) No entry found None HIV Retroviridae ELISA [Ref.17448989]HIV-1:inhibition of virus infection in P4-CCR5 clls(IC50>100 µM). No hemolysis information or data found in the reference(s) presented in this entry [Ref.17448989]No cytotoxicity against P4-CCR5 cells up tp 1000 µM. DRAVPe00230 DRAVPe00230.cif Linear Free Free None L membrane The peptide can inhibit HIV-1 entry by binding to the gp41 FP and preventing its insertion into the target cell membrane. 2303.79 C112H171N23O27S CDGHQRTWY P 6.14 2 2 0 2 9 39 118 1.3 hour 3 min 2 min 92.5 0 0 17448989 Cell. 2007 Apr 20;129(2):263-75. "Münch J, Ständker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pöhlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F." Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. 10.1016/j.cell.2007.02.042 Anti-HIV DRAVPe00231 YTSLIHSLIEEGQNQQEKNEQELLELDKWASLWNWF 36 T-20S[138G] Synthetic construct(derived from Enfuvirtide) No entry found None HIV Retroviridae MAGI assay [Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=1.3± 0.5 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50=65± 8.8 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50=141±26 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50=185±68 nM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00231 DRAVPe00231.cif Linear Free Free None L membrane "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." 4420.86 C201H296N50O63 CMPRV EL 4.3 3 7 -4 9 13 -86.39 -6825 2.8 hour 10 min 2 min 89.44 17990 514 19073606 J Biol Chem. 2009 Feb 20;284(8):4914-20. "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20. 10.1074/jbc.M807169200 Anti-HIV DRAVPe00232 YTSLIHSLIEEAQNQQEKNEQELLELDKWASLWNWF 36 T-20S[138A] Synthetic construct(derived from Enfuvirtide) No entry found None HIV Retroviridae MAGI assay [Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=0.6 ± 0.1 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50=3.6± 1.7 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50=3.5 ±0.9 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50=3.2 ± 1.0 nM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00232 DRAVPe00232.cif Linear Free Free None L membrane "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." 4434.89 C202H298N50O63 CGMPRV EL 4.3 3 7 -4 8 14 -80.28 -6738 2.8 hour 10 min 2 min 92.22 17990 514 19073606 J Biol Chem. 2009 Feb 20;284(8):4914-20. "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20. 10.1074/jbc.M807169200 Anti-HIV DRAVPe00233 YTSLIHSLIEEVQNQQEKNEQELLELDKWASLWNWF 36 T-20S[138V] Synthetic construct(derived from Enfuvirtide) No entry found None HIV Retroviridae MAGI assay [Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=0.4 ± 0.2 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50=31 ± 14 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50=22 ± 3.5 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50=23 ± 5.7 nM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00233 DRAVPe00233.cif Linear Free Free None L membrane "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." 4462.94 C204H302N50O63 CGMPR EL 4.3 3 7 -4 8 14 -73.61 -6515 2.8 hour 10 min 2 min 97.5 17990 514 19073606 J Biol Chem. 2009 Feb 20;284(8):4914-20. "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20. 10.1074/jbc.M807169200 Anti-HIV DRAVPe00234 YTSLIHSLIEELQNQQEKNEQELLELDKWASLWNWF 36 T-20S[138L] Synthetic construct(derived from Enfuvirtide) No entry found None HIV Retroviridae MAGI assay [Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=0.7± 0.1 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50=13± 6 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50=2.9 ±0.7 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50=2.2± 0.4 nM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00234 DRAVPe00234.cif Linear Free Free None L membrane "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." 4476.97 C205H304N50O63 CGMPRV L 4.3 3 7 -4 8 14 -74.72 -6427 2.8 hour 10 min 2 min 100.28 17990 514 19073606 J Biol Chem. 2009 Feb 20;284(8):4914-20. "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20. 10.1074/jbc.M807169200 Anti-HIV DRAVPe00235 YTSLIHSLIEEIQNQQEKNEQELLELDKWASLWNWF 36 T-20S[138I] Synthetic construct(derived from Enfuvirtide) No entry found None HIV Retroviridae MAGI assay [Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=0.5 ± 0.1 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50=4.9± 2 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50=2.9 ±0.8 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50=2.4 ± 0.6 nM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00235 DRAVPe00235.cif Linear Free Free None L membrane "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." 4476.97 C205H304N50O63 CGMPRV EL 4.3 3 7 -4 8 14 -72.78 -6427 2.8 hour 10 min 2 min 100.28 17990 514 19073606 J Biol Chem. 2009 Feb 20;284(8):4914-20. "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20. 10.1074/jbc.M807169200 Anti-HIV DRAVPe00236 YTSLIHSLIEEMQNQQEKNEQELLELDKWASLWNWF 36 T-20S[138M] Synthetic construct(derived from Enfuvirtide) No entry found None HIV Retroviridae MAGI assay [Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=0.7± 0.2 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50=4.4± 0.1 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50=1.7±0.5 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50=1.2± 0.4 nM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00236 DRAVPe00236.cif Linear Free Free None L membrane "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." 4495 C204H302N50O63S CGPRV EL 4.3 3 7 -4 8 13 -80 -6684 2.8 hour 10 min 2 min 89.44 17990 514 19073606 J Biol Chem. 2009 Feb 20;284(8):4914-20. "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20. 10.1074/jbc.M807169200 Anti-HIV DRAVPe00237 YTSLIHSLIEEPQNQQEKNEQELLELDKWASLWNWF 36 T-20S[138P] Synthetic construct(derived from Enfuvirtide) No entry found None HIV Retroviridae MAGI assay [Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=446± 167 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50>1000 nM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00237 DRAVPe00237.cif Linear Free Free None L membrane "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." 4460.92 C204H300N50O63 CGMRV EL 4.3 3 7 -4 8 13 -89.72 -6919 2.8 hour 10 min 2 min 89.44 17990 514 19073606 J Biol Chem. 2009 Feb 20;284(8):4914-20. "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20. 10.1074/jbc.M807169200 Anti-HIV DRAVPe00238 YTSLIHSLIEETQNQQEKNEQELLELDKWASLWNWF 36 T-20S[138T] Synthetic construct(derived from Enfuvirtide) No entry found None HIV Retroviridae MAGI assay [Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=0.9± 0.2 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50=39± 8.5 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50=161±35 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50=124±43nM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00238 DRAVPe00238.cif Linear Free Free None L membrane "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." 4464.91 C203H300N50O64 CGMPRV EL 4.3 3 7 -4 9 13 -87.22 -7176 2.8 hour 10 min 2 min 89.44 17990 514 19073606 J Biol Chem. 2009 Feb 20;284(8):4914-20. "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20. 10.1074/jbc.M807169200 Anti-HIV DRAVPe00239 YTSLIHSLIEEFQNQQEKNEQELLELDKWASLWNWF 36 T-20S[138F] Synthetic construct(derived from Enfuvirtide) No entry found None HIV Retroviridae MAGI assay [Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=9.4± 2.6 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50=203± 89 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50=393 ± 119 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50=478 ± 116 nM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00239 DRAVPe00239.cif Linear Free Free None L membrane "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." 4510.98 C208H302N50O63 CGMPRV EL 4.3 3 7 -4 8 14 -77.5 -6621 2.8 hour 10 min 2 min 89.44 17990 514 19073606 J Biol Chem. 2009 Feb 20;284(8):4914-20. "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20. 10.1074/jbc.M807169200 Anti-HIV DRAVPe00240 YTSLIHSLIEEYQNQQEKNEQELLELDKWASLWNWF 36 T-20S[138Y] Synthetic construct(derived from Enfuvirtide) No entry found None HIV Retroviridae MAGI assay [Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=25 ±9nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50=516 ±223 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50>1000 nM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00240 DRAVPe00240.cif Linear Free Free None L membrane "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." 4526.98 C208H302N50O64 CGMPRV EL 4.3 3 7 -4 9 13 -88.89 -6933 2.8 hour 10 min 2 min 89.44 19480 556.57 19073606 J Biol Chem. 2009 Feb 20;284(8):4914-20. "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20. 10.1074/jbc.M807169200 Anti-HIV DRAVPe00241 YTSLIHSLIEEWQNQQEKNEQELLELDKWASLWNWF 36 T-20S[138W] Synthetic construct(derived from Enfuvirtide) No entry found None HIV Retroviridae MAGI assay [Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=29± 14 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50>1000 nM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00241 DRAVPe00241.cif Linear Free Free None L membrane "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." 4550.02 C210H303N51O63 CGMPRV EL 4.3 3 7 -4 8 14 -87.78 -6686 2.8 hour 10 min 2 min 89.44 23490 671.14 19073606 J Biol Chem. 2009 Feb 20;284(8):4914-20. "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20. 10.1074/jbc.M807169200 Anti-HIV DRAVPe00242 YTSLIHSLIEENQNQQEKNEQELLELDKWASLWNWF 36 T-20S[138N] Synthetic construct(derived from Enfuvirtide) No entry found None HIV Retroviridae MAGI assay [Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=19± 4 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50>1000 nM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00242 DRAVPe00242.cif Linear Free Free None L membrane "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." 4477.91 C203H299N51O64 CGMPRV EL 4.3 3 7 -4 9 13 -95 -7583 2.8 hour 10 min 2 min 89.44 17990 514 19073606 J Biol Chem. 2009 Feb 20;284(8):4914-20. "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20. 10.1074/jbc.M807169200 Anti-HIV DRAVPe00243 YTSLIHSLIEEQQNQQEKNEQELLELDKWASLWNWF 36 T-20S[138Q] Synthetic construct(derived from Enfuvirtide) No entry found None HIV Retroviridae MAGI assay [Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=34± 11 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50>1000 nM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00243 DRAVPe00243.cif Linear Free Free None L membrane "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." 4491.94 C204H301N51O64 CGMPRV EL 4.3 3 7 -4 8 13 -95 -7473 2.8 hour 10 min 2 min 89.44 17990 514 19073606 J Biol Chem. 2009 Feb 20;284(8):4914-20. "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20. 10.1074/jbc.M807169200 Anti-HIV DRAVPe00244 YTSLIHSLIEEDQNQQEKNEQELLELDKWASLWNWF 36 T-20S[138D] Synthetic construct(derived from Enfuvirtide) No entry found None HIV Retroviridae MAGI assay [Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=210± 94 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50>1000 nM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00244 DRAVPe00244.cif Linear Free Free None L membrane "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." 4478.89 C203H298N50O65 CGMPRV EL 4.16 3 8 -5 8 13 -95 -7791 2.8 hour 10 min 2 min 89.44 17990 514 19073606 J Biol Chem. 2009 Feb 20;284(8):4914-20. "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20. 10.1074/jbc.M807169200 Anti-HIV DRAVPe00245 YTSLIHSLIEEEQNQQEKNEQELLELDKWASLWNWF 36 T-20S[138E] Synthetic construct(derived from Enfuvirtide) No entry found None HIV Retroviridae MAGI assay [Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=283± 80 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50>1000 nM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00245 DRAVPe00245.cif Linear Free Free None L membrane "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." 4492.92 C204H300N50O65 CGMPRV E 4.21 3 8 -5 8 13 -95 -7600 2.8 hour 10 min 2 min 89.44 17990 514 19073606 J Biol Chem. 2009 Feb 20;284(8):4914-20. "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20. 10.1074/jbc.M807169200 Anti-HIV DRAVPe00246 YTSLIHSLIEEHQNQQEKNEQELLELDKWASLWNWF 36 T-20S[138H] Synthetic construct(derived from Enfuvirtide) No entry found None HIV Retroviridae MAGI assay [Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=210± 85 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50>1000 nM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00246 DRAVPe00246.cif Linear Free Free None L membrane "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." 4500.95 C205H300N52O63 CGMPRV EL 4.53 4 7 -3 8 13 -94.17 -7385 2.8 hour 10 min 2 min 89.44 17990 514 19073606 J Biol Chem. 2009 Feb 20;284(8):4914-20. "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20. 10.1074/jbc.M807169200 Anti-HIV DRAVPe00247 YTSLIHSLIEEKQNQQEKNEQELLELDKWASLWNWF 36 T-20S[138K] Synthetic construct(derived from Enfuvirtide) No entry found None HIV Retroviridae MAGI assay [Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=708±145 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50>1000 nM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00247 DRAVPe00247.cif Linear Free Free None L membrane "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." 4491.98 C205H305N51O63 CGMPRV EL 4.54 4 7 -3 8 13 -96.11 -7474 2.8 hour 10 min 2 min 89.44 17990 514 19073606 J Biol Chem. 2009 Feb 20;284(8):4914-20. "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20. 10.1074/jbc.M807169200 Anti-HIV DRAVPe00248 YTSLIHSLIEERQNQQEKNEQELLELDKWASLWNWF 36 T-20S[138R] Synthetic construct(derived from Enfuvirtide) No entry found None HIV Retroviridae MAGI assay [Ref.19073606]HIV-1WT:inhibition of virus replication in HeLa cells(EC50=362± 114 nM);##HIV-1V38A:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1N43D/S138A:inhibition of virus replication in HeLa cells(EC50>1000 nM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00248 DRAVPe00248.cif Linear Free Free None L membrane "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." 4519.99 C205H305N53O63 CGMPV EL 4.54 4 7 -3 8 13 -97.78 -8411 2.8 hour 10 min 2 min 89.44 17990 514 19073606 J Biol Chem. 2009 Feb 20;284(8):4914-20. "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20. 10.1074/jbc.M807169200 Anti-HIV DRAVPe00249 WMEWDREINNYTSLIHSLIEEAQNQQEKNEQELL 34 C34S[138A] Synthetic construct(derived from C34) No entry found None HIV Retroviridae MAGI assay [Ref.19073606]HIV-1 NL4-3:inhibition of virus replication in HeLa cells(EC50=2.0± 0.4 nM);##HIV-1(NL4-3V38A):inhibition of virus replication in HeLa cells(EC50=1.7± 0.3 nM);##HIV-1(NL4-3N43D):inhibition of virus replication in HeLa cells(EC50=2.0 ±0.6 nM);##HIV-1(NL4-3N43D/S138A):inhibition of virus replication in HeLa cells(EC50=1.3 ±0.6 nM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00249 DRAVPe00249.cif Linear Free Free None L membrane "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." 4232.6 C184H280N50O63S CFGPV E 4.21 3 8 -5 8 10 -119.41 -9649 2.8 hour 3 min 2 min 83.24 12490 378.48 19073606 J Biol Chem. 2009 Feb 20;284(8):4914-20. "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20. 10.1074/jbc.M807169200 Anti-HIV DRAVPe00250 WMEWDREINNYTSLIHSLIEELQNQQEKNEQELL 34 C34S[138L] Synthetic construct(derived from C34) No entry found None HIV Retroviridae MAGI assay [Ref.19073606]HIV-1 NL4-3:inhibition of virus replication in HeLa cells(EC50=1.5± 0.4 nM);##HIV-1(NL4-3V38A):inhibition of virus replication in HeLa cells(EC50=1.2± 0.6 nM);##HIV-1(NL4-3N43D):inhibition of virus replication in HeLa cells(EC50=0.5 ±0.2 nM);##HIV-1(NL4-3N43D/S138A):inhibition of virus replication in HeLa cells(EC50=0.4±0.2 nM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00250 DRAVPe00250.cif Linear Free Free None L membrane "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." 4274.68 C187H286N50O63S ACFGPV E 4.21 3 8 -5 8 10 -113.53 -9338 2.8 hour 3 min 2 min 91.76 12490 378.48 19073606 J Biol Chem. 2009 Feb 20;284(8):4914-20. "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20. 10.1074/jbc.M807169200 Anti-HIV DRAVPe00251 WMEWDREINNYTSLIHSLIEETQNQQEKNEQELL 34 C34S[138T] Synthetic construct(derived from C34) No entry found None HIV Retroviridae MAGI assay [Ref.19073606]HIV-1 NL4-3:inhibition of virus replication in HeLa cells(EC50=2.6± 0.2 nM);##HIV-1(NL4-3V38A):inhibition of virus replication in HeLa cells(EC50=4.8± 1.3 nM);##HIV-1(NL4-3N43D):inhibition of virus replication in HeLa cells(EC50=32 ± 5.5 nM);##HIV-1(NL4-3N43D/S138A):inhibition of virus replication in HeLa cells(EC50=24 ±6.6nM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00251 DRAVPe00251.cif Linear Free Free None L membrane "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." 4262.63 C185H282N50O64S ACFGPV E 4.21 3 8 -5 9 9 -126.76 -10087 2.8 hour 3 min 2 min 80.29 12490 378.48 19073606 J Biol Chem. 2009 Feb 20;284(8):4914-20. "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20. 10.1074/jbc.M807169200 Anti-HIV DRAVPe00252 WMEWDREINNYTSLIHSLIEEWQNQQEKNEQELL 34 C34S[138W] Synthetic construct(derived from C34) No entry found None HIV Retroviridae MAGI assay [Ref.19073606]HIV-1 NL4-3:inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1(NL4-3V38A):inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1(NL4-3N43D):inhibition of virus replication in HeLa cells(EC50>1000 nM);##HIV-1(NL4-3N43D/S138A):inhibition of virus replication in HeLa cells(EC50>1000 nM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00252 DRAVPe00252.cif Linear Free Free None L membrane "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." 4347.74 C192H285N51O63S ACFGPV E 4.21 3 8 -5 8 10 -127.35 -9597 2.8 hour 3 min 2 min 80.29 17990 545.15 19073606 J Biol Chem. 2009 Feb 20;284(8):4914-20. "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20. 10.1074/jbc.M807169200 Anti-HIV DRAVPe00253 WMEWDREINNYTSLIHSLIEEPQNQQEKNEQELL 34 C34S[138P] Synthetic construct(derived from C34) No entry found None HIV Retroviridae MAGI assay [Ref.19073606]HIV-1 NL4-3:inhibition of virus replication in HeLa cells(EC50=46±11 nM);##HIV-1(NL4-3V38A):inhibition of virus replication in HeLa cells(EC50=436± 125 nM);##HIV-1(NL4-3N43D):inhibition of virus replication in HeLa cells(EC50=250 ± 80 nM);##HIV-1(NL4-3N43D/S138A):inhibition of virus replication in HeLa cells(EC50=176±50 nM). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00253 DRAVPe00253.cif Linear Free Free None L membrane "The peptide prevents interactions between the C-HR and the N-terminal HR (N-HR) of gp41, thus interfering with conformational changes that are required for viral fusion." 4258.64 C186H282N50O63S ACFGV E 4.21 3 8 -5 8 9 -129.41 -9830 2.8 hour 3 min 2 min 80.29 12490 378.48 19073606 J Biol Chem. 2009 Feb 20;284(8):4914-20. "Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M." Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20. 10.1074/jbc.M807169200 Anti-HIV DRAVPe00254 WQEWEQKITALLEQAQIQQEKNEYELQKLDKWASLWEWF 39 1249 Synthetic construct No entry found None HIV Retroviridae MAGI/cMAGI infectivity assay [Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.003 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.013 μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.022 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.363 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=8.140 μg/ml). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00254 DRAVPe00254.cif Linear Acetylation Amidation None L membrane "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion." 4995.58 C233H338N56O67 CGHMPRV EQ 4.43 4 8 -4 4 16 -109.49 -7562 2.8 hour 3 min 2 min 77.69 28990 762.89 17640899 Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7.  "Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK." "Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus." 10.1073/pnas.0701478104 DRAVPa0873 Anti-HIV DRAVPe00255 MTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELL 36 651 Synthetic construct No entry found None HIV Retroviridae MAGI/cMAGI infectivity assay [Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.008 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.033μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.060 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.151 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=7.599 μg/ml). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00255 DRAVPe00255.cif Linear Acetylation Amidation None L membrane "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion." 4480.9 C193H296N52O67S2 ACFGPV E 4.21 3 8 -5 10 9 -116.67 -10192 30 hour >20 hour >10 hour 75.83 12490 356.86 17640899 Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7.  "Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK." "Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus." 10.1073/pnas.0701478104 DRAVPa0971 Anti-HIV DRAVPe00256 MTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLEL 38 2410 Synthetic construct No entry found None HIV Retroviridae MAGI/cMAGI infectivity assay [Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.008 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.032μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.039 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.137 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=4.975 μg/ml). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00256 DRAVPe00256.cif Linear Acetylation Amidation None L membrane "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion." 4723.18 C204H314N54O71S2 ACFGPV E 4.14 3 9 -6 10 10 -109.74 -10381 30 hour >20 hour >10 hour 82.11 12490 337.57 17640899 Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7.  "Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK." "Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus." 10.1073/pnas.0701478104 Anti-HIV DRAVPe00257 TTWEEWDREINEYTSRIESLIRESQEQQEKNEQELREL 38 2429 Synthetic construct No entry found None HIV Retroviridae MAGI/cMAGI infectivity assay [Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.012 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.021μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.056 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.037 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=0.167 μg/ml). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00257 DRAVPe00257.cif Linear Acetylation Amidation None L membrane "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion." 4826.14 C205H319N59O76 ACFGHMPV E 4.29 5 12 -7 9 8 -177.89 -16817 7.2 hour >20 hour >10 hour 61.58 12490 337.57 17640899 Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7.  "Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK." "Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus." 10.1073/pnas.0701478104 Anti-HIV DRAVPe00258 MTWMAWDRAIANYAALIHALIEAAQNQQEKNEAALLEL 38 2638 Synthetic construct No entry found None HIV Retroviridae MAGI/cMAGI infectivity assay [Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.061 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.079μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.079 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.120 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=0.250 μg/ml). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00258 DRAVPe00258.cif Linear Acetylation Amidation None L membrane "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion." 4312.93 C192H300N52O57S2 CFGPSV A 4.57 3 5 -2 5 20 1.05 -3352 30 hour >20 hour >10 hour 108.42 12490 337.57 17640899 Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7.  "Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK." "Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus." 10.1073/pnas.0701478104 Anti-HIV DRAVPe00259 TTWEAWDRAIAEYAARIEALIRASQEQQEKNEAELREL 38 290676 Synthetic construct No entry found None HIV Retroviridae MAGI/cMAGI infectivity assay [Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.006 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.013μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.022 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.072 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=1.314 μg/ml). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00259 DRAVPe00259.cif Linear Acetylation Amidation None L membrane "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion." 4489.93 C195H307N57O65 CFGHMPV AE 4.52 5 9 -4 5 16 -87.89 -11171 7.2 hour >20 hour >10 hour 82.63 12490 337.57 17640899 Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7.  "Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK." "Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus." 10.1073/pnas.0701478104 Anti-HIV DRAVPe00260 MTWEAWDRAIAEYAARIEALIRAAQEQQEKNEAALREL 38 2544 Synthetic construct No entry found None HIV Retroviridae MAGI/cMAGI infectivity assay [Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.007 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.026μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.033 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.014 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=0.021 μg/ml). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00260 DRAVPe00260.cif Linear Acetylation Amidation None L membrane "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion." 4445.98 C194H307N57O61S CFGHPSV A 4.64 5 8 -3 3 18 -60.26 -9296 30 hour >20 hour >10 hour 87.89 12490 337.57 17640899 Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7.  "Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK." "Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus." 10.1073/pnas.0701478104 Anti-HIV DRAVPe00261 TTWEAWDRAIAEYAARIEALIRAAQEQQEKNEAILREL 38 267209 Synthetic construct No entry found None HIV Retroviridae MAGI/cMAGI infectivity assay [Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.007 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.021μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.034 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.024 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=0.039 μg/ml). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00261 DRAVPe00261.cif Linear Acetylation Amidation None L membrane "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion." 4457.97 C196H311N57O62 CFGHMPSV A 4.64 5 8 -3 4 18 -60 -9477 7.2 hour >20 hour >10 hour 95.53 12490 337.57 17640899 Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7.  "Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK." "Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus." 10.1073/pnas.0701478104 Anti-HIV DRAVPe00262 TTWEAWDRAIAEYAARIEALIRALQEQQEKNEAALREL 38 267221 Synthetic construct No entry found None HIV Retroviridae MAGI/cMAGI infectivity assay [Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.011 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.035μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.028 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.035 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=0.050 μg/ml). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00262 DRAVPe00262.cif Linear Acetylation Amidation None L membrane "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion." 4457.97 C196H311N57O62 CFGHMPSV A 4.64 5 8 -3 4 18 -61.84 -9477 7.2 hour >20 hour >10 hour 95.53 12490 337.57 17640899 Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7.  "Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK." "Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus." 10.1073/pnas.0701478104 DRAVPa1316 Anti-HIV DRAVPe00263 TTWEAWDRAIAEYAARIEALIRAAQELQEKNEAALREL 38 267226 Synthetic construct No entry found None HIV Retroviridae MAGI/cMAGI infectivity assay [Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.007 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.021μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.035 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.030 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=0.020 μg/ml). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00263 DRAVPe00263.cif Linear Acetylation Amidation None L membrane "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion." 4400.92 C194H308N56O61 CFGHMPSV A 4.64 5 8 -3 4 19 -47.89 -8742 7.2 hour >20 hour >10 hour 98.16 12490 337.57 17640899 Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7.  "Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK." "Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus." 10.1073/pnas.0701478104 Anti-HIV DRAVPe00264 TTWEAWDRAIAEYAARIEALIRALQEQQEKNEAILREL 38 267225 Synthetic construct No entry found None HIV Retroviridae MAGI/cMAGI infectivity assay [Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.019 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.043μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.079 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.038 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=0.196 μg/ml). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00264 DRAVPe00264.cif Linear Acetylation Amidation None L membrane "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion." 4500.05 C199H317N57O62 CFGHMPSV A 4.64 5 8 -3 4 18 -54.74 -9166 7.2 hour >20 hour >10 hour 103.16 12490 337.57 17640899 Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7.  "Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK." "Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus." 10.1073/pnas.0701478104 Anti-HIV DRAVPe00265 TTWEAWDRAIAEYAARIEALIRAAQEQQEKLEAALREL 38 267227 Synthetic construct No entry found None HIV Retroviridae MAGI/cMAGI infectivity assay [Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.012 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.045μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.028 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.025 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=0.044 μg/ml). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00265 DRAVPe00265.cif Linear Acetylation Amidation None L membrane "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion." 4414.94 C195H310N56O61 CFGHMNPSV A 4.64 5 8 -3 3 19 -47.89 -8632 7.2 hour >20 hour >10 hour 98.16 12490 337.57 17640899 Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7.  "Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK." "Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus." 10.1073/pnas.0701478104 DRAVPa1317 Anti-HIV DRAVPe00266 TTWEAWDRAIAEYAARIEALIRAAQEQQEKLEAVLREL 38 291022 Synthetic construct No entry found None HIV Retroviridae MAGI/cMAGI infectivity assay [Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.022 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.049μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.093 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.046 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=0.242 μg/ml). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00266 DRAVPe00266.cif Linear Acetylation Amidation None L membrane "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion." 4443 C197H314N56O61 CFGHMNPS A 4.64 5 8 -3 3 19 -41.58 -8409 7.2 hour >20 hour >10 hour 103.16 12490 337.57 17640899 Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7.  "Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK." "Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus." 10.1073/pnas.0701478104 Anti-HIV DRAVPe00267 TTWEAWDRAIAEYAARIEALIRALQELQEKNEAALREL 38 290822 Synthetic construct No entry found None HIV Retroviridae MAGI/cMAGI infectivity assay [Ref.17640899]HIV IIIB:inhibition of virus infection on CEM4 cells(IC50=0.030 μg/ml);##HIV 098:inhibition of virus infection on CEM4 cells(IC50=0.054μg/ml);##HIV 098-T20:inhibition of virus infection on CEM4 cells(IC50=0.084 μg/ml);##HIV 098-T1249:inhibition of virus infection on CEM4 cells(IC50=0.147 μg/ml);##HIV 098-T651:inhibition of virus infection on CEM4 cells(IC50=0.242 μg/ml). No hemolysis information or data found in the reference(s) presented in this entry No cytotoxicity information or data found in the reference(s) presented in this entry DRAVPe00267 DRAVPe00267.cif Linear Acetylation Amidation None L membrane "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing